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Purpose: Biomaterials are natural or synthetic materials that come into contact with biological 
tissue. Contact lenses are the most commonly used biomaterials, being worn by an estimated 140 
million people worldwide. While contact lens wear could be considered successful, up to 50% of 
patients discontinue contact lens wear, primarily due to the development of contact lens 
discomfort. Due to the interaction of contact lenses with the ocular surface, the ocular environment 
is of great interest when considering factors contributing to contact lens discomfort. One of these 
factors may be cytokines released by human corneal epithelial cells, which have the potential to 
initiate ocular inflammation. The purpose of the investigations presented in this thesis were to 
assess cytokine adhesion to various contact lens materials, as an excessive binding of cytokines to 
contact lenses may contribute to the pathology of contact lens discomfort. 
 
Methods and Materials: Conventional hydrogels and silicone hydrogel contact lens materials 
were soaked in solutions containing proinflammatory cytokines IL-1!, IL-6, IL-8 and TNF-". 
These cytokines were either recombinant proteins derived from a standard, lyophilized blend, or 
obtained directly from human corneal epithelial cells. Over various time points, samples of the 
soaking solutions were collected and later analyzed using the Meso Scale Discovery platform. This 
platform evaluates biomarker concentrations via electrochemiluminescence and was used in these 
investigations to detect and measure the concentration of the cytokines of interest in the soaking 
solution. This served as an indirect measurement of the amounts of cytokines that had adhered to 
the contact lens materials.  
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Results: The presence of the cytokines of interest in the soaking solutions were detected using the 
Meso Scale Discovery platform and the amount of uptake onto the contact lens materials were 
quantified. Additional surface modifications to the contact lens materials mimicking the ocular 
surface of a clinically-worn contact lens were explored. Balafilcon A, comfilcon A, etafilcon A 
and omafilcon A were the only contact lens materials that appeared to exhibit some uptake of the 
cytokines of interest, although this amount varied between experiments and between the cytokines 
of interest. There was no uptake of IL-6 quantified on any of the contact lens materials investigated.   
 
Discussion and Conclusion: To our knowledge, data does not exist in the literature for the 
quantification of IL-1!, IL-6, IL-8 and TNF-" uptake onto contact lens materials through the use 
of electrochemiluminescence. This work, in part, helped to address issues surrounding ocular 
inflammation and contributed to providing a better understanding of the role of inflammatory 
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Chapter 1: Introduction - Ocular Immunology 
1.1 The Cornea 
 As the avascular outer tunic of the eye, the human cornea features many unique 
characteristics that allow it to serve as an important refractive structure.1 The small diameter of the 
collagen fibrils of which the cornea is comprised, in addition to the regular arrangement of these 
fibers, allows the cornea to exist as a highly organized tissue.1 This organization, in conjunction 
with the meticulous spacing of the collagen fibrils permitting destructive interference of adjacent 
light rays, prevent light scatter and contribute to the overall transparency of the cornea, a key 
requirement for the cornea’s refractive ability.1 
 Histologically, when viewed anteriorly to posteriorly, the cornea is comprised of the 
following five layers: the corneal epithelium, Bowman’s membrane, the corneal stroma, 
Descemet’s membrane and the corneal endothelium (Figure 1-1).1 Each layer contributes a 
respective role in the protection of the cornea and the maintenance of its organization and 
regularity.1 This is extremely important as the integrity of the cornea can be otherwise 
compromised, leading to the deterioration of vision and an unhealthy ocular state.1 As a result, 
there are numerous physical, mechanical and immunological defenses in place to aid in the 
maintenance and protection of this integrity, in addition to providing overall protection to all ocular 




Figure 1-1: Histological Cross-Section of the Human Cornea Outlining its Five Distinctive Layers.1 Figure Reprinted from 
Clinical Anatomy and Physiology of the Visual System, 3rd Edition (Remington, 2012), with Permission from Elsevier. 
 
1.2 Ocular Defense Mechanisms 
Uniquely, the eyes remain passively exposed to microorganisms and debris from the 
environment, yet in most cases (unless an infection results or there is damage to the ocular 
structures), the present defense mechanisms are sufficient to allow for quick recognition of foreign 
entities and subsequent elimination of any pathogens.2,3 This protection to the eye also specifically 
helps to maintain the transparency of the cornea and supports vision preservation.3 The eyes’ 
defense mechanisms are a combination of physical, mechanical and immunological barriers.3  
1.2.1 Physical and Mechanical Defenses  
The simplest physical defenses are the bony orbit and eyelids, which act as physical barriers 
to protect the eyes from trauma that could weaken the integrity of the cornea.3 Further, eyelashes 
are an example of a mechanical defense that protects the eyes from any debris and foreign 
particles.4 Additionally, such debris and foreign particles, upon contact with the ocular surface, 
will be washed off by the aid of a blink reflex, another mechanical defense that continuously 
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spreads tears over the ocular surface.2,3 This action helps to remove microbes from the ocular 
surface by washing them towards the ocular surface drainage system and prevent their settling onto 
the eye.4  
1.2.2 Immunological Defense: Tears  
The human tear film, playing a crucial role in the nourishment, protection and hydration of 
the ocular surface, including the cornea, is a bi-phasic structure consisting of a superficial lipid 
phase and an underlying aqueous-mucin phase.5 The lipid phase, as the name implies, consists of 
lipids largely secreted by the meibomian glands within the tarsal plate of the eyelid, through their 
orifices just at the eyelid margin, and to a lesser extent, lipids contributed by the glands of Moll 
and Zeiss within the subcutaneous areolar tissue of the eyelid.1,5 The lipid phase both stabilizes the 
tear film and prevents tear evaporation.5,6 The aqueous-mucin phase, on the other hand, constitutes 
the bulk of the tear film and plays several important roles in the overall function of the tear film, 
including, but not limited to: protection of the corneal epithelium, facilitating the movement of 
oxygen and nutrients for nourishment of the avascular cornea, regulation of pH, elimination of 
toxins and debris, and providing an optically smooth surface for light refraction.5,7 Within this 
phase, there are as many as 1400 unique proteins, in addition to the presence of peptides, 
electrolytes, small metabolites and mucins (glycosylated proteins), of either cleaved, membrane-
spanning or gel-forming types.5-7 These secretions are produced by two accessory glands (glands 
of Krause which exist in higher concentration near the fornix and glands of Wolfring within the 
tarsal plate of the eyelid), although recently, it has also been suggested that the secretions of the 
main lacrimal gland (which are similar to that of the accessory lacrimal glands), can also contribute 
to the aqueous-mucin phase of the tear film.1,5 Epithelial cells of the cornea and conjunctiva may 
contribute small amounts of electrolytes, fluids and mucins to the tear film as well.5,6 Mucins 
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specifically help to maintain ocular hydration by providing a wettable surface and contributing to 
the epithelial barrier to prevent pathogen binding.6,8  
In addition to preventing corneal dryness and flushing away foreign particles and debris, 
certain constituents of the tear film also help to prevent the onset of infections.3 This includes 
lysozymes, immunoglobulins (antibodies), and cytokines, all of which play an integral role in 
maintaining an immunological barrier for the ocular surface.3 Lysozymes are enzymes capable of 
breaking down microbial cell walls.4 Immunoglobulins (Ig) are plasma proteins produced during 
an immune response due to the presence of an antigen.9 The antigen can be any foreign substance, 
such as a bacterium or a virus, to which an antibody will bind and destroy.4 One important 
immunoglobulin found in the tear film is IgA, which will bind pathogens to prevent their adhesion 
to the corneal epithelium.3 Further, IgA-secreting plasma cells also exist within the conjunctiva, 
lacrimal gland and lacrimal drainage tissue of the eyes, all three of which are involved in a key 
immunological defense of the eye known as eye-associated lymphoid tissue (EALT).10-12   
1.2.3 Immunological Defense: Inflammatory Cells and Markers 
Immunity is provided to the body in either a non-specific manner (innate immunity), or as 
a specific response (adaptive immunity).9 Innate immunity is conserved through evolution and is 
present at birth, while adaptive immunity is acquired throughout an individual’s lifetime as a result 
of the systemic immune system producing antibodies against new, “non-self” antigens (foreign 
entities), as they are encountered.9 Antibodies are a class of proteins known as immunoglobulins, 
which initiate immune responses either by binding the pathogen or by recruiting other immune 
cells to destroy it instead.9 The structure of an antibody consists of two identical heavy and light 
chains, each with a constant region determining its effector function, as well as a variable region 
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possessing an antigen-binding site.9 The antigen, on the other hand, has an epitope region that is 
recognized by the antigen receptor of the antibody.9 
At the forefront of both the innate and adaptive immune systems are leukocytes, or white 
blood cells.9 Leukocytes develop from the bone marrow where most will also mature.9 Upon 
maturation, these cells can circulate in the bloodstream, within the lymphatic system, or they can 
be transported to tissues where they will reside.9 The lymphatic system is a specialized system of 
vessels that drain immune cells and extracellular fluids from tissues as “lymph”, which eventually 
empties back into the bloodstream via the thoracic duct.9 Prior to maturation, immune cells are 
naïve and inactivated, that is until they encounter an antigen and subsequent development into 
effector cells allows them to carry out a variety of effector mechanisms with molecular and cellular 
functions.9 Within the bone marrow, pluripotent hematopoietic stem cells can give rise to common 
lymphoid progenitor cells or common myeloid progenitor cells.9 The former are precursors to 
antigen-specific lymphocytes and innate cell lineages without antigen-specific receptors, while the 
latter are precursors to granulocyte/macrophage progenitor cells or megakaryocyte/erythrocyte 
progenitor cells.9  
Arising from the common lymphoid progenitor cell are B lymphocytes (B cells), T 
lymphocytes (T cells), natural killer (NK) cells and innate lymphoid cells (ILCs).9 Immature 
dendritic cells may also arise from a common lymphoid progenitor cell; however, the majority 
arise from a common myeloid progenitor cell instead.9 B lymphocytes mature in the bone marrow 
where they originate, whereas T lymphocytes mature in the thymus, although they too originate in 
the bone marrow.9 Both of these cells remain as naïve lymphocytes with little functionality until 
they encounter an antigen and differentiate into functional, effector lymphocytes.9 This encounter 
depends on the interaction of the antigen with either B-cell receptors (BCRs), or T-cell receptors 
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(TCRs), on the surfaces of these cells.9 Genetically, BCRs consist of the same genes that encode 
antibodies.9 In fact, the membrane-bound form of an antibody, which is specific to each antigen, 
is the BCR on the surface of the B cell for that antigen.9 Shortly after the antigen binds to its BCR, 
proliferation and differentiation of the B cell into its effector form ensues, producing plasma cells 
which secrete antibodies in order to target and destroy the antigen.9 While TCRs are related to 
immunoglobulins, they are also distinct from BCRs due to their inability to independently 
recognize and bind antigens, but rather their dependence on major histocompatibility (MHC) 
molecules to present antigens to them.9 MHC molecules are cell-surface glycoproteins and exist 
in two classes: MHC class I and MHC class II.9 Similar to B cells, T cells will proliferate and 
differentiate into one of three classes of functional, effector T cells, upon binding of an antigen to 
the appropriate TCR on their cell surface.9 This includes the cytotoxic T cells which kill pathogens 
or infected cells, T Helper (Th) cells which secrete cytokines to signal and activate other cells 
(such as B cells), to destroy or engulf pathogens, in addition to regulatory T cells (Treg), which 
serve a protective function by limiting tissue damage through suppression of lymphocyte activity 
as required.9 Cytotoxic T cells express CD8 protein which selectively recognizes MHC class I-
bound peptides, while T Helper cells express CD4 protein which selectively recognizes MHC class 
II-bound peptides.9 The majority of the cells within the body express MHC class I molecules, since 
these molecules commonly present peptides from viruses to CD8 T cells and viruses can infect 
any cell with a nucleus.9 Conversely, only antigen-presenting cells such as dendritic cells, 
macrophages and B cells will express MHC class II molecules.9 
Arising from the common myeloid progenitor are immature dendritic cells, granulocytes 
(neutrophils, eosinophils and basophils), mast cells and monocytes.9 Immature dendritic cells will 
mature upon encountering a pathogen, while monocytes and mast cells complete their maturation 
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in tissues.9 Upon maturation, monocytes will differentiate into either dendritic cells or 
macrophages.9 The common myeloid progenitor also gives rise to megakaryocytes which produce 
platelets for blood clotting, as well as erythroblasts which mature into erythrocytes (red blood 
cells).9  
Macrophages, granulocytes and dendritic cells are three types of phagocytic cells within 
the immune system.9 Macrophages, the mature form of monocytes, exist in virtually all tissue types 
and are long-lived, engulfing and killing pathogens and producing other inflammatory mediators 
to in turn recruit additional immune cells.9 In comparison, granulocytes are short-lived and possess 
granules within their cytoplasms, which store various degradative enzymes and toxic proteins.9 
Once these cells engulf a pathogen, they become activated and release the appropriate enzymes or 
proteins from their granules in order to effectively destroy it.9 Of the granulocytes, neutrophils are 
the most abundant in comparison to eosinophils and basophils.9 Eosinophils and basophils are also 
important for initiating allergic responses, in addition to mast cells, which also have granules 
consisting of histamine and various proteases.9 Moreover, through a process called 
micropinocytosis, dendritic cells ingest or “drink” large amounts of particulate matter and 
extracellular fluid, and will degrade any pathogens which they take up in this way.9 More 
importantly, however, dendritic cells, along with macrophages and neutrophils, are sensor cells 
and they play an important role in detecting an infection and initiating an immune response.9 
Macrophages, neutrophils and dendritic cells express pattern recognition receptors (PRRs), 
that allow them to recognize simple molecules as well as pathogen-associated molecular patterns 
(PAMPs).9 PAMPs are present in microorganisms and are distinct from the molecular patterns of 
the host’s cells.9 PRRs include toll-like receptor (TLR) proteins and NOD-like receptor (NLR) 
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proteins, both of which will detect PAMPs from extracellular bacteria.9 Activation of PRRs leads 
to the production of cytokines and chemokines which help to amplify the immune response.9  
Cytokines are small, regulatory proteins that are secreted by cells during inflammation and 
can either stimulate or inhibit normal cell functions.4,10,13 This includes activation or deactivation 
of cells involved in either the innate or adaptive immune system, in order to amplify or suppress 
an immune response.4,10 Cytokines are “hormone-like”, as they are involved in either autocrine or 
paracrine signaling, if they act on the cell that secreted them, or act on an adjacent or nearby cell, 
respectively.4 For example, helper T cells can release interleukin-2 (IL-2), a cytokine that can both 
activate nearby immune cells or stimulate the same helper T cell that secreted it to proliferate, in 
turn secreting more IL-2 to strengthen the immune response.4  
Interleukins (ILs), interferons (IFNs), chemokines and tumor necrosis factors (TNFs) are 
all various groups of cytokines.9 Interleukins are cytokines that were initially thought to be secreted 
from one leukocyte to act on another, and though they are mainly secreted by subtypes of 
leukocytes such as macrophages and helper T cells, it is now known that other tissues in the body 
can also secrete and respond to interleukins.3,14 Interferons are cytokines that are secreted by NK 
cells and lymphocytes.4,10,14 Some IFNs, such as IFN-&, activate macrophages, while other IFNs, 
such as IFN-' and IFN-!, have antiviral effects.4,10,14 These cytokines will target virus-infected 
host cells and promote the production of antiviral proteins to prevent viral replication, in addition 
to inducing an antiviral state in neighbouring cells.3,14 Chemokines are small cytokines of 
molecular weight 6-12 kDa that act as chemoattractants.10,15 An example of a chemokine is IL-8 
which is 6-8 kDa in size.15 Chemokines induce the directional migration of leukocytes such as 
neutrophils to areas of inflammation via chemotaxis.4,10 Tumor necrosis factors, mainly produced 
by macrophages, can also act on macrophages in addition to neutrophils, by promoting the 
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accumulation of these cells at the site of inflammation and stimulating them to kill the present 
microbes.10,14  Further, TNFs also induce apoptosis within cells.14  
In the human eye, cytokine-releasing cells exist within the conjunctiva, and resident 
macrophages exist in the corneal stroma; thus, a variety of interleukins are also found in the eye.3 
As mentioned, macrophages produce interleukins, some of which include IL-1', IL-10, IL-12 and 
IL-18 in the eye.10 IL-1' has also been found in corneal epithelial cells where it is stored and can 
be released if the cell membrane is damaged either due to infection or trauma.3 Corneal 
keratocytes, specialized fibroblast cells of the cornea, synthesize IL-6 under the influence of IL-
1' and TNF-'.3 Further, TNF-', which is present in the conjunctival epithelium, has shown to be 
an inducer of IL-1!, an interleukin which can upregulate IL-6 and IL-8 in corneal epithelial 
cells.16,17  
The epithelial cells of both the cornea and the conjunctiva are known to secrete proteins 
and cytokines that are microbicidal and immunomodulatory.18 Moreover, these cells also use toll-
like receptor signaling systems to respond to pathogens and unusual molecular patterns that are 
associated with danger.18 Detecting and distinguishing between beneficial and pathogenic 
microorganisms is a key factor in immunity.19 Typically, microorganisms possess PAMPs and 
TLRs will bind conserved motifs on the PAMPs, to allow for the detection of pathogens and the 
subsequent activation of the cell to secrete inflammatory cytokines, along with other co-
stimulatory molecules.19,20 In addition to being expressed by corneal epithelial cells and 
conjunctival epithelial cells, keratocytes (fibroblasts), also present in the eye, express TLRs.14,20  
During ocular allergy, typically upon initial exposure to an antigen, IgM is the first 
immunoglobulin to be produced from B cells and serve as antigen receptors.4,10 If the antigen is 
encountered again, B cells will switch their production from IgM to IgG, a process that requires 
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gene rearrangement and is said to be controlled in part by lymphokines.10 IL-4, in particular, is an 
example of a lymphokine that stimulates B cells to switch their production to either IgG or IgE.10 
IgG is the most abundant immunoglobulin and is also found in abundance within the eye.4,10 IgG 
neutralizes toxins and enhances phagocytosis to protect against bacteria and viruses.4 IL-4 
regulates B cell development, and IL-5 is also said to play a role in inducing B cells to differentiate 
into IgM and IgG-secreting plasma cells.10 Furthermore, IL-4 activates mast cells, while IL-5 is a 
regulator of eosinophils.10 After the production of IgE, this immunoglobulin will immediately 
become bound to the surface of mast cells and subsequent binding of the antigen to IgE on the 
mast cell will stimulate degranulation and the release of histamines and cytokines.10 Mast cells, in 
addition to releasing IL-4, will also release IL-6, IL-8, and TNF-'.10 Eosinophils participate in 
allergic responses by releasing toxic enzymes contained within their granules when activated, 
causing inflammation.14  
When epithelial cells are exposed to conditions that are desiccating, such as in dry eye 
disease, the secretion of chemokines CCL20, CXCL9, CXCL10 and CXCL11 from the epithelial 
cells will in turn help recruit Th1 and Th17 cells from circulation.18 NK cells will also be activated 
and will release IFN-&.18 Th1 cells secrete IL-2 and IFN-&.3,10 Th17 cells produce IL-17, IL-21, 
and IL-22.10  
Allergy cytokines include IL-4, IL-5, IL-10, IL-13 and IFN-&.10 IL-4 can stimulate naïve 
T cells to differentiate into Th2 cells, which are associated with disease downregulation or allergy 
initiation.10,21 Th2 cells can secrete their own IL-4, and during allergic conjunctivitis, a Th2 
response causes over-expression of this cytokine.13,21 Th2 cells can also secrete IL-5, IL-10 and 
IL-13.10 As previously noted, IL-4 can stimulate the differentiation of B cells into IgG or IgE-
secreting plasma cells and also activate mast cells, while IL-5 can induce differentiation of B cells 
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into IgM or IgG-secreting plasma cells, and regulate eosinophils.10,21 During chronic and severe 
ocular allergies such as vernal keratoconjunctivitis (VKC), an upregulation of IL-5 is observed, 
while an upregulation of IFN-&, IL-10 and IL-13 is associated with atopic keratoconjunctivitis 
(AKC).22 Recall, IFN-& is produced by Th1 cells, which are associated with the initiation of 
disease, as well as NK cells.3,10,18 IL-17, produced by Th17 cells, is another notable cytokine that 
has been identified in severe ocular allergies, in addition to other inflammatory diseases of the 
ocular surface including dry eye syndrome and uveitis.22,23 Although traditionally it was believed 
that allergies were mediated by a Th2 response only, it is now also believed that Th1-mediated 
inflammatory responses are involved in severe ocular allergies and diseases.22   
Anti-inflammatory cytokines include IL-4, IL-10, IL-13 and TGF-!.24,25 All four of these 
cytokines can be produced by Th2 cells and although IL-4, IL-10 and IL-13 are also involved in 
allergies, as noted earlier, Th2 cells are not only associated with allergy initiation, but they are also 
associated with disease downregulation (or anti-inflammatory effects).10 IL-4 can block the 
expression of proinflammatory cytokines IL-1, TNF-', IL-6, IL-8, in addition to CCL3 (formerly 
MIP 1-').21,26 Moreover, it can also prevent macrophage-derived nitric oxide production, suppress 
parasite killing and block the cytotoxic activity of macrophages.21 IL-10 is involved in the down-
regulation of proinflammatory cytokine receptors and can block proinflammatory cytokine 
synthesis by monocytes or macrophages, thereby suppressing the expression of TNF-', IL-6 and 
IL-1!.21,24 Furthermore, IL-10 can inhibit Th1 cytokines such as IL-2 and IFN-&.21 Similarly to 
IL-4, IL-13 can also downregulate IL-1, IL-8, TNF-' and CCL3 synthesis.21 Lastly, TGF-! can 
inhibit both Th1 cells and macrophages to block cytokine production, thereby suppressing IL-1, 
IL-2, IL-6 and TNF-' expression.24 
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Evidently, numerous immune cells are present within the eye. Apart from the existing 
immunoglobulins and macrophages which secrete interleukins and tumor necrosis factors, other 
subtypes of leukocytes, such as T cells and NK cells also exist within the eye, along with 
fibroblasts (keratocytes), epithelial cells, neutrophils and dendritic cells.3,10,14,18 In fact, within the 
conjunctiva there is a substantial population of T cells, NK cells, and dendritic cells.18 Neutrophils 
are also present and they play a protective role in preventing microorganisms from invading the 
corneal epithelium.3 Further, they can move through the endothelial cells of the limbal vasculature 
via a process known as diapedesis, where they will adhere to vascular endothelial cell receptors.3  
1.2.4 Immunological Defense: MALT, Introduction to EALT 
Any internal surface of the body that is lined by a mucus-secreting epithelium is referred 
to as “mucosal tissue”.9 This epithelium will always act as the first line of defense against 
pathogens.9 Within the body, mucosal surfaces include the respiratory tract, gastrointestinal tract, 
urogenital tract, the middle ear and exocrine glands such as the salivary and mammary glands.9 
When specifically considering ocular tissues, the conjunctiva and lacrimal gland are also classified 
as mucosal tissues.9 Mucosal surfaces are unique in the sense that they are often in direct contact 
with the external world and therefore encounter a substantially greater diversity of antigens (and 
pathogens) more frequently, in comparison to other tissues within the body.9 Thus, these surfaces 
present as a convenient route for antigens to enter the body.9 To cope with this, all mucosal tissues 
are protected by a large and distinctive immune system known as the “mucosal immune system”, 
which differs from the systemic immune system in many ways, as it must be specialized in order 
to combat this wide variety of antigens that may be encountered.9   
Mucosa-associated lymphoid tissue (MALT), is a generic term that refers to the extensive 
lymphoid tissue system composed of lymphocytes, found at mucosal surfaces, which can exist 
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either in an organized manner or scattered within.9 Under this term falls tissue-specific MALT 
including gut-associated lymphoid tissue (GALT) and recently identified eye-associated lymphoid 
tissue (EALT).9,11 Nasal-associated lymphoid tissue (NALT) and bronchus-associated lymphoid 
tissue (BALT) exist habitually in some species such as mice, but are only present in adult humans 
during an infection.9 It has been hypothesized that the mucosal immune system may have in fact 
been the first part of the vertebrate immune system to have evolved, due to the coevolution of 
vertebrates and commensal bacteria.9 In fact, differences in GALT and lymphoid tissue of the 
systemic immune system appear to be determined very early on in life.9 All mucosa-associated 
lymphoid organs are categorized as peripheral (secondary) lymphoid organs, along with the lymph 
nodes and the spleen.9 Secondary lymphoid organs maintain mature, naïve lymphocytes and 
initiate adaptive immune responses.9 On the contrary, primary lymphoid organs are where 
lymphocytes originate and these include the bone marrow and thymus.9 
The mucosal immune system and the systemic immune system differ in many ways.9 For 
example, while it is completely natural to find numerous effector cells (e.g. effector lymphocytes), 
scattered at mucosal surfaces, within healthy non-lymphoid tissue, this would indicate the presence 
of an infection.9 Within the mucosal immune system, however, these effector cells may exist as a 
result of a local response to the harmless antigens that are present, such as gut commensal 
microorganisms.9 Other interesting distinctions between the mucosal immune system and the 
systemic immune system is that the former includes the presence of microfold cells (M cells), 
retinoic acid-producing dendritic cells and large populations of macrophages with unique 
characteristics.9  
Unique to the mucosal immune system, M cells are specialized epithelial cells involved in 
the uptake of antigens and the facilitation of antigen presentation by macrophages and dendritic 
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cells.9 Within GALT, M cells are found in Peyer’s patches of the small intestine, scattered among 
the traditional, non-specialized epithelial cells.9 Where these epithelial cells are covered by a thick 
layer of mucus, M cells lack this glycocalyx and hence present as an easily exposed and convenient 
route for antigens to enter the gut lumen.9 Some antigens, such as several types of bacteria, are 
readily recognized by a glycoprotein (GP2) on the surface of M cells, which binds bacterial FimH 
(adhesion) protein found within bacterial type 1 pilli.9 This initiates transcytosis, a process 
whereby the antigen is transported from the cell interior to the basal cell membrane as a membrane-
bound vesicle that is then released into the extracellular space.9 Conveniently so, the basal cell 
membrane of the M cell is convoluted such that a pocket is formed which encircles T lymphocytes 
and B lymphocytes, in addition to creating a close vicinity where local contact between 
lymphocytes and myeloid cells (e.g. dendritic cells), is encouraged.9 Once released into the 
extracellular space, local dendritic cells, as well as those recruited via chemotaxis, will bind the 
antigen and the antigen-dendritic cell complex will migrate to areas containing naïve, antigen-
specific T lymphocytes.9 The chemotaxis of the recruited dendritic cells occurs in response to the 
binding of CCL9 and CCL20 chemokines released from epithelial cells to their respective 
receptors (CCR1 and CCR6) on dendritic cells.9 Collectively, the dendritic cells and the now 
primed T lymphocytes will activate B lymphocytes and initiate the release of IgA antibodies.9 IgA 
is the principal antibody of the immune response for mucosal surfaces.9  
 While the presence of M cells within EALT remains controversial, with some research 
groups claiming successful identification of these cells within cadaveric human lacrimal sacs and 
within the conjunctiva of rabbits, felines, canines, and mice, other groups have reported no 
evidence of M cells within the conjunctiva of such animal models.27 If present within the human 
conjunctiva, however, and within the lacrimal sac, initiation of an immune response within EALT, 
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or even within MALT of other mucosal surfaces other than the gut, will likely involve a similar 
process as outlined above.9 
In 2001, Knop and Knop claimed to have found evidence for M cells within the lacrimal 
sac of human cadaveric tissue.28 Using immunohistochemistry and electron microscopy, they 
observed flat, covering epithelial cells within follicle-associated epithelia, displaying a thin 
cytoplasm containing many small vesicles, characteristic of M cells within Peyer’s patches.28 In 
2005, using complete conjunctival sacs from normal, young adult rabbits, Knop and Knop 
identified specialized epithelial cells with different cytoplasms than ordinary epithelial cells, using 
both transmission electron microscopy and scanning electron microscopy.29 These M cells existed 
in follicle-associated epithelia, displayed lighter cytoplasms and active mRNA transcription as 
suggested by bright euchromatic nuclei and a prominent nucleolus, in addition to the presence of 
many vesicles for antigen transport, among mitochondria, ribosomes and few rough endoplasmic 
reticula.29 In 2002 and later in 2011, with the use of similar methods, Giuliano and colleagues 
provided morphological evidence of M cells within the nictitating membranes of canines and 
felines, respectively.30,31 In both animal models, the M cells did not display the typical dense brush 
border observed with ordinary epithelial cells and instead displayed pocket formation that enclosed 
T lymphocytes, B lymphocytes and macrophages.30,31 Furthermore, in the investigation involving 
the canine model, the use of heat-killed Staphylococcus aureus bacteria showed selective 
attachment to M cell apical membranes and further provided evidence of transcytosis across the 
surfaces of these cells into the pockets where the bacteria was engulfed by the residing 
macrophages.30 Finally, in 2010, Seo and colleagues found evidence for M cells using a murine 
model when investigating eye mucosa as a vaccine delivery route.32 They found M cells with long 
and irregular microvilli similar to the rabbit model rather than the canine model, displaying the 
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ability to sample and internalize Salmonella typhimurium and Yersinia pseudotuberculosis 
bacteria.32  
Another unique feature of mucosal immunity is the presence of retinoic acid-producing 
dendritic cells that induce tolerance within mucosal tissue.9 Outside of mucosal tissue, dendritic 
cells do not produce retinoic acid, however, they do so within the mesenteric lymph nodes and the 
lamina propria and Peyer’s patches of the small intestine.9 Recently, retinoic acid-producing 
dendritic cells have also been identified within ocular tissue and are believed to play a role in 
ocular immune privilege.33 Recalling the antigen-dendritic cell complex that forms as a result of 
antigen presentation to dendritic cells once transported across the cell by M cells, there is migration 
of this complex to areas containing naïve T lymphocytes, depending on where the antigen was first 
encountered.9 This migration may be to T-cell dependent areas of Peyer’s patches or to the 
mesenteric lymph nodes.9 Typically, 5-10% of dendritic cells will migrate to the former on a daily 
basis.9 Migration of dendritic cells occurs as a result of “licensing” – a process whereby chemokine 
receptor CCR7 is induced on the surface of immature dendritic cells, thereby activating them.9 
Under inflammatory conditions or during an infection, if naïve T lymphocytes are able to recognize 
an antigen presented by the dendritic cells, they will become “primed”, in a process which involves 
replacement of CCR7 (which they also express), and L-selection adhesion molecule, with gut-
homing molecules CCR9 and '4:!7.9 In contrast, unsuccessful recognition of an antigen will result 
in the exit of T lymphocytes via efferent lymphatics into the bloodstream.9 By expressing these 
gut-homing molecules, the regulatory T lymphocytes are able to exit mesenteric lymph nodes and 
return back to the gut, where they can help to fight invading organisms.9 Additionally, under 
normal, non-inflammatory conditions, interaction of dendritic cells with naïve T lymphocytes in 
mesenteric lymph nodes will produce antigen-specific FoxP3+ Tregs.9 These Tregs will still express 
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gut-homing molecules CCR9 and '4:!7, however, they will be homed back to the gut in order to 
suppress inflammation to harmless antigens or commensals.9 Interestingly so, the production of 
Tregs and their ability to express these gut-homing molecules requires the production of retinoic 
acid by dendritic cells.9 These dendritic cells express retinal dehydrogenase enzymes and can 
metabolize dietary vitamin A or vitamin A produced by stromal cells in mesenteric lymph nodes.9 
Retinoic acid signaling plays several important roles in mammalian eye development and 
is required for interactions between the optic vesicle and lens placode, as well as for proper retinal 
and optic nerve development.34 In 2011, Zhou and colleagues investigated the role of retinoic acid 
in immune privilege.33 Due to its role in visual development, retinoic acid exists in abundance 
within the eye, particularly within ocular fluids such as the aqueous humor.33 Aqueous humor is a 
fluid produced by the ciliary processes (pars plicata), of the ciliary body, which nourishes the 
avascular cornea and the lens by providing oxygen and glucose.1 The presence of various 
neuropeptides within the aqueous humor may also induce an immunosuppressive property, as 
some studies in the literature had previously suggested that aqueous humor could inhibit ocular T 
lymphocytes from producing IFN-& and instead convert these T lymphocytes to TGF-!-producing 
Tregs, though details of the mechanism remained largely unknown.33 Through the use of a murine 
model, Zhou and colleagues highlighted the roles of aqueous humor and TGF-! in the production 
of FoxP3+ Tregs.33 Similarly to requiring retinoic acid for Treg production within the gut, retinoic 
acid appeared to be essential for this pathway as well, though this investigation studied the effects 
of retinoic acid on Treg production in the absence of dendritic cells.33 Results from this study 
demonstrated that the presence of aqueous humor inhibited the proliferation of naïve T 
lymphocytes and prevented these cells from developing into effector cells.33 Furthermore, IL-17 
and IFN-& secretions, which correlated to naïve T lymphocytes acquiring either Th17 or Th1 
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effector functions, respectively, were found to be inhibited by aqueous humor.33 Thus, not only 
was Th17 and Th1 effector function blocked by the aqueous humor, but mRNA levels of IL-17A, 
IL-21, IL-22, IL-23R and Th-17-associated transcription factor ROR&t (retinoic acid receptor-
related orphan receptor &t), were drastically reduced.33 Instead, T lymphocytes were converted to 
FoxP3+ Tregs rather than being committed to the Th17 or Th1 lineage, and they also demonstrated 
to be progressively more stable with additional rounds of aqueous humor stimulation.33 
Interestingly, Zhou and colleagues found that retinoic acid was required to enhance this process as 
there was substantial mRNA expression of retinoic receptor RAR' in the presence of aqueous 
humor.33 Moreover, neutralization of TGF-!	to block its function in turn blocked the induction of 
this receptor, suggesting that TGF-! was required for upregulating RAR' expression and 
indirectly enhancing the effects of the aqueous humor on T lymphocytes.33  
In 2016, Ahadome and colleagues suggested evidence for retinoic acid-producing dendritic 
cells within ocular mucosa, similar to those found in the gut mucosa.35 However, in this case, these 
dendritic cells induced fibrosis in a severe ocular allergy setting.35 Fibrosis is a condition involving 
excessive collagen deposits and appears to be commonly present during allergic inflammation, 
such as atopic dermatitis and atopic keratoconjunctivitis when considering ocular allergy.35 In the 
eye, fibrosis may lead to blindness depending on its severity.35 Retinoic acid, among other retinoid 
or vitamin A metabolites, have shown involvement in fibrosis, in addition to promoting fibroblast 
growth and proliferation.35 Also through the use of a murine model, this study demonstrated that 
two dendritic cell subsets, CD11b+ and cDC2, had increased activity of aldehyde dehydrogenase 
(ALDH) enzyme, which is required for the conversion of retinal to all-trans-retinoic acid (ATRA), 
or isomerized 9-cis-retinoic acid (9-CisRA).35 Increased activity of ALDH resulted in fibrosis 
within the conjunctiva of the mouse model under allergy eye disease conditions, whereas depletion 
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of these dendritic cells inhibited ALDH and conversely played a protective role in preventing the 
development of fibrosis under such conditions.35 Further, evaluation of two nuclear receptors, 
retinoic acid receptor (RAR) and retinoid X receptor (RXR), both of which are involved in retinoic 
acid signaling, revealed that inhibition of the latter prevented fibrosis, whereas inhibition of the 
former did not.35 Additionally, when primary conjunctival fibroblasts were exposed to 9-CisRA, 
the results were fibrogenic, while exposure to 9-CisRA in the presence of an RXR inhibitor was 
not, suggesting that 9-CisRA is a high-affinity, fibrogenic ligand of RXR, that shows increased 
expression with increased ALDH activity under allergic eye disease conditions.35  
Large populations of macrophages with unique characteristics is another aforementioned 
feature of mucosal immunity.9 Within the lamina propria of a healthy intestine of the human body, 
the largest population of macrophages is found, however, these macrophages differ from those 
residing in other tissues.9 First, while other macrophages are maintained locally, intestinal 
macrophages require constant replenishment from blood monocytes.9 This may be in response to 
the high levels of commensal bacteria within the gut.9 Second, rather than producing inflammatory 
cytokines or reactive oxygen/nitrogen species, they are anti-inflammatory cells that constitutively 
produce large amounts of IL-10.9 Thirdly, they uniquely act as powerful scavengers that ingest or 
degrade antigens, while simultaneously limiting inflammation through maintenance of an antigen-
specific tolerant environment that can sustain FoxP3+ Treg cells as they migrate back from 
mesenteric lymph nodes.9 While there appears to be little evidentiary support within the literature 
to confirm the presence of IL-10-producing macrophages within ocular mucosa that possess 
similar characteristics to those of the intestinal mucosa, the ocular mucosa does have other unique 
immune cells whose functions appear to be well-suited to the immune-privileged environment of 
the eye.36,37 For example, in a study by Williams and colleagues in 2014, using human conjunctival 
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epithelial cells, it was found that the majority of the resident CD8 T lymphocytes evaluated were 
of CD45RA- CCR7- effector memory cells, and almost all of these cells expressed mucosal homing 
molecule 'E:!7.36 This is similar to the expression of gut homing molecule '4:!7 on primed 
intestinal T lymphocytes.9 Upon further investigation, it was also found that these conjunctival 
CD8 T lymphocytes constitutively expressed Granzyme B, a protease produced by CD8 T 
lymphocytes that induces apoptosis in target cells.9,36 Moreover, these cells also had the ability to 
produce IFN-&.36 Williams and colleagues concluded that the expression of these molecules by 
CD8 T lymphocytes serves an immune surveillance function at the ocular surface, and may 
confirm that recruitment of T lymphocytes to the ocular mucosa is mechanistically similar to 
homing within the intestine.9,36 Where IL-10 does appear to exist in abundance within the eye is 
in the cornea during inflammatory conditions.37 Under normal circumstances, IL-10 is absent in 
the healthy cornea, however, its expression is highly upregulated within infiltrating corneal 
macrophages (CD11+ cells) during inflammation.37 Further, it appears that the secretion of IL-10 
by these cells serves an anti-inflammatory but pro-lymphangiogenic function.37 
Lymphangiogenesis is a term that describes the formation of new lymphatic vessels or 
secondary ingrowth of lymphatic vessels in tissue.37,38 Lymphangiogenesis first occurs during 
embryogenesis and will rarely occur into adulthood unless it is inflammation-induced.38 The 
process involves vascular endothelial growth factor receptor-3 (VEGFR-3), and transcription 
factor Prospero-related homeobox-1 (Prox1).38 During embryogenesis, vascular endothelial 
growth factor-C (VEGF-C), or VEGF-D, will bind to VEGFR-3, which is expressed in lymphatic 
endothelial cells and is a key protein involved in lymphangiogenesis regulation.38 VEGF-C and 
VEGF-D are produced in elevated amounts at sites of inflammation by various immune cells such 
as macrophages, dendritic cells, neutrophils and mast cells, and their binding to VEGFR-3 will 
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activate its signaling.38 Additionally, the expression of VEGFR-3 in blood vascular endothelial 
cells has also been shown to be induced by Prox1 and is thereby another method of regulating 
lymphangiogenesis.38 Experiments involving VEGFR-3 and Prox1 have shown that the two appear 
co-localized in lymphatic vessels, suggesting that a connection exists, and down-regulation of 
VEGFR-3 expression in lymphatic endothelial cells can be achieved through silencing of Prox1.38 
Additionally, there may also be involvement of transcription factor NF-*B (nuclear factor kappa-
light-chain-enhancer of activated B cells), if induced through inflammatory stimuli.38 Prox1 may 
become activated by NF-*B and the two may collectively activate the VEGFR-3 promotor, in 
order to increase expression of this receptor in lymphatic endothelial cells.38 As a result, pre-
existing lymphatic endothelial cells may become more responsive to the binding of VEGF-C and 
VEGF-D for activating VEGFR-3, resulting in more enhanced lymphangiogenesis.38   
In tissues other than the eye, lymphangiogenesis is an important process during 
inflammation because lymphatic vessels act as a drainage system for immune cells and debris at 
the site of inflammation, allowing the termination of an ongoing inflammatory response.37 
Moreover, they allow for tissue pressure regulation and prevention of edema or chronic 
inflammation within tissues, which would otherwise occur if the vessels were to be blocked, as 
shown in recent studies.37 As previously mentioned, however, the cornea is avascular, which 
means that it is also devoid of lymphatic vessels and several anti-lymphangiogenic mechanisms 
help to actively ensure this avascular state.1,37 As a result, nourishment is provided to the cornea 
from the aqueous humor via diffusion and also through limbal capillaries (from the conjunctiva 
and episclera).1 Thus, while lymphangiogenesis has physiological functions in other tissues, within 
the eye and specifically within the cornea, lymphangiogenesis is considered to be pathological.37 
Under normal conditions, expression of soluble forms of VEGFR-1, VEGFR-2 and VEGFR-3, in 
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addition to the expression of thrombospondin-1, constitute anti-(lymph)angiogenic factors within 
the corneal epithelium.39 Soluble VEGFR-1 acts as a decoy receptor for VEGF-A to limit 
hemangiogenesis and soluble VEGFR-3 acts as a decoy receptor, binding VEGF-C and VEGF-D 
such that they cannot bind the membrane-bound form.39 Soluble VEGFR-2 helps to prevent 
lymphatic invasion at the central cornea and thrombospondin-1 binds CD36 to regulate VEGF-C 
production by monocytes and macrophages.39 In the cornea, if lymphangiogenesis occurs from 
pre-existing limbal lymphatic vessels, the mechanism is also mediated by VEGFR-3 and ligands 
VEGF-C and VEGF-D.39 Alternatively, if the process occurs independent of limbal lymphatics, 
then CD11b+ macrophages in the corneal stroma will express Prox1 and lymphangiogenic marker 
LYVE-1 (lymphatic vessel endothelial hyaluronan receptor-1).39 Additionally, damaged corneal 
tissue produces proinflammatory cytokines TNF-', IL-1 and chemokines CCL2 and CCL20, 
which will in turn recruit neutrophils and macrophages and promote lymphangiogenesis as they 
produce VEGF-C and VEGF-D.39 
In 2015, with the use of a murine model to investigate the role of IL-10 in corneal 
lymphangiogenesis, Hos and colleagues found this cytokine to be indirectly involved in regulating 
lymphangiogenesis and reducing inflammation through macrophages.37 When comparing healthy 
corneas with corneas where inflammation was induced through the placement of a corneal suture, 
IL-10 mRNA expression was upregulated during suture placement and declined two weeks post 
suture removal.37 Additionally, IL-10 protein expression appeared co-localized with CD11b, 
which is expressed by macrophages, suggesting the presence of IL-10 in infiltrating corneal 
macrophages during inflammation.37 In vitro, experiments whereby peritoneal macrophages were 
stimulated using recombinant IL-10 revealed through real-time polymerase chain reaction (RT-
PCR) technique, significantly increased expression of this cytokine, indicating an autocrine effect 
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or a positive feedback loop.37 Moreover, macrophage anti-inflammatory markers arginase-1 and 
CD163, in addition to LYVE-1 (lymphangiogenic marker) were also significantly upregulated.37 
Analysis of VEGF-A, VEGF-C and VEGF-D following IL-10 stimulation revealed 
decreased expression of VEGF-A, significantly upregulated expression of VEGF-C and a low but 
unchanged expression of VEGF-D.37 Note, VEGF-A is pro-hemangiogenic while VEGF-C and 
VEGF-D are pro-lymphangiogenic.37 As it appeared that IL-10 resulted in macrophages with anti-
inflammatory, anti-hemangiogenic but pro-lymphangiogenic phenotypes, possibly with the 
involvement of VEGF-C, further immunohistochemistry staining on inflamed corneas 2 weeks 
post suture placement showed co-localization of VEGF-C and LYVE-1.37 Suture placement in a 
IL-10-/- (deficient) murine model, revealed the mRNA expression of VEGF-A to instead increase, 
while the mRNA expression of VEGF-C decreased.37 IL-10-/- mice without suture placement had 
similar VEGF-A and VEGF-C mRNA expression levels as their wild-type littermates.37 
Morphometric analysis showed significantly reduced lymphangiogenesis in the inflamed corneas 
of IL-10-/- mice with no change in hemangiogenesis, consistent with the previous finding and 
suggesting that a loss of IL-10 reduced VEGF-C expression, leading to reduced 
lymphangiogenesis during inflammatory conditions.37 Interestingly, when lymphatic endothelial 
cells were incubated with either VEGF-C, IL-10 or a combination thereof, cell proliferation 
appeared to increase in the presence of VEGF-C, however, RT-PCR demonstrated no changes in 
mRNA expression of VEGF-C or LYVE-1 upon incubation with IL-10.37 This suggested that IL-
10 did not directly affect proliferation of these cells or the expression of these two markers.37 
Rather, the effect of IL-10 appeared to be indirect through anti-inflammatory VEGF-C-secreting 
macrophages.37 Further, IL-10-/- mice also showed significantly higher levels of IL-1!, TNF-' and 
CD11b+ in suture-induced inflamed corneas and these levels remained elevated following suture 
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removal.37 Thus, it appeared that a deficiency in IL-10 lead to a more severe and persistent 
inflammatory response even post stimulus removal.37 Upon conditional deletion of a gene (Stat3) 
in the myeloid cell lineage of mice, it was determined that treatment of isolated peritoneal 
macrophages from these mice with IL-10 was insufficient for upregulating VEGF-C or LYVE-1 
mRNA expression, demonstrating a dependence for the Stat3 gene and the importance of 
macrophages in this process.37 Corneal suture placement in these mice mimicked the phenotypes 
of IL-10-/- mice, as less evidence of lymphangiogenesis and higher presence of inflammatory 
CD11b+ cells was observed.37 Local treatment with IL-10 in mice with conditional deletion of 
Stat3 resulted in higher egress of inflammatory cells and therefore faster resolution of corneal 
inflammation.37 Overall, it appeared that the crucial but indirect role for IL-10 during inflammatory 
corneal conditions was to modulate lymphangiogenesis through macrophages and the upregulation 
of VEGF-C and LYVE-1 expression.37  
1.2.5 Immunological Defense: Ocular Surface Immune System Anatomy, EALT 
Within the eye, MALT is comprised of conjunctiva-associated lymphoid tissue (CALT) 
and lacrimal drainage-associated lymphoid tissue (LDALT), collectively referred to as eye-
associated lymphoid tissue (EALT).11 The lymphoid tissue is continuous from the lacrimal gland 
throughout the conjunctiva via excretory ducts (CALT) and into the lacrimal drainage system 
(LDALT).11 CALT and LDALT and their associated structures (i.e., the lacrimal gland, the 
conjunctiva and the lacrimal drainage system), are connected via tears that flow over the ocular 
surface.11 Additionally, specialized blood vessels known as high endothelial venules, or HEV, 
exist within the conjunctiva and the lacrimal drainage system, and allow for a regulated migration 
and exchange of lymphocytes between ocular tissue and other mucosal organs.11 HEV provide a 
regulated inflow of these lymphocytes, while lymph vessels offer a regulated outflow.11 Figure 1-2 
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below provides a visual representation of the EALT system.12 Upon examination of the anatomy 
of the mucosal immune system that exists at the surface of the eye, it becomes increasingly evident 
that the ocular mucosa shares numerous immune cells, structures and features with extraocular 
mucosa located elsewhere in the body, such as in the gut.  
First, the cornea is devoid of lymphoid cells; however, MHC class II-positive antigen-
presenting Langerhan cells exist in the epithelium of the peripheral cornea.12 Langerhan cells are 
a type of immature dendritic cells which are typically found within the skin, although they have 
also been identified to exist in the eye.9,12 The conjunctiva, in contrast to the cornea, has many 
blood vessels, lymph vessels and high endothelial venules.12 Lymphoid tissue within the 
conjunctiva consists of lymphocytes found in both the basal epithelial layer and lamina propria, in 
addition to IgA-producing plasma cells.12 CD8 T lymphocytes are found in abundance within the 
conjunctiva basal epithelial layer, while CD4 T lymphocytes exist in abundance within the 
conjunctival lamina propria – a distribution similar to the mucosa located in the small intestine 
epithelia and lamina propria.12 Numerous macrophages and dendritic cells also exist in the 
conjunctiva and similarly to the gut mucosa, there is evidence of lymphoid follicles composed 
mainly of B lymphocytes with parafollicular T lymphocytes present as well.12 Of interest, is the 
age-dependent frequency of these lymphoid follicles within the conjunctiva, as it is estimated that 
roughly 40% of individuals in their mid-seventies will lose these follicles, while for the other 60%, 
the number of follicles may decrease to about 10 per conjunctival sac on average.12  
Second, at the lacrimal gland, CD8 T lymphocytes predominate over CD4 T lymphocytes 
and IgA-producing plasma cells exist in abundance.12 Further, while the lacrimal gland rarely 
appears to contain lymphoid follicles, it has been reported in the literature that T lymphocytes may 
distinctly form groups around intralobular ducts within the gland instead.12 In contrast to the 
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lacrimal gland, but similarly to the conjunctiva, the lacrimal drainage system does contain 
lymphoid follicles among having lymphoid tissue as well.12 The lacrimal drainage system is 
continuous with the conjunctiva and the lacrimal sac through the lacrimal puncta, the canaliculi 
and the nasolacrimal duct into the nose.4 This system comprises a moist, mucous membrane with 
lymphoid tissue and follicles identified within the canaliculi and lacrimal sac as well.12,28 
Lymphoid tissue protects the ocular surface by detecting antigens and producing effector 
cells to process and initiate an immune response.11,27 Specialized M cells within the EALT system 
are responsible for phagocytosing an antigen and delivering it to antigen-presenting cells (such as 
dendritic cells).12 The antigen will then be presented to the lymphoid follicles and subsequent 
activation of the lymphocytes within the follicles will occur.11 The lymphocytes will proliferate 
and differentiate into effector cells of either B-lineage or T-lineage.11 Typically, the center of 
lymphoid follicles is composed of B cells with a few T cells located there as well; however, T cells 
are mainly found to be parafollicular, surrounding the B cells instead (Figure 1-2).12,40 Although 
the cornea is avascular and does not contain lymphoid cells under physiological conditions, the 
EALT system also plays a role in corneal immune protection based on its topographical 
location.11,12 During eye closure, conjunctival lymphoid tissue is projected in such a way that it 
co-localizes with the cornea (Figure 1-3).11  
Taken together, it is understood that although the ocular immune system possesses its own 
unique features, which must exist in order to protect the integrity of the cornea and to help preserve 
vision, there are also numerous features that are shared and conserved with the mucosal immune 
system elsewhere. Further, it is evident that the ocular mucosa plays an integral role in the 
protection of ocular tissues, which may have previously been underestimated or thought to have 
not existed at all.  
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Figure 1-2: EALT (Blue Cells = Plasma Cells, Purple Cells = B Lymphocytes, Black Cells = T Lymphocytes).12 Figure 







Figure 1-3: Topographical Location of CALT Within the Conjunctiva Relative to the Cornea.40 Figure Modified and 
Reprinted from Experimental Induction and Three-Dimensional Two-Photon Imaging of Conjunctiva-Associated Lymphoid 
Tissue (Steven et al., 2008). Permission for Modification and Use Obtained from the Copyright Holder: Association for 
Research in Vision & Ophthalmology (ARVO). 
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Chapter 2: Introduction - Contact Lenses 
2.1 Contact Lenses as Biomaterials  
A biomaterial is defined as any natural or synthetic material that comes into contact with 
biological tissue.41 By this definition, a contact lens (CL) is classified as a biomaterial due to its 
interaction with the cornea, conjunctiva and tear film upon placement onto the ocular surface. 
Generally, biomaterials are considered to be inert, although today, drugs that can slowly release 
from the biomaterial may be included in the device matrix.41 Within the fields of ophthalmology 
and optometry, biomaterials are used for both vision preservation and restoration.42 For example, 
intraocular lenses (artificial lens implants placed surgically into the eye), can replace a cataract 
(clouding lens) that is obstructing vision.41,42 On the other hand, contact lenses are used for 
correcting vision43, for cosmetic purposes41 and with recent advancements, may have potential to 
be used as drug-delivering devices for treating ocular diseases and infections in the future.43-47 
Currently, contact lenses are estimated to be worn by 140 million people worldwide, rendering 
them the most commonly used biomaterial.48 Contact lenses have evolved greatly over the past 
several decades and their properties continue to be developed upon today, with the goal of 
improving comfort for extended wear remaining at the forefront of their advancement. 
2.2 A Brief Introduction to the History of Contact Lenses 
Contact lenses first rose to popularity roughly 50 years ago upon the introduction of “soft” 
contact lens materials to the market.49 These lenses, also termed “conventional hydrogels”, 
consisted of poly-2-hydroxyethyl methacrylate (pHEMA) derivatives and offered slightly more 
oxygen permeability in comparison to the preceding “hard” contact lenses that were composed of 
polymethyl methacrylate (PMMA) polymer.49,50 PMMA offers no oxygen permeability to the 
corneal surface and has very limited hydrophilicity.50 In contrast, pHEMA is a relatively 
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hydrophilic polymer, yet the oxygen permeability of contact lenses of such material largely 
depends on their water content and remains relatively low due to the low solubility of oxygen in 
water.51 As a result, where the use of PMMA-derived contact lenses results in hypoxic corneal 
conditions among other ocular health risks, pHEMA-derived contact lenses also fail to eliminate 
these health risks.49,50 Fortunately, by 1999, the introduction of a new class of soft contact lens 
materials, termed “silicone hydrogels” or “SiHys”, allowed for such hypoxic conditions to be 
overcome.49 Interestingly, clinical studies have also shown reduced bulbar and limbal hyperemia 
in patients wearing SiHy lenses when compared to those who wear conventional hydrogels.52 
While SiHy lenses are hydrophobic in nature due to the incorporation of silicone, these lenses 
actually offer five to six times greater oxygen permeability to the corneal surface in comparison to 
conventional hydrogels, due to the high solubility of silicone in oxygen.51,53,54 Furthermore, the 
formation of Si-O-Si linkages within siloxane macromers also allows for increased gas 
transmission.53,54 In the case of SiHy lenses, their oxygen permeability depends largely on their 
silicone content rather than the water content of the lens.51 Early generation SiHy lenses had 
surface treatments or an internal wetting agent incorporated into their bulk material in order to 
increase hydrophilicity, as these early “untreated”, relatively hydrophobic lenses, would cause 
discomfort due to their poor wettability.51 Such surface treatments, in addition to other 
characteristics of the lens (including water content and ionicity), are the basis for which the Food 
and Drug Administration (FDA) categorizes contact lens materials.55  
2.3 Categorization of Contact Lenses  
Currently, there are a total of five classes of contact lenses according to the FDA.55 The 
first four groups classify conventional hydrogels based on total water content and ionicity (Table 
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2-1).55 The fifth group subdivides silicone hydrogels into five subgroups based on total water 
content, ionicity and other characteristics (Table 2-2).55  
Table 2-1: FDA Categorization of Conventional Hydrogels.55 
FDA Group Water Content Ionicity 
Group I Low (<50%) Nonionic (neutral charge) 
Group II High (>50%) Nonionic (neutral charge) 
Group III Low (<50%) Ionic (negative charge) 
Group IV High (>50%) Ionic (negative charge) 
 
Table 2-2: FDA Categorization of Group V Silicone Hydrogels into Subgroups.55 
Subgroup Characteristics 
Group V-A Low water content (<50%), nonionic, surface treated. 
Group V-B1 Low water content (<50%), nonionic, contain hydrophilic 
monomers, no surface treatments.  
Group V-B2 Low water content (<50%), nonionic, contain a semi-
interpenetrating network, with no surface treatments.  
Group V-C High water content (>50%), nonionic. 
Group V-D Low water content (<50%) or high water content (>50%), 
ionic.  
 
2.4 Contact Lens Discomfort 
While contact lens wear is generally considered successful, clinical studies report that 
between 12% to 51% of contact lens wearers will discontinue CL use primarily as a result of 
experiencing contact lens discomfort (CLD).56 CLD is a term encompassing the occurrence of 
adverse ocular sensations such as dryness, itchiness, scratchiness, watering and tiredness, whether 
continuous or episodic, that is experienced as a result of low compatibility between a contact lens 
and the ocular environment.56 Visual disturbances such as blurry vision may or may not occur, 
however, CLD will often lead to decreased contact lens wear time and eventual discontinuation 
altogether.56 Numerous factors can lead to CLD, whether these factors are due to the contact lens 
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characteristics themselves, such as water content or base curve, or environmental aspects such as 
age, gender, ocular health or air quality (Figure 2-1).57 Although conventional hydrogels and SiHy 
lenses differ in their material composition and levels of oxygen permeability, the same level of 
CLD appears to exist with both of these classes of materials.52  
 
Figure 2-1: Contact Lens Discomfort Classification.57 Figure Reprinted from The TFOS International Workshop on Contact 
Lens Discomfort: Report of the Definition and Classification Subcommittee (Nichols et al., 2013), with Permission from the 
Copyright Holder: Association for Research in Vision & Ophthalmology (ARVO). 
 
One clinical study comparing a SiHy lens with three conventional hydrogels found no 
significant differences in ratings reported for dryness or comfort between the two classes of contact 
lens materials in either asymptomatic or symptomatic patients.52 Instead, the study found higher 
levels of dryness reported by symptomatic patients, in addition to reports of reduced comfort, over 
the 7-hour study period in comparison to asymptomatic patients.52 This result, however, was 
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consistent whether the symptomatic patients wore silicone or conventional hydrogels.52 Previous 
studies have also presented similar results.52  
When considering the factors leading to CLD, the ocular environment is of great interest 
due to the interaction of a contact lens with the ocular surface upon its placement onto the cornea. 
Though not directly a cause of CLD, the tear film, due to the components it is comprised of, may 
potentially play a role in discomfort.  
2.5 Interaction of a Contact Lens with the Tear Film 
 As evident through sections 1.2.2 and 1.2.3, numerous proteins (including inflammatory 
markers), mucins and lipids are found on the ocular surface and circulating within tears. Craig and 
colleagues have effectively depicted the interaction of such molecules with a contact lens and with 
the tear film as it sits on the corneal epithelium (Figure 2-2).  
 
Figure 2-2: Comparative Schematic of an in situ NaFl Cross-Section of a CL on the Corneal Surface vs. Interaction of a CL 
in an Updated Tear Film Model.5 Figure Reprinted from The TFOS International Workshop on Contact Lens Discomfort: 
Report of the Contact Lens Interactions with the Tear Film Subcommittee (Craig et al., 2013), with Permission from the 
Copyright Holder: Association for Research in Vision & Ophthalmology (ARVO). 
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 Of interest in Figure 2-2 are the presence of cleaved membrane-spanning mucins and gel-
forming mucins within the aqueous-mucin phase, which increase in concentration toward the 
corneal epithelium, as a heavy concentration of membrane-spanning mucins constitutes a 
glycocalyx.5 Recalling the roughly 1400 unique proteins that also exist within this phase, one such 
protein outlined in Figure 2-2 is positively-charged lysozyme protein that has been shown in the 
literature to readily deposit on the surface of negatively charged contact lens materials such as 
conventional etafilcon A lenses.5,7,58,59 Typically, SiHy lenses attract lipids more readily than they 
do proteins.58 Additionally of note are the IgA proteins that exist within the aqueous-mucin phase, 
which as previously mentioned, are the principal class of antibodies that provide immunity to 
mucosal tissues such as the eyes.5,9 
 It is inevitable that these proteins, mucins and lipids will come into contact with a contact 
lens at the cornea-contact lens interface. Nonetheless, whether these molecules will actually 
deposit onto the surface of the lens or be taken up into its bulk material, depends largely on the 
chemical properties of the lens itself, such as its principal monomers or its ionicity (charge). The 
interaction (and subsequent deposition), of proteins and lipids onto contact lens materials appears 
to be well understood within the literature.58-60 However, the deposition of inflammatory proteins 
such as cytokines, and any resulting consequences which may be caused as a result of their 
deposition, is much less clear and has attracted little interest to date.  
 Based on what is reported in the literature, it appears that if there is deposition of proteins 
or lipids onto the surface of a contact lens, whether that be onto a silicone or conventional hydrogel, 
this interaction may, in turn, result in CLD, ocular surface dryness, reduced visual acuity or 
potentially lead to ocular inflammation and disease.56,59 Of interest is the underexplored potential 
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effects of the uptake and deposition of inflammatory markers onto these contact lens materials as 
well, and to what extent this may contribute to CLD or dry-eye syndrome. 
2.6 Dry-eye syndrome 
 Intraocular immunology appears to be quite complicated, yet similar to the body, many of 
the same immune cells exist within ocular tissue and they secrete various cytokines. It can be said 
then, that a basal level of cytokines exists within the eye; however, these levels may be regulated 
differently based on ocular conditions and environmental conditions. For example, every night 
during sleep when the eyes are closed, a physiological but proinflammatory shift takes place on 
the ocular surface.18 During the first hours of sleep, complement activation is increased in the tear 
film, and a significant influx of neutrophils later follows.18 Complement is a defense system 
consisting of over 30 complement proteins that act in a cascade to collectively destroy microbes 
through cytolysis, phagocytosis, and inflammation.4 Further, when the eyes are closed, and there 
is limited oxygen reaching the eye, otherwise described as hypoxic conditions, an increase in toll-
like receptor expression in the epithelial cells of the conjunctiva is also observed.18 
Dry-eye syndrome (DES) is an inflammatory disorder involving many cytokines and 
chemokines.22 Extensive research has been conducted in an attempt to identify which cytokines 
and chemokines are involved in DES.22 Studies have shown that there are elevated levels of IL-
1', IL-1!, IL-6, IL-8 and TNF-' in tears and conjunctival epithelium of DES patients.16,22 This 
could, in part, be due to two major signaling pathways that exist in corneal and conjunctival 
epithelial cells, known as MAPK and NF-*B.18 MAPKs, an acronym for mitogen-activated protein 
kinases, are a group of key signaling molecules that participate in a well-conserved signaling 
pathway cascade.61 Tear hyperosmolarity, a universal feature of dry eye, in conjunction with other 
desiccating stresses on the ocular surface, will activate this signaling pathway, leading to the 
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secretion of IL-1!, IL-8, TNF-' and metalloproteinases.18,61 Additionally, these proteins initiate a 
protein phosphorylation cascade that ultimately activates nuclear transcription factors including 
NF-*B (nuclear factor kappa-light-chain-enhancer of activated B cells), which will further 
stimulate the secretion of IL-8 and metalloproteinases as well.18,61 As noted previously, TNF-', a 
key initiator of ocular inflammation, has been shown to induce IL-1!, which also has high potential 
to initiate ocular inflammation through its significant upregulation of other proinflammatory 
cytokines including IL-6 and IL-8.16,17 Suitably, IL-1! is described as a potent proinflammatory 
cytokine and furthermore, it can also stimulate helper T cells to differentiate into Th17, which as 
previously mentioned, secretes IL-17, IL-21 and IL-22.10,15 IL-6 promotes neutrophil migration to 
areas of inflammation through the production of CXCL2 (previously known as MIP-2) and CCL3 
(previously known as MIP 1-').26,62 Also, as noted earlier, IL-8 will induce directional migration 
of leukocytes (mainly neutrophils) to sites of inflammation.4,10,15   
2.6.1 Contact Lens-Related Dry Eye 
Contact lens-related dry eye (CLDE) is an issue that affects roughly 50% of all contact lens 
wearers.63 It is already known that up to 51% of contact lens wearers may discontinue their use of 
contact lenses due to discomfort.56 One symptom of contact lens discomfort is dryness and in some 
patients, CL wear alone can cause dry eye symptoms which have the potential to alter the tear film 
altogether.56,63 As a result of the discomfort, reduced visual acuity may be experienced, compelling 
patients to either discontinue CL use or to decrease their lens wear time.56,63 As mentioned, dry 
eye can lead to the activation of MAPK and NF-*B signaling pathways within corneal and 
conjunctival epithelial cells, leading to the secretion of several cytokines; thus, cytokines may also 
influence contact lens-related dry eye.18,61 The deposition of proteins and lipids onto contact lens 
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materials may also be a contributing factor to CLDE, and this has been extensively studied in the 
literature.6,8,59  
2.7 Protein and Lipid Deposition onto Contact Lens Materials 
The deposition of proteins and lipids onto contact lenses depends largely on the lens 
chemistry (principle monomers), which influences its water content and ionicity.55 One study 
investigating lysozyme deposition on contact lens materials found significantly more deposition 
of this protein onto etafilcon A (FDA group IV) in comparison to omafilcon A (FDA group II) and 
silicone hydrogels (FDA group V).59 This occurs due to the principle monomer of etafilcon A, 
methacrylic acid, carrying a negative charge, which has an increased affinity for positively charged 
lysozyme at physiological pH.59 Omafilcon A is zwitterionic due to its principle monomer 
phosphorylcholine and can largely resist protein deposition.59 Another study investigating lipid 
and protein deposition on etafilcon A and polymacon A (FDA group I) lenses, found higher 
deposition of lipids on the latter in comparison to the former, however, etafilcon A had higher 
protein deposition than polymacon A.60 Once again, the ionic charge of etafilcon A appeared to 
predominantly control protein deposition.60 On the other hand, lipid deposition has been shown to 
be greater on nonionic lenses (such as polymacon A), in comparison to ionic lenses (such as 
etafilcon A).60 It is proposed that silicone hydrogels readily attract lipids more so than they do 
proteins, however, any amount of protein that deposits onto silicone hydrogels, though less than 
that deposited on conventional hydrogels, is still an important consideration, as any denaturation 
of these proteins on the ocular surface can lead to inflammatory conditions.58 A study involving 
two conventional hydrogels and four silicone hydrogel lenses found that the silicone hydrogel 
lenses studied had less lysozyme deposition compared to the conventional hydrogels studied.58 Of 
the conventional hydrogels, etafilcon A had the highest lysozyme deposition at 1800 +g/lens.58 
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While the amount of protein deposition can vary among different silicone hydrogels, depending 
on the specific principle monomers, balafilcon A accumulated up to 44 +g/lens – the highest 
among the silicone hydrogels tested, yet small in comparison to the conventional hydrogels.58  
2.8 Quantification of Inflammatory Markers within the Eye, Deposition onto Contact 
Lenses 
In the literature, there exist many studies where various inflammatory markers have been 
quantified in the tear film of non-CL wearers and CL wearers, under both normal and diseased 
conditions. In 1998, a study by Nakamura and colleagues on 270 healthy, normal subjects who did 
not wear CLs, attempted to establish a baseline for the basal amounts of IL-1', IL-1!, IL-6 and 
IL-8 present within tears.64 Tear samples were collected, pooled and assayed using an ELISA 
(enzyme-linked immunosorbent assay).64 A large range was reported from 10.9 ± 1.2 pg/mL to 
731.4 ± 116.2 pg/mL (mean ± SD), for IL-1' and IL-8 concentrations.64 IL-1! was quantified at 
12.9 ± 2.3 pg/mL, while IL-6 levels were reported as 226.2 ± 29.6 pg/mL.64 
In 2013, Wei and colleagues quantified IL-1!, IL-6, IFN-& and TNF-' levels from the 
tears of normal subjects and CL-wearers assessed for symptoms of dry eye disease.65 Tears were 
collected using microcapillary tubes, pooled and sampled with a Milliplex immunoassay using 
Luminex.65 The cytokine concentrations reported (as mean ± SD), were higher in CL wearers 
(15.56 ± 12.94 pg/mL, 14.86 ± 0.19 pg/mL, 1.25 ± 3.69 pg/mL and 14.82 ± 15.8 pg/mL for IL-
1!, IL-6, IFN-& and TNF-', respectively), in comparison to the non-CL wearer subjects (7.42 ± 
5.62 pg/mL, 13.43 ± 8.74 pg/mL, 0.27 ± 0.88 pg/mL and 7.46 ± 8.74 pg/mL for IL-1!, IL-6, 
IFN-& and TNF-', respectively).65 Previously in 2009, Massingale and colleagues had also 
analyzed the expression of IL-1! and TNF-' in the tears of dry eye syndrome patients (non-CL 
wearers) and healthy controls.66 Utilizing a similar microcapillary method as Wei and colleagues 
to collect and pool tear samples, Massingale and colleagues used RT-PCR to analyze mRNA levels 
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of their cytokines of interest, in addition to a Multiplex bead immunoassay to quantify protein 
expression levels.66 As reported by Wei and colleagues, Massingale and colleagues also found 
increased concentrations (reported as mean ± SD), of IL-1!, IL-6 and TNF-' (644.3 ± 148.8 
pg/mL, 1625.7 ± 430.9 pg/mL and 435.7 ± 145.6 pg/mL, respectively), in comparison to healthy 
controls (436.3 ± 116.7 pg/mL, 632.3 ± 167.9 pg/mL and 250.6 ± 63.2 pg/mL, respectively).66 
Further, the same trend was also observed after quantifying levels of cytokines IL-2, IL-4, IL-5, 
IL-8, IL-10 and IFN-&.66 Interestingly, of all the cytokines assayed, the cytokine of highest 
concentration was IL-8, in both healthy controls (16791.4 ± 2841.2 pg/mL) and subjects with dry 
eye (48508.6 ± 9397.3 pg/mL).66  
 In 2014, Yamaguchi and colleagues investigated whether a correlation existed between 
human tear cytokine levels and patients suffering from bacterial keratitis (BK).67 28 healthy 
controls and 26 subjects with unilateral BK (affecting one eye only), were recruited and diluted 
tear samples were collected from both eyes of the healthy controls, as well as from the affected 
eye and unaffected eye of the BK subjects.67 Tears were diluted as sterile saline was injected into 
the inferior conjunctival fornix using a micropipette.67 The following cytokines were quantified 
using a Luminex microbeads immunoassay: IL-1Ra, IL-1!, IL-2, IL-5, IL-6, IL-7, IL-8, IL-10, 
IL-17a, fibroblast growth factor-2 (FGF-2), granulocyte/macrophage colony-stimulating factor 
(GM-CSF), chemokine ligand-2 (CCL-2) and triggering receptor expressed on myeloid cells-1 
(TREM-1).67 Interestingly, there were upregulated levels (mean ± SD) of IL-1!, IL-6 and IL-8 
(66.6 ± 26.8 pg/mL, 7174 ± 2430 pg/mL and 810 ± 315 pg/mL, respectively), in the affected eye 
of BK subjects, in comparison to the eyes of the healthy controls (13.0 ± 4.0 pg/mL, 171.8 ± 32.1 
pg/mL and 56.5 ± 33.8 pg/mL, respectively).67 In contrast, CCL-2, IL-10 and IL-17A appeared to 
be upregulated in the unaffected, contralateral eye of the BK subjects (813 ± 478 pg/mL, 86.7 ± 
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38.3 pg/mL and 3350 ± 881 pg/mL, respectively), in comparison to the eyes of the healthy controls 
(73.7 ± 25.3 pg/mL, 17.5 ± 4.9 pg/mL and 1350 ± 337 pg/mL, respectively).67 Uniquely, TREM-
1 was the only cytokine reported to be upregulated in both the affected and unaffected eyes of the 
BK subjects (551 ± 231 pg/mL) versus healthy controls (31.3 ± 12.4 pg/mL).67  
Similarly, in 2015, Santacruz and colleagues also examined the expression of 
proinflammatory cytokines in the tears of subjects with either gram-positive or gram-negative, 
unilateral BK in comparison to healthy controls.68 For both cases of BK, subjects had upregulated 
levels of IL-1!, IL-6 and IL-8 in the affected eye in comparison to the contralateral, unaffected 
eye, similar to what was reported by Yamaguchi and colleagues.68 Levels of IL-1!, IL-6 and IL-8 
were reported (mean ± SD) as 64 ± 40 pg/mL, 758 ± 1166 pg/mL and >2500 pg/mL, respectively, 
in the case of gram-positive BK subjects and 423 ± 240 pg/mL, 1596 ± 971 pg/mL and >2500 
pg/mL, respectively, in the case of gram-negative BK subjects.68 Levels reported in the unaffected 
eyes were 58 ± 89 pg/mL, 25 ± 17 pg/mL and 420 ± 377 pg/mL, respectively.68 Tears were 
collected using sterile capillary tubes, while cytokines were quantified using a cytometric bead 
assay.68 Likewise to what was reported by Massingale and colleagues, Santacruz and colleagues 
also observed IL-8 (of all cytokines tested), to exist in the highest concentration in tears of both 
normal controls and BK subjects.68  
The presence of proinflammatory cytokines and matrix metalloproteinases (MMPs) in the 
tears of patients with noninfectious corneal ulcers was investigated by Sakimoto and colleagues in 
2014.69 MMPs are zinc-dependent enzymes that can degrade the extracellular matrix and cell 
surface proteins.69 Subjects with noninfectious corneal ulcers within the peripheral cornea, as 
examined via a slit-lamp, were recruited in addition to normal subjects with no corneal ulcers, and 
the tears of all subjects were collected using Schirmer strips.69 A multiplex bead immunoassay was 
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utilized to quantify concentrations of IL-1!, IL-6, TNF-' and MMP-1, MMP-2, MMP-3, MMP-
8, MMP-9, MMP-10 and MMP-13.69 IL-6 and TNF-' mean concentrations in the tears of the 
normal subjects were quantified (mean ± SD), as 17.5 ±	20.3 pg/mL and 8.8 ±	6.2 pg/mL, 
respectively.69 IL-1! was undetectable in this control group.69 In contrast, levels of IL-1!, IL-6 
and TNF-' were upregulated in the tears of corneal ulcer patients and were reported as 377.6 ± 
239.7 pg/mL, 1394 ± 1399 pg/mL and 52.6 ± 59.7 pg/mL, respectively.69 Of the MMPs evaluated, 
while all appeared upregulated in the tears of the corneal ulcer group rather than the control group, 
only levels of MMP-8 and MMP-9 were statistically significant between the two groups.69 MMP-
8 levels were reported as 78.2 ± 19.5 pg/mL and 1523.5 ± 1035.1 pg/mL (mean ± SD) in the 
control and corneal ulcer groups, respectively, while MMP-9 levels were reported as 161.5 ± 19.4 
pg/mL and 1608.5 ± 1051.5 pg/mL in the control and corneal ulcer groups, respectively.69 
Inflammatory cytokines can stimulate the production of MMP-8 from corneal epithelial cells under 
inflammatory conditions and the upregulation of MMP-9 can result in tissue destruction, leading 
to the formation of ulcers.69 Thus, the high levels of proinflammatory cytokine expression and 
overexpression of MMP-8 and MMP-9 observed in the tears of the corneal ulcer group appeared 
to correspond to their condition, as compared to the control group with no signs of ulceration.69 
To assess whether there were any changes to the levels of inflammatory mediators in the 
tears of individuals who routinely wore CLs, González-Pérez and colleagues in 2012 recruited 
subjects for a year-long study which evaluated the tears of CL wearers in comparison to non-CL 
wearers.70 Subjects either wore monthly SiHy lenses (lotrafilcon A), or corneal refractive therapy 
rigid gas permeable lenses (Paragon CRT) on an overnight basis, while control subjects had never 
worn any CLs at all.70 Corneal Refractive Therapy (CRT), also known as overnight 
orthokeratology (Ortho-K), is a procedure whereby reverse geometry contact lenses are worn 
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overnight to help flatten the curvature of the central cornea in a short-term attempt for reducing 
myopia.70 Tear samples were collected using microcapillary tubes and later analyzed through 
ELISA assays for IL-6, IL-8 and MMP-9 concentrations.70 Interestingly, no significant differences 
were found for expression levels of IL-6, IL-8 or MMP-9 between the tears of the SiHy and control 
groups.70 Conversely, levels of all three of these proteins were significantly upregulated in the 
tears of the CRT group in comparison to the control group.70 IL-6 and IL-8 levels were quantified 
as 4.7 ± 1.2 pg/mL and 935.3 ± 254.4 pg/mL, respectively, in the CRT group, 2.6 ±	0.6 pg/mL 
and 659.5 ± 105.1 pg/mL, respectively, in the SiHy group, and 2.2 ± 0.5 and 601.5 ± 72.7, 
respectively, in the control group (all reported as mean ± SD).70 MMP-9 levels were reported in 
ng/mL (mean ± SD) as 74.3 ± 23.0 (CRT), 45.0 ± 7.8 (SiHy) and 39.2 ± 8.3 (control).70  
In 2016, Chao and colleagues also investigated changes in tear cytokine concentrations 
following discontinuation of CL wear.71 They recruited subjects who were habitual wearers of 
either SiHy or conventional CLs (wearing CLs for at least six hours per day, over five days per 
week, for at least one year).71 Tears were collected and pooled from the lateral canthus of each eye 
using glass capillary tubes, once immediately after CL removal on visit 1, as well as on each 
subsequent visit 1-, 2-, 3-, 4- and 7 (±	1) days-post CL removal.71 Levels of IL-1!, IL-1RA, IL-6, 
IL-10, IL-12p70 and TNF-	' were quantified using multiplex bead assays.71 Chao and colleagues 
reported no significant differences in the expression of any of these cytokines in the tears of the 
subjects over the duration of the study post CL removal.71  
Given that tears must inevitably interact with a CL at the ocular surface, the results from 
the studies by González-Pérez and colleagues and Chao and colleagues, suggesting that CL wear 
may not induce any significant changes in tear expression levels of the cytokines of interest, could 
also suggest that minimal interactions (or uptake), exists for these cytokines onto the CL materials 
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tested. Recently, however, in 2019, Chao and colleagues reported absorption of inflammatory 
mediators onto CL materials in an in vitro experiment, upon soaking lenses in individual and 
combined solutions of IL-8, IL-1RA or MMP-9.72 This investigation was not a clinical study; 
rather, comfilcon A, omafilcon A, balafilcon A and etafilcon A were soaked in both 500 pg/mL 
and 100 pg/mL solutions of IL-8, IL-1RA and MMP-9 individually, as well as in 500 pg/mL and 
100 pg/mL combined solutions of all three molecules.72 1:1 2% trifluoroacetic acid:acetonitrile 
was used to extract these inflammatory mediators from the surfaces of the lenses and both the 
extracted concentrations and residual concentrations still remaining on the lenses were quantified 
using ELISA assays.72 The extracted concentrations revealed levels of absorption of each 
inflammatory mediator, while residual concentrations revealed whether or not the mediator 
remained tightly bound to the surface of the lens.72   
In terms of individual solutions, for IL-8 there were no statistical differences in absorption 
between any of the soft lens materials; however, there were greater residual concentrations on 
omafilcon A (336 ± 25 pg/mL) rather than etafilcon A (106 ± 133 pg/mL), only for the 500 pg/mL 
solution.72 At 500 pg/mL, omafilcon A also absorbed more MMP-9 (466 ± 9 pg/mL) than 
balafilcon A (437 ± 11 pg/mL) or etafilcon A (428 ± 13 pg/mL).72 There were no statistical 
differences observed between any of the lenses at individual 100 pg/mL solutions of IL-8 or MMP-
9.72 As well, there were no statistical differences in individual IL-1RA concentrations, either at 
500 pg/mL or 100 pg/mL, for any of the materials.72 Furthermore, there was less residual 
concentration of MMP-9 on etafilcon A (128 ± 22 pg/mL), in comparison to omafilcon A (174 ± 
3 pg/mL), comfilcon A (168 ± 34 pg/mL) and balafilcon A (186 ± 14 pg/mL) contact lens 
materials.72 Analysis of the both 500 pg/mL and 100 pg/mL combined solutions revealed IL-8 to 
be absorbed in the highest concentration onto all of the materials, with etafilcon A demonstrating 
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the greatest absorption.72 Residual concentrations of IL-8, however, in addition to IL-1RA and 
MMP-9 were minimal for all materials, including on etafilcon A, suggesting that these mediators 
did not remain firmly bound to the lens surfaces when combined together.72 
As evident through the literature, there have been many studies investigating the levels of 
inflammatory mediators in the tears of patients who are either CL wearers, exhibit symptoms of 
dry eye or have inflammatory conditions as a result of an infection (bacterial keratitis), or some 
other health condition (corneal ulcers). Many of the investigations within the literature are based 
on clinical studies, where not only can discrepancies exist between the subjects themselves (patient 
variability), but discrepancies can also exist between the methods utilized to quantify these 
mediators.73 For example, a study by Dionne and colleagues in 2016 which aimed to compare 
between two methods of tear inflammatory mediator analysis, Quantibody microarray and 
Luminex assay, found the former to detect more significant differences and more cytokines within 
its range of detection than the latter.73 Furthermore, Dionne and colleagues suggest that differences 
in tear method collection (e.g., microcapillary tubes vs. Schirmer strips), whether or not the tears 
are diluted, how the tears are stored following collection, the time of collection, subtle differences 
in collection techniques by different clinicians, differences in assay protocols including the 
minimum amount of proteins recommended to be used and the limit of detection of the assays, are 
just some of the many discrepancies that can influence the results of a study.73  
 In addition to these factors, consideration may also be given to the half-life of the 
inflammatory markers resulting in some of the large discrepancies that is observed in the literature. 
For example, in the case of IL-1!, IL-6, IL-8 and TNF-', the half-lives of these cytokines in vivo 
are reported in the literature as approximately 3-4 hours74, 1 hour75, < 4 hours76, and 20 minutes77, 
respectively. Thus, depending on the method of tear collection utilized to quantify tear cytokine 
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levels73, or the amount of time in between collection and quantification73, it is possible that 
degradation of the cytokines could occur and hence result in largely variable results to be reported 
by different researchers. Furthermore, in cases where it would appear that there is uptake of these 
cytokines onto biomaterials, if the cytokines begin to quickly degrade due to their half-lives, this 
degradation may interfere with the ability to properly quantify their values and therefore 
incorrectly present as uptake instead. In vivo half-life is highly impacted by the presence of 
proteases in the tear film due to their ability to degrade proteins.9,69,78 The in vitro studies to be 
presented in this thesis did not incorporate proteases.  
As evident from above and as outlined in Table 3-3 for cytokines IL-1!, IL-6, IL-8 and 
TNF-', there is no standard level of cytokine expression that should be measured within tears, but 
rather a large range exists. As many of the studies in the literature are clinical studies, the aim of 
this thesis was to investigate the inherent properties of various CL materials solely through in vitro 
experiments, in order to determine whether these materials intrinsically allow for the uptake of 
cytokines, with no potential interference from patient variability, as in in vivo investigations.   
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Chapter 3: Introduction - Thesis Rationale 
3.1 Objectives 
It was important to understand whether conventional hydrogels and SiHy contact lens 
materials could uptake and deposit inflammatory proteins, namely cytokines, onto their lens 
surface, as this would provide tremendous insight into the interaction of inflammatory proteins 
with CL materials and its potential effects such as contact lens discomfort. The aim of this thesis 
was to investigate various types of CL materials to find one that exhibited substantial uptake of 
proinflammatory cytokines, acting as a reservoir for these inflammatory markers, in the context of 
inflammatory ocular conditions such as DES or allergies, where the CL could be utilized as an 
application to an over-reactive immune system. Depending on the amount of uptake and wear 
modality of the lens, the CL could aid in dampening the immune response (daily lens wear), 
without causing collateral damage to the ocular tissue, as the inflammatory markers would be 
removed from the ocular surface by the end of the day. In contrast, the CL could further facilitate 
an immune response (reusable lens wear), as the inflammatory markers linger on the lens surface 
and continue to interact with the ocular surface. The purpose of this work was to, in part, help 
address issues surrounding DES and CLD. To our knowledge, data in the literature does not exist 
where the uptake of cytokines onto conventional hydrogels and SiHy contact lens materials has 
been quantified through electrochemiluminescence and compared.  
3.2 Cytokines of Interest 
The cytokines of interest evaluated in this thesis were IL-1!, IL-6, IL-8, and TNF-'. These 
cytokines were chosen because elevated levels of all of these four cytokines have been observed 
in dry eye syndrome patients.16,22 Furthermore, IL-1! is a potent proinflammatory cytokine that 
has the highest potential of initiating ocular inflammation.16,22 It is induced by TNF-' and 
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upregulates IL-6 and IL-8.16,17 Additionally, three of these cytokines, IL-1!, IL-8 and TNF-' are 
secreted by the two major signaling pathways, MAPK and NF-*B, that exist within corneal and 
conjunctival epithelial cells.18,61 As previously described, there are other cytokines that are 
important to the development and maintenance of inflammation within the eye; however, the four 
cytokines chosen seemed to be more universally present in a variety of inflammatory conditions.  
As mentioned above, IL-1! is a potent proinflammatory cytokine that is important for 
initiating a host-defense response in cases of infection or injury.79 Of the other cytokines within 
the IL-1 family, IL-1! was chosen as it is widely studied in the literature and appears to be the 
best characterized cytokine of its family.79 A variety of cells are capable of producing and secreting 
IL-1!, including the monocytes and macrophages of the immune system.79 The production of IL-
1! begins through a priming step that produces the inactive precursor, pro-IL-1!, upon recognition 
of PAMPs by PRRs on the surface of the appropriate cell.79 As noted previously in section 1.2.3, 
macrophages, dendritic cells and neutrophils are sensor cells that express PRRs.9 Following this 
step, interactions between a cytosolic PRR, an adapter molecule and pro-caspase-1, results in the 
formation of a multi-protein complex known as an inflammasome, which activates the protease 
caspase-1 that cleaves pro-IL-1! into its mature form (IL-1!).79 IL-1! can secrete from the cell in 
a quick manner, however, the mechanism of its secretion does not follow a conventional route, as 
this cytokine lacks a signal sequence.79 Typically, proteins are secreted through an endo-membrane 
system formed by the endoplasmic reticulum and Golgi apparatus.79 This process involves 
recognition of the signal sequence by a signal recognition particle, translocation of the protein into 
the endoplasmic reticulum lumen and trafficking of the protein through the endoplasmic reticulum 
and Golgi apparatus until the extracellular destination is reached.79 Lopez-Castejon and colleagues, 
however, suggest that due to lacking a signal sequence, IL-1! is instead secreted through various 
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routes that depend on both the strength of the inflammatory stimulus and the levels of extracellular 
IL-1! required to support an inflammatory response that is effective.79 Lopez-Castejon and 
colleagues have recently proposed three mechanisms of IL-1! secretion, named, “Rescue and 
Direct”, “Protected Release” and “Terminal Release”.79 
The first mechanism, “Rescue and Direct”, involves an appropriate secretion stimulus to 
redirect IL-1! localized to vesicles (and therefore subject to degradation), back into the 
extracellular space.79 Since only a small fraction of IL-1! is typically localized to vesicles, this 
mechanism is proposed to occur either when there is little extracellular demand for IL-1!, or as a 
supplement to extracellular IL-1! that is secreted through other mechanisms.79 The second 
mechanism, “Protected Release”, involves either the release of IL-1! from the shedding of plasma 
membrane microvesicles (100-600 nm), or secretion from exosomes (small vesicles, 50-80 nm).79 
IL-1! in microvesicles is bioactive and has been shown in the literature to release upon contact 
with cells expressing IL-1RI receptor.79 Additionally, there is evidence in the literature to suggest 
that the microvesicles shed from dendritic cells contain IL-1! and caspase-1, and will release these 
proteins upon ATP stimulation, thereby providing a mechanism for eliciting an inflammatory 
response at target sites distant from the site of inflammation.79 Secretion of IL-1! from exosomes 
also allows for signaling processes to occur at distant sites, as exosomes, in addition to shed 
microvesicles from antigen-presenting cells, have been shown to also contain MHC II molecules.79 
The third mechanism, “Terminal Release”, is proposed to occur only when there is extreme 
inflammatory stress and once the cell is committed to apoptosis.79 In this case, large quantities of 
active IL-1! is rapidly secreted across the disintegrating plasma membrane.79  
IL-6 is a pleiotrophic cytokine.80 During inflammation, it is first synthesized within the 
local lesion but can quickly move through the bloodstream into the liver, where it can induce the 
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synthesis of various proteins including C-reactive protein, serum amyloid A, fibrinogen, 
haptoglobin and '1-antichymotrypsin, while lowering the production of fibronectin, albumin and 
transferrin molecules.80 As IL-6 reaches the bone marrow, it induces the maturation of 
megakaryocytes, leading to thrombocytosis, as a result of the release of platelets.80 IL-6 plays an 
important role in both the innate and adaptive immune systems.80 In conjunction with TGF-!, IL-
6 can promote the differentiation of naïve CD4+ T cells into Th17 cells, while simultaneously 
inhibiting TGF-!-induced Treg differentiation.80 As noted previously, one cytokine produced by 
Th17 cells is IL-17, which has been identified in severe ocular allergies, in addition to other 
inflammatory diseases of the ocular surface including dry eye syndrome and uveitis.22,23 
Upregulation of this Th17/Treg balance by IL-6 is known to disrupt immunological tolerance and 
lead to autoimmune or chronic inflammatory diseases.80 In contrast, IL-6 also induces both the 
differentiation of naïve CD8+ T cells into cytotoxic T cells and B cells into plasma cells that 
produce antibodies.80 Recall, CD8 T cells selectively recognize MHC class I-bound peptides, 
which commonly present peptides from viruses to CD8 T cells, while plasma cells secrete 
antibodies that target and destroy an antigen.9 The stimulation of NF-*B signaling pathway, which 
occurs upon recognition of PAMPs by PRRs, will enhance mRNA transcription of IL-6 (in 
addition to IL-1! and TNF-').80  
The transcription factor NF-*B is also an important element of IL-8 expression.81 
Typically, in an unstimulated cell, deacetylation of histones, active repression of NF-*B by NF-
*B repressing factor, and the binding of octamer-1, allow the transcription of the IL-8 gene 
(CXCL8) to remain repressed.81 NF-*B, activating protein (AP-1) and CCAAT/enhancer-binding 
protein beta (C/EBP!), are binding sites of the IL-8 promoter element. In the cell cytoplasm, NF-
*B is stored in an inactivated form due to the binding of I*B' and I*B! inhibitory proteins.81 
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During stress, two I*B kinases known as IKK'/! and IKK&/Nemo, will phosphorylate the I*B 
proteins and result in the activation of NF-*B.81 The inhibitory proteins are quickly degraded and 
NF-*B will translocate to the cell nucleus where it can bind the CXCL8 promoter.81 AP-1 and 
C/EBP! synergize with NF-*B to ensure optimum expression of CXCL8.81 
Like IL-6, TNF-' is also a pleiotropic cytokine that is produced by a variety of different 
cell types, although the primary synthesizers of TNF-' are cells of the monocytic lineage.82 TNF 
receptor 1 (TNFR1) and TNF receptor 2 (TNFR2) are the two transmembrane receptors through 
which TNF-' acts.82 The former is expressed in all mammalian tissue in a constitutive manner, 
while the expression of the latter is highly regulated and tends to only be expressed in immune 
cells.82 TNF-' has high affinity for both receptors, though its binding onto TNFR1 is an 
irreversible mechanism, while its binding onto TNFR2 involves rapid binding and dissociation.82 
In fact, in some cells, TNFR2 may be regarded as a ligand passer to TNFR1, which acts to increase 
local concentrations of TNF-'.82 In response to an inflammatory signal, matrix metalloproteinases 
cleave TNFR1 and TNFR2 from the cell surface.82 Most cellular responses to TNF-' are due to 
activation of TNFR1, including cytotoxicity, cell growth, upregulation of both adhesion and 
cytokine genes, as well as activation of NF-*B.82 In contrast, while TNFR2 may also be important 
for cytotoxicity and NF-*B activation, activation of this receptor is mainly responsible for the 
proliferation of lymphoid cells.82 Like IL-1!, TNF-' is also a potent proinflammatory cytokine 
that appears to also be an early mediator present in abundance during inflammation.82 As outlined 
in Table 3-1 below, TNF-' can induce the production of IL-1!, among other proinflammatory 
cytokines and for this reason, it is regarded as a “master regulator”.16,17,82 PRRs such as TLRs can 
induce macrophages to produce TNF-', which can in turn further activate macrophages.82 TNF-' 
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signalling is also important to processes such as cell proliferation, differentiation, survival and 
apoptosis.82 
Table 3-1 briefly summarizes a few of the interactions existing between the cytokines of 
interest. Table 3-2 provides information in regard to their size, isoelectric point (pI), and other 
ocular conditions in which these cytokines may be upregulated. Isoelectric point refers to the pH 
of a solution where there is no net charge on the protein.83 The surface of a protein will be 
predominately positively charged if the pI of the protein is above the pH of the solution (pI > pH).83 
In contrast, the surface of a protein will be predominately negatively charged if the pI of a protein 
is below the pH of the solution (pI < pH).83  
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Key initiator in ocular inflammation and induces IL-1β.16,17 
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Table 3-2: Size (kDa) and Isoelectric Points of the Cytokines of Interest, Ocular Conditions 
They Pertain To 
 
The basal levels of these cytokines (pg/mL) observed in normal patients, as well as elevated 
levels during CL wear or inflammatory conditions, as reported in the literature, are summarized in 
Table 3-3 below. As evident from the discrepancy in the numbers, there seems to exist a large 
degree of variability in the measured levels, and a consistent or specific quantity of these cytokines 
does not appear to exist among different individuals. Given that this broad range exists in the 
literature, there is no single concentration for the cytokines of interest that is recognized as an ideal 
concentration to investigate for uptake onto contact lens materials. This does not, however, negate 
the objectives of this thesis and what was aimed to be measured. Thus, concentrations utilized for 
the uptake experiments presented in this thesis were chosen to represent all of low, moderate and 
high concentrations, ranging from as low as 2.36 pg/mL to as high as 10,047 pg/mL.  
Additionally, it is important to note that individuals may have varying cytokine thresholds 
for what they deem to be “comfortable” and that while there exists a basal level of these cytokines 
within the eye, these basal levels may vary between an individual who wears contact lenses and 
another individual who does not.64-70,93-95  
 






6.9 - 7.085 
Uveitis16, proliferative diabetic retinopathy 






4.986, 5.0 - 6.087 














5.0 - 7.091, 5.392 
Dry eye syndrome22, uveal melanoma88, 
PDR, DME16 
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Table 3-3: Basal Levels of Cytokines (pg/mL) Reported in the Literature for Normal 
Patients versus Levels Reported for Contact Lens (CL) Wearers (including SiHys), and 
Patients with Dry Eye Syndrome (DES), Bacterial Keratitis (BK) or Corneal Ulcers (CU). 
 
3.3 The Contact Lenses of Interest and their Lens Chemistry  
 Overall, ten commercially-available contact lenses were utilized throughout the work 
presented in this thesis and among them, eight different types of soft lens materials were used 
collectively. The United States Adopted Name (USAN) of these materials are etafilcon A, 
omafilcon A, polymacon A (all conventional hydrogels), and balafilcon A, comfilcon A, delefilcon 
A and senofilcon A (all SiHy lenses). The proprietary names of the lenses used are: 1-Day Acuvue® 
Moist (etafilcon A), Acuvue® 2 (etafilcon A), Proclear® 1 Day (omafilcon A), SofLens® 38 
(polymacon A), PureVision® (balafilcon A), Biofinity® (comfilcon A), Dailies Total1® (delefilcon 
A), Acuvue Oasys® 1-Day with HydraLuxe™ Technology (senofilcon A), Acuvue Oasys® 2-week 
with Hydraclear® Plus (senofilcon A) and Clariti™ 1 Day (somofilcon A). Full specifications for 
the contact lenses of interest are outlined in Table 3-4 below. 
 The contact lenses were chosen from three of the five FDA classes of contact lens materials. 
Three conventional hydrogels were chosen from FDA groups I, II and IV, covering those of low 
Cytokine Basal Levels (pg/mL) CL, DES, BK, CU Levels (pg/mL) 
IL-1β 7.42±5.6265, 12.9±2.364, 13.0±4.067, 
58±8968, 436.3±116.766 
 
15.56±12.94 (CL)65, 66.6±26.8 (BK)67,  
377.6±239.7 (CU)69, 664.3±148.8 (DES)66 
IL-6 2.2±0.570, 13.43±8.7465, 17.5±20.369, 
25±1768, 100-40093, 171.8±32.167, 
226.2±29.664, 632.3±167.966, 731.4 ± 
116.294 
2.6±0.6 (SiHy CL)70, 14.86±0.19 (CL)65 
1394±1399 (CU)69, 1625.7±430.9 
(DES)66, 7174±2430 (BK)67 
IL-8 56.5±33.867, 420±37768, 
601.5±72.770, 731.4±116.264, 
16,791.4±2,841.266 
14.82±15.8 (CL)65, 659.5±105.1 (SiHy 
CL)70, 810±315 (BK)67, 48,508.6±9,397.3 
(DES)66 
TNF-α 7.46±8.7465, 8.8±6.269, 14±768, 
250.6±63.2l66 
52.6±59.7 (CU)69, 435.7±145.6 (DES)66 
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water content/nonionic, high water content/nonionic and high water content/ionic properties 
(Table 2-1).55 Further, these materials had previously been utilized in the literature for 
investigating protein and lipid deposition on contact lenses.58-60 No contact lenses were chosen 
from FDA group III (conventional), as the only commercially-available contact lens of a low water 
content/ionic property is Metrosoft (deltafilcon A), which is not commonly used. Instead, for a 
low water content/ionic lens, SiHy material balafilcon A (group V) was chosen due to this lens 
already having shown protein deposition based on investigations within the literature.55,58 
Balafilcon A is within subgroup D of the SiHy lenses (FDA group V), and SiHy lenses from group 
V subgroups B-1, B-2 and C were chosen as well (Refer to Table 2-2 and Table 3-4).55  
 In addition to CLD, soft contact lens wear can also be accompanied by the risk of corneal 
infiltrative events (CIEs).96 CIEs are inflammatory events of the cornea which include, but are not 
limited to: microbial keratitis, infiltrative keratitis (including asymptomatic infiltrative keratitis), 
or contact lens-induced acute red eye.96 There is evidence within the literature suggesting that the 
use of reusable silicone hydrogel contact lens materials will increase the risk of CIEs by two-fold 
in comparison to lower oxygen permeability, poly-HEMA-based conventional hydrogel 
materials.96,97 Furthermore, when comparing reusable lenses to daily disposable ones, some studies 
have reported up to a 12.5-fold increased risk of CIEs associated with the use of reusable 
lenses.96,97 Thus, the use of daily disposable contact lenses could potentially reduce this risk, as 
demonstrated by one study which found a low rate of CIEs at 0.4% per year for daily disposable 
silicone hydrogels and 0% per year for daily disposable conventional hydrogels, while a rate of 
3.3% to 10.7% was associated with reusable lens wear.96  
With the above taken into consideration, as well as the greater risk associated with silicone 
hydrogel materials for CIEs, it was important to incorporate both reusable and daily disposable 
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silicone hydrogel lenses in the studies performed. Of the conventional lenses chosen, 1-Day 
Acuvue Moist and Proclear 1 Day are designed for daily disposable lens wear, while SofLens 38 
is designed for reusable lens wear. Of the SiHy lenses chosen, Dailies Total1, Acuvue Oasys 1-
Day with HydraLuxe Technology and Clariti 1 Day are designed for daily disposable lens wear, 
while PureVision and Biofinity are reusable lenses that are typically replaced after one month of 
use. It was important to have a wide variety of contact lens materials to not only maximize the 
number of different materials on which inflammatory marker uptake could be studied, but to also 
investigate uptake under different wear modalities. In fact, in order to investigate whether any 
differences existed between two lenses of the same material but different wear modalities (i.e., 
effect of thickness differences between daily wear or resuable wear contact lens materials), Acuvue 
2 (conventional, etafilcon A material) and Acuvue Oasys 2-week with Hydraclear Plus (SiHy, 
senofilcon A material), were added for comparisons with 1-Day Acuvue Moist (conventional, 
etafilcon A material) and Acuvue Oasys 1-Day with HydraLuxe Technology (SiHy, senofilcon A 
material).  
3.4 Hypothesis  
Commercially-available contact lens materials were investigated for the continuous uptake 
of proinflammatory cytokines IL-1!, IL-6, IL-8 and TNF-'. It was hypothesized that the lenses 
evaluated would exhibit deposition of these cytokines onto their surface, as measured through 
electrochemiluminescence (pg/mL), comparable to the deposition of other proteins as reported in 
the literature. The properties of all lenses utilized throughout this thesis are specified in Table 3-4.
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Table 3-4: Specifications for Contact Lenses of Interest55,59,98-100
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Chapter 4: Materials and Methods 
4.1 Preface 
This chapter will outline any materials and methods common to all experiments presented 
within this thesis. Any materials, methods, or concentrations specific to an individual experiment 
will be discussed where appropriate in the subsequent chapters.  
4.2 List of Contact Lenses Investigated in All Experiments  
 The following is a list of all contact lenses utilized throughout the experiments in this 
thesis: 1-Day Acuvue® Moist (Johnson & Johnson, Jacksonville, FL); Acuvue® 2 (Johnson & 
Johnson, Jacksonville, FL); Acuvue Oasys® 1-Day with HydraLuxe™ Technology (Johnson & 
Johnson, Jacksonville, FL); Acuvue Oasys® 2-week with Hydraclear® Plus (Johnson & Johnson, 
Jacksonville, FL); Biofinity® (CooperVision, Lake Forest, CA); Clariti™ 1 Day (CooperVision, 
Lake Forest, CA); Dailies Total1® (Alcon, Fort Worth, TX); Proclear® 1 Day (CooperVision, Lake 
Forest, CA); PureVision® (Bausch + Lomb, Rochester, NY) and SofLens® 38 (Bausch + Lomb, 
Rochester, NY). The specifications of these lenses are reported in Table 3-4.   
4.3 A Simplified, General Outline of the Experimental Design 
 For all experiments utilizing contact lenses, the lenses were first rinsed to remove any 
residual packaging solution. This involved two 20-minute soaks in phosphate-buffered saline 
(PBS) solution (Lonza BioWhittaker, Walkersville, MD), followed by a third soak overnight 
(between 12-24 hours). Each lens was placed in an individual well of a Costar 12-well polystyrene 
plate (Corning, Corning, NY) containing 4 mL of PBS per well and in between each soak, the 
existing PBS solution was pipetted out and replaced with fresh PBS solution. The plates were 
placed on a VWR Advanced 3500 orbital shaker (VWR International, Radnor, PA) to ensure a 
dynamic environment.    
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 Following this, all contact lenses were dried on Fisherbrand lens paper (Fisher Scientific, 
Hampton, NH) and were placed, along with any other autoclaved, sterile membranes (if 
applicable), in a cytokine solution prepared from the Meso Scale Discovery (MSD) 
Proinflammatory Panel I Human Calibrator Blend in Diluent 2 (Meso Scale Diagnostics, LLC, 
Rockville, MD). Drying the contact lenses was a necessary step for preventing any excess liquid 
on the lens surfaces from interfering with the concentration of the prepared cytokine solution. The 
calibrator blends used were the same as that provided in the assay kit utilized for all experiments: 
The V-PLEX® Human Proinflammatory Panel II (4-plex) assay kit (Meso Scale Diagnostics, LLC, 
Rockville, MD), where the calibrator blend generates the standard curves for the cytokines of 
interest. Although the MSD® calibrator blend is a lyophilized blend of ten different cytokines (see 
section 4.4), of which only four were tested in the thesis experiments, it was utilized in order to 
better model ocular conditions, as a variety of different cytokines are found within the eye, and 
therefore the four cytokines of interest would not be found in isolation.  
 Samples were collected at desired time points and stored within 0.6 mL Axygen microtubes 
(Axygen, Inc, Union City, CA) in a -80℃ freezer until the concentration of the four cytokines of 
interest could be analyzed with the MSD assay. For cost purposes, samples were not analyzed until 
a total of thirty-seven samples were collected to fill an entire 96-well MSD assay plate (samples 
were run in duplicates – refer to Table 4-3).  A general summary of the experimental design is 
provided in Figure 4-1 below. 
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Figure 4-1: Experimental Design. 
 
 
4.4 Components of the V-PLEX Human Proinflammatory Panel II (4-plex) Assay Kit 
 
The Meso Scale Discovery MESO® QuickPlex Imager (Meso Scale Diagnostics, LLC, 
Rockville, MD) and commercially-available assay kit (V-PLEX Human Proinflammatory Panel II 
(4-plex) kit), were used as the basis for quantifying the uptake of cytokines onto biomaterials. This 
assay is specific to the quantification of the four cytokines of interest, IL-1", IL-6, IL-8, and TNF-
#, hence the name “4-plex”. There are seven components to this kit, as outlined below. 
1. Proinflammatory Panel 1 (human) Calibrator Blend: A lyophilized blend of ten 
cytokines of known concentration used for generating a standard curve signal for each 
cytokine of interest. This signal is given as electrochemiluminescence (ECL) vs. 
picogram/milliliter (pg/mL). The ten cytokines within this blend are IFN-$, IL-1", IL-2, 
IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13 and TNF-#. Depending on the specific lot of each 
calibrator blend supplied, there is a slight variation between the concentrations of each 
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cytokine once reconstituted, however, sample concentrations are provided in Table 4-1 to 
outline the general range of concentration for each cytokine. 
2. Proinflammatory Panel 1 (human) Controls 1, 2, 3: A set of three lyophilized controls, 
containing a blend of cytokines at known concentrations (pg/mL). These controls are used 
for validating the generated standard curves. By preparing the controls and obtaining a 
concentration reading using the MESO QuickPlex® Imager, a percent recovery is 
calculated by the MSD software, which indicates the accuracy of the generated standard 
curves. Similar to the calibrator blend, there is slight variation in the concentrations of the 
cytokines within each reconstituted control; however, sample concentrations are provided 
in Table 4-2. Note that each succeeding control has lower concentrations than the preceding 
one.   
3. Diluent 2: A proprietary PBS-based solution used for reconstituting the calibrator blend 
and the controls, as well as diluting the samples to be analyzed. According to Meso Scale 
Discovery Scientific Support, Diluent 2 also contains fetal bovine serum, bovine serum 
albumin (stabilizer), sodium chloride (salt), animal IgG, and small amounts of background 
lowering agents and blocking agents.  
4. Diluent 3: A proprietary solution for preparing the detection antibody solution.  
5. Detection Antibodies: Anti-human IL-1", IL-6, IL-8 and TNF-# antibodies, each 
conjugated with an electrochemiluminescent label (MSD SULFO-TAG™ reagent).  
6. Wash Buffer: Used to wash the plate prior to adding samples, antibodies and read buffer. 




According to Meso Scale Discovery Scientific Support, while half-life studies have not been 
performed on the cytokines lyophilized in the MSD calibrator blend and MSD controls, 
appropriate tests have been conducted for these proteins to confirm that they do not significantly 
change before their expiration dates. Thus, all materials utilized for the experiments presented in 
this thesis were fresh materials used within their expiration date, and appropriate experimental 
controls were incorporated into the study design to account for any potential changes in activity 
over the study periods. Additionally, the MSD Diluent 2 that is utilized for reconstituting the MSD 
calibrator blend and the MSD controls, contains stabilizers such as bovine serum albumin. Serum 
albumin may aid in extending the stability of the cytokines.101  
 
Table 4-1: Sample Concentrations (pg/mL) of Cytokines in MSD Lyophilized Calibrator 
Blend When Reconstituted in 1 mL Diluent 2, as Obtained from a Certificate of Analysis. 


















Table 4-2: Sample Concentrations (pg/mL) of Cytokines in MSD Lyophilized Controls 1, 2 
and 3 When Reconstituted in 1 mL Diluent 2, as Obtained from a Certificate of Analysis.  









IFN-' 682 155 52.3 
IL-1( 215 50.4 11.0 
IL-2 431 41.2 3.83 
IL-4 101 20.1 2.88 
IL-6 275 41.2 9.03 
IL-8 223 36.9 5.91 
IL-10 133 23.3 3.61 
IL-12p70 168 34.0 6.12 
IL-13 150 46.4 12.3 
TNF-) 89.6 16.0 2.72 
 
4.5 The Basis of the MSD Assay: Sandwich Immunoassays and Electrochemiluminescence  
 The Meso Scale Discovery assay utilizes the concepts of sandwich immunoassays and 
electrochemiluminescence to quantify the concentration of various cytokines in a solution. The 
specific protocol for the assay was followed as per the manufacturer’s guidelines; however, there 
were three overall main steps to the assay that allowed the analytes within a sample to become 
sandwiched between a capture antibody and a detection antibody – hence the term “sandwich 
immunoassay”.102   
 Each well of the 96-well MSD plate that comes standard in the assay kit has a working 
electrode – hence “electro-”, which is pre-coated with ten capture antibodies on independent, well-
defined spots.102 Initially, prior to the addition of the samples to the wells, the plate is washed with 
the MSD wash buffer. Although this is not an essential step, it is recommended in order to ensure 
uniformity of results.102 Upon the addition of the samples to the wells of the plate, the analytes 
bind the capture antibodies that are immobilized on the working electrode surface within each 
well.102,103 During the second step, the plate is washed and a solution of the detection antibodies is 
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prepared using Diluent 3 and added to the wells of the plate.102,103 These detection antibodies are 
conjugated with an electrochemiluminescent label, the MSD SULFO-TAG reagent, which also 
binds the analyte, completing the sandwich.102,103 As the plate is washed for the third time and the 
MSD read buffer is added to the wells, the proper chemical environment, hence “chemi-”, is 
created for the plate to be read, and the data to be analyzed, using the MESO QuickPlex 
Imager.102,103  
The MSD read buffer contains tripropylamine (TPA) and the MSD SULFO-TAG reagent 
contains Ru(bpy)32+, both of which become oxidized to TPA•+ and Ru(bpy)33+, respectively.103,104 
TPA•+ then will be reduced to TPA•, which is a highly active radical, capable of reducing 
Ru(bpy)33+ to excited state *Ru(bpy)32+.102,103 *Ru(bpy)32+
 will drop to a lower energy state and 
emit light, hence “luminescence”, which can then be measured as an electrochemiluminescent 
signal (ECL signal), that is used to quantify the concentration of cytokines in solution.103,104  
4.6 Validation of the MSD Assay and Creating the Plate Map 
During each MSD assay, four individual standard curves are generated for the cytokines of 
interest using the lyophilized MSD calibrator blend (“Calibrator 1”). A sample standard curve for 
IL-8 is given in Figure 4-2 below, although the standard curves for the remaining cytokines also 
follow a similar trend. Calibrator 1 is the highest calibrator concentration and it is used to prepare 
seven subsequent calibrator solutions through 4-fold serial dilutions. “Calibrator 8” is the zero 
calibrator and only contains a volume of Diluent 2 (with no cytokines). The cytokine 
concentrations to be chosen for testing uptake onto contact lenses or other membranes must fall 
within the range of the standard curve for each cytokine in order to be quantifiable.  
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Figure 4-2: A Sample MSD Assay Standard Curve for IL-8, as Obtained from an Experiment. 
 
The MSD controls are used to validate the standard curves generated. Each control has a 
known concentration of cytokines that are also measured by the MESO QuickPlex Imager. A 
percent recovery for each cytokine is calculated by the software, based on the cytokine 
concentrations measured from the controls and the cytokine concentrations measured from the 
standard curves generated with the calibrator solutions. In this way, the controls can provide 
insight into the accuracy of the generated standard curves, which in turn provides information in 
regard to the accuracy of the calculated cytokine concentrations in the unknowns (samples).  
The eight calibrator solutions, three control solutions and samples are added to the wells 
of the MSD plate in duplicates, as outlined in Table 4-3. Up to thirty-seven samples can be 
measured at one time in order to fill the 96-well plate, however, this number varies depending on 
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if replicates are to be tested for a sample (e.g., n = 3 or n = 4). The MSD software calculates a 
cytokine concentration for each well and then averages the concentrations for duplicate wells to 
give a mean calculated concentration.  
Table 4-3: Sample Plate Map for MSD Assay Plate Including Calibrators (“Cal”), Controls 
(“Cntrl”) and Samples (“S”), Measured in Duplicates.  
 1 2 3 4 5 6 7 8 9 10 11 12 
A Cal 1 Cal 1 Cntrl 1 Cntrl 1 S6 S6 S14 S14 S22 S22 S30 S30 
B Cal 2 Cal 2 Cntrl 2 Cntrl 2 S7 S7 S15 S15 S23 S23 S31 S31 
C Cal 3 Cal 3 Cntrl 3 Cntrl 3 S8 S8 S16 S16 S24 S24 S32 S32 
D Cal 4 Cal 4 S1 S1 S9 S9 S17 S17 S25 S25 S33 S33 
E Cal 5 Cal 5 S2 S2 S10 S10 S18 S18 S26 S26 S34 S34 
F Cal 6 Cal 6 S3 S3 S11 S11 S19 S19 S27 S27 S35 S35 
G Cal 7 Cal 7 S4 S4 S12 S12 S20 S20 S28 S28 S36 S36 
H Cal 8 Cal 8 S5 S5 S13 S13 S21 S21 S29 S29 S37 S37 
 
4.7 The Sensitivity of the MSD Assay  
 While running an MSD assay, it is important to be considerate of the lower limit of 
quantification (LLOQ) and upper limit of quantification (ULOQ) for each cytokine. These values 
are outlined in Table 4-4 below. Typically, samples are diluted 2-fold with Diluent 2 prior to being 
pipetted onto the plate, to ensure that the concentrations of the cytokines, though unknown, will 
fall within the LLOQ and ULOQ. The dilution factor is inputted into the MSD software such that 
it is taken into account for the concentration calculations. If the values calculated fall outside of 
the detection range, results cannot be assumed to be accurate and the assay would have to be 




Table 4-4: Lower Limit of Quantification (LLOQ) and Upper Limit of Quantification 
(ULOQ) in pg/mL for All Cytokines Included in the V-PLEX Human Proinflammatory 
Panel II (4-plex) Kit, as of 2018.102 
Cytokine LLOQ (pg/mL) ULOQ (pg/mL) 
IFN-' 1.76 938 
IL-1( 0.646 375 
IL-2 0.890 938 
IL-4 0.218 158 
IL-6 0.633 488 
IL-8 0.591 375 
IL-10 0.298 233 
IL-12p70 1.22 315 
IL-13 4.21 353 
TNF-) 0.690 248 
 
4.8 Method of Data Analysis and Presentation 
 All data was normalized, graphed, and statistically analyzed using GraphPad Prism V6 
software (GraphPad Software Inc., San Diego, CA). Details of the specific statistical analyses 
performed will be given in the results sections of subsequent chapters. Most of the data presented 
throughout the thesis is graphed as a percentage of uptake normalized to control values for each 
time point. The amount of uptake was determined by quantifying cytokine concentrations 
remaining in solution at specific time points for samples containing either a contact lens and/or 
another material (excluding controls), and normalizing these values to the cytokine concentrations 
measured for the control samples at that time point, which were set at 100%. Thus, the method of 
data collection is through the use of a subtractive assay, in that the amounts quoted relative to the 
100% control reflect the values remaining in the solution, while any difference is surmised to have 
been taken up onto the surface of the materials of interest. 
All data is graphed as mean ± SD of percent pg/mL in solution as normalized to controls. 
To interpret these graphs, a value of 100% would indicate no uptake, while any values falling 
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lower than 100% could indicate little to significant amounts of uptake, depending on the exact 
percentage and the statistics in comparison to the control. In certain instances, some sample values 
were calculated to be above 100% of the control, depending on the magnitude of variation that 
existed between the absolute values, as these differences translated to larger differences in the 
percent of control on a picogram scale (especially for smaller absolute values). For example, given 
a control value of 100 pg and a sample value of 101 pg, or a control value of 10 pg and a sample 
value of 10.1 pg, in both cases the sample values would be 101% (1% difference from the control 
that is set at 100%), even though there is a 1 pg difference in the case of the former and only a 0.1 
pg difference in the case of the latter. In another example, if the average absolute value for a control 
is 15.21 pg and for a biomaterial is 15.94 pg, this is the difference of 0.73 pg (where a picogram 
is a factor of 10-12 of a gram), however, the percent of control for the biomaterial would be 104%, 
which is higher than the control that is set to 100%. This does not necessarily indicate that the 
biomaterials are eluting a component into the solution that is mimicking cytokines, or that there 




Chapter 5: Method Optimization 
5.1 A Survey of Different Biomaterials  
5.1.1 Introduction: Pilot Study #1  
 Initially, it was unknown whether contact lenses would exhibit uptake of cytokines or how 
the experimental design could be optimized to ensure maximum uptake (if any). To our 
knowledge, no studies exist in the literature where the MSD assay has been utilized to investigate 
the inherent property of an unworn contact lens for cytokine uptake. As such, a variety of 
biomaterials, including contact lenses, were surveyed in a pilot study.  
 The pilot study investigated the uptake of cytokines IL-1", IL-6, IL-8 and TNF-# onto 
silicone sheeting, cotton, gauze and filter paper membranes, in addition to etafilcon A, delefilcon 
A, omafilcon A and senofilcon A contact lens materials. Silicone sheeting was chosen due to the 
incorporation of silicone in SiHy lenses and in other synthetic biomaterials, such as the use of 
silicone rubber in cardiac pacemakers.41,105 Cotton and gauze were chosen as they are utilized in a 
wide array of medical applications. Filter paper was chosen as it is slightly liquid absorbent, readily 
available, and has been used in the literature for spotting blood and later analyzing the dried blood 
sample for inflammatory markers.106  
 Senofilcon A (Acuvue Oasys 1-Day with HydraLuxe Technology), delefilcon A (Dailies 
Total1), etafilcon A (1-Day Acuvue Moist) and omafilcon A (Proclear 1 Day), were chosen as two 
SiHy and two conventional hydrogel materials, respectively, to be studied. The rationale behind 
choosing these materials was to utilize ones that had previously shown potential for uptake of 
Levofloxacin antibiotic in solution (data not shown). It was hypothesized that if these contact lens 
materials could exhibit drug uptake, then they could potentially uptake cytokines as well. 
Furthermore, evidence of protein deposition onto etafilcon A and omafilcon A was reported in the 
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literature, and since cytokines are small proteins, these materials were specifically incorporated in 
the pilot study.59  
5.1.2 Materials and Methods: Pilot Study #1 
The silicone sheeting (Specialty Manufacturing Inc., Saginaw, MI), Whatman filter paper 
(Sigma-Aldrich, St. Louis, MO) and Millipore filter paper (Sigma-Aldrich, St. Louis, MO), were 
cut into 10.5 mm pieces using a circular lens punch. The cotton was cut from the tips of Puritan 3-
inch cotton tip applicators (Hardwood Products Company, Guilford, ME), and the gauze rolls 
(Wasip Ltd., Toronto, ON) were cut into 5 mm x 5 mm squares. All materials were autoclaved 
(except the contact lenses which come in sterile blister packs), and the contact lenses were soaked 
in PBS, as described in section 4.3. The cytokine solution was prepared from the MSD calibrator 
blend, as also described in section 4.3, except PBS was utilized rather than Diluent 2. The solution 
contained IL-1", IL-6, IL-8 and TNF-# at concentrations of 19 pg/mL, 23 pg/mL, 18.5 pg/mL and 
12 pg/mL, respectively. These concentrations were chosen from the approximate lower range of 
the values reported in the literature, as a dynamic, large range exists (Table 3-3). While reported 
concentrations of IL-8 in the literature are greater than 18.5 pg/mL, this value was obtained as a 
result of diluting the other three cytokines to desired concentrations within the lower range. Since 
all of these cytokines are lyophilized into a single pellet, diluting the concentration of one would 
inevitably dilute the concentration of others. Additionally, it was important to choose cytokine 
concentrations within the LLOQ and ULOQ of the MSD instrument (Table 4-4).   
All materials were placed in wells of 24-well Greiner Cellstar polystyrene plates (Sigma-
Aldrich, St. Louis, MO), and 1 mL of the prepared cytokine solution was added to each well. 
Control wells contained only 1 mL of the cytokine solution and no contact lenses or other 
membranes. The samples in each well were evaluated for cytokine uptake after 24 hours of 
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incubation at 37℃ and 25 rpm (rotations per minute) in the Innova 4300 Incubator Shaker (New 
Brunswick Scientific, Edison, NJ), to simulate body temperature and to ensure a dynamic soaking 
environment.   
5.1.3 Results: Pilot Study #1 
After 24 hours, the mean cytokine concentrations obtained from the control wells, as 
quantified by the MSD, were 18 pg/mL, 15 pg/mL, 9 pg/mL, and 3.5 pg/mL for IL-1", IL-6, IL-
8, and TNF-#, respectively. Results are summarized in Figure 5-1 to Figure 5-4, and a summary 
of the statistical analyses are summarized in Figure 5-5 to Figure 5-8. Ordinary one-way ANOVAs 
with Tukey’s Multiple Comparisons test were performed and differences were considered 
significant if p < 0.05.  
 




Relative to the control after 24 hours (100%), there appeared to be little uptake of IL-1" 
(Figure 5-1) by gauze (92 ± 3 %) and silicone sheeting (98 ± 2 %) materials, as well as by 
senofilcon A (93 ±	3 %). There were no statistical differences (p > 0.05) between these materials 
and the control (Figure 5-5). In comparison, cotton (2 ± 1 %, adjusted P-value < 0.0001), Millipore 
filter paper (62 ± 3%, adjusted P-value < 0.0001) and Whatman filter paper (89 ± 1 %, adjusted 
P-value 0.0373) materials, as well as delefilcon A (76 ± 5 %, adjusted P-value < 0.0001), etafilcon 
A (83 ± 4 %, adjusted P-value 0.0005) and omafilcon A (73 ±	3%, adjusted P-value < 0.0001), 
exhibited greater uptake (Figure 5-1) and were all statistically different from the control after 24 
hours (Figure 5-5). 
 
 
Figure 5-2: Percent pg/mL of IL-6 Remaining in Individual Solutions (n = 3) of Nine Different Biomaterials at 24 Hours. 
 
	 71 
Relative to the control after 24 hours (100%), there appeared to be little uptake of IL-6 
(Figure 5-2) by Whatman filter paper (85 ± 0.9 %), gauze (100 ± 5 %) and silicone sheeting (105 
± 10 %) materials, as well as by senofilcon A (109 ± 9 %). There were no statistical differences 
(p > 0.05) between these materials and the control (Figure 5-6). Delefilcon A (123 ± 7 %, adjusted 
P-value 0.0019), etafilcon A (128 ± 5 %, adjusted P-value 0.0002) and omafilcon A (118 ± 4 %, 
adjusted P-value 0.0241), also did not exhibit uptake (Figure 5-2), even though they were 
statistically different from the control after 24 hours, due to having values above 100% of the 
control (Figure 5-6). Cotton (13 ± 2 %, adjusted P-value < 0.0001) and Millipore filter paper (21 
±	0.6 %, adjusted P-value < 0.0001) materials did exhibit great uptake (Figure 5-2) and were 
statistically different from the control after 24 hours (Figure 5-6). 
Relative to the control after 24 hours (100%), there appeared to be little uptake of IL-8 
(Figure 5-3) by silicone sheeting (81 ± 29 %) and delefilcon A (70 ± 15 %), omafilcon A (70 ± 
1 %) and senofilcon A (70 ± 14 %). There were no statistical differences (p > 0.05) between these 
materials and the control (Figure 5-7). Cotton (13 ± 2 %, adjusted  P-value < 0.0001), Millipore 
filter paper (40 ±	2%, adjusted P-value 0.0001), Whatman filter paper (50 ± 4 %, adjusted P-value 
0.0009) and gauze (59 ± 3 %, adjusted P-value 0.0074) materials, as well as etafilcon A (58 ± 4 
%, adjusted P-value 0.0065) exhibited greater uptake (Figure 5-3) and were all statistically 
different from the control after 24 hours (Figure 5-7). 
Relative to the control after 24 hours (100%), there appeared to be little uptake of TNF-# 
(Figure 5-4) by Whatman filter paper (70 ± 10 %), gauze (86 ± 6 %) and silicone sheeting (87 ± 
22 %) materials, as well as by delefilcon A (66 ± 30%), omafilcon A (76 ± 10 %) and senofilcon 
A (72 ± 1 %). There were no statistical differences (p > 0.05) between these materials and the 
control (Figure 5-8). In comparison, cotton (22 ± 2 %, adjusted P-value < 0.0001), Millipore filter 
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paper (38 ±	9 %, adjusted P-value 0.0007) and etafilcon A (54 ± 7 %, adjusted P-value 0.0157), 
exhibited greater uptake (Figure 5-4) and were all statistically different from the control after 24 
hours (Figure 5-8).   
 
 









Figure 5-5: Results of Statistical Analyses (Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons Test), for the 
Data Presented in Figure 5-1: (Percent pg/mL of IL-1( Remaining in Individual Solutions (n = 3) of Nine Different 
Biomaterials at 24 Hours). Differences were Considered Significant if p < 0.05. “FP” = Filter Paper; Solid Red = Statistical 






Figure 5-6: Results of Statistical Analyses (Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons Test), for the 
Data Presented in Figure 5-2: (Percent pg/mL of IL-6 Remaining in Individual Solutions (n = 3) of Nine Different 
Biomaterials at 24 Hours). Differences were Considered Significant if p < 0.05. “FP” = Filter Paper; Solid Red = Statistical 




Figure 5-7: Results of Statistical Analyses (Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons Test) for the  
Data Presented in Figure 5-3: (Percent pg/mL of IL-8 Remaining in Individual Solutions (n = 3) of Nine Different 
Biomaterials at 24 Hours). Differences were Considered Significant if p < 0.05. “FP” = Filter Paper; Solid Red = Statistical 






Figure 5-8: Results of Statistical Analyses (Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons Test) for the 
Data Presented in Figure 5-4: (Percent pg/mL of TNF-) Remaining in Individual Solutions (n = 3) of Nine Different 
Biomaterials at 24 Hours). Differences were Considered Significant if p < 0.05. “FP” = Filter Paper; Solid Red = Statistical 




5.1.4 Introduction: Pilot Study #2 
The second pilot study aimed to investigate the uptake of IL-1", IL-6, IL-8 and TNF-# by 
balafilcon A (PureVision), comfilcon A (Biofinity), polymacon A (SofLens 38) materials and 
Schirmer tear test strips (White Ophthalmics, Calgary, AB). Of the biomaterials tested in pilot 
study #1, cotton and silicone materials were incorporated into the study design of pilot study #2, 
along with etafilcon A (1-Day Acuvue Moist) and senofilcon A (Acuvue Oasys 1-Day with 
HydraLuxe Technology). Schirmer strips were investigated due to their clinical application and 
their use in the literature for collecting human tear samples to quantify cytokines or matrix 
metalloproteinases.78 
Filter papers, gauze, delefilcon A and omafilcon A were not tested in the second pilot study. 
Delefilcon A contact lens material is unique due to having a water gradient that transitions from 
33% at the silicone hydrogel core to 80% at the non-silicone hydrogel lens surface.99 As a result 
of having both a silicone core and a non-silicone surface, this material was excluded from further 
studies, as it would complicate the investigations when attempting to determine whether SiHy or 
conventional hydrogel materials uptake cytokines differently. Polymacon A was added to contrast 
etafilcon A, both of which are conventional hydrogel materials, however, since etafilcon A has 
high water content and is ionic, polymacon A was chosen for its low water content and nonionic 
nature (Table 3-4).55 Comfilcon A and balafilcon A were chosen from two different subgroups of 
silicone hydrogel lenses (Table 2-2).55 They are both lenses of low water content, though 
comfilcon A is nonionic (FDA group V B-1), and balafilcon A is ionic (FDA group V D).55 
Senofilcon A contrasts balafilcon A in terms of ionicity and contrasts comfilcon A in terms of 
water content.55 Additionally, during the first pilot study, all four contact lenses tested were daily 
disposables. Thus, the addition of SofLens 38 (polymacon A), Biofinity (comfilcon A) and 
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PureVision (balafilcon A), added variety for wear modality, as all three of these contact lenses can 
be worn on a reusable basis.  
5.1.5 Materials and Methods: Pilot Study #2 
The silicone sheeting was cut into 10.5 mm pieces using a circular lens punch, cotton was 
cut from the tips of Puritan 3-inch cotton tip applicators and the Schirmer tear test strips were cut 
into 0.5 cm x 1.0 cm rectangular pieces. All materials were autoclaved (except the Schirmer strips 
which are provided in sterile packaging, and the contact lenses which are provided in sterile blister 
packs), and the contact lenses were soaked in PBS, as described in section 4.3. The cytokine 
solution was prepared from the MSD calibrator blend, as also described in section 4.3 (except PBS 
was again utilized rather than Diluent 2), and contained IL-1", IL-6, IL-8 and TNF-# at 
concentrations of 16 pg/mL, 20 pg/mL, 15 pg/mL and 10 pg/mL, respectively. Similar 
concentrations to the first pilot study were chosen, which also fell within the approximate lower 
range of the values reported in the literature (Table 3-3).  
All materials were placed in wells of 24-well Greiner Cellstar polystyrene plates and 1 mL 
of the prepared cytokine solution was added to each well. Control wells contained only 1 mL of 
the cytokine solution and no contact lenses or other membranes. The samples in each well were 
evaluated for cytokine uptake after 24 hours of incubation at 32℃ and 25 rpm for a dynamic 
environment in the Innova 4300 Incubator Shaker (New Brunswick Scientific, Edison, NJ). In 
contrast to the first pilot study, in the second pilot study, the biomaterials were incubated at eye 
temperature rather than at body temperature, as the investigation mainly incorporated ophthalmic 
biomaterials, rather than equally investigating biomaterials used elsewhere in the body.  
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5.1.6 Results: Pilot Study #2  
After 24 hours, the mean cytokine concentrations obtained from the control wells, as 
quantified by the MSD, were 14 pg/mL, 14 pg/mL, 10.5 pg/mL and 6 pg/mL for IL-1", IL-6, IL-
8 and TNF-#, respectively. Results are summarized in Figure 5-9 to Figure 5-12, and a summary 
of the statistical analyses are summarized in Figure 5-13 to Figure 5-16. For IL-1", IL-8 and TNF-
#, Welch’s ANOVAs with T2 Multiple Comparisons test were performed, while for IL-6, an 
ordinary one-way ANOVA with Tukey’s Multiple Comparisons test was performed. Differences 
were considered significant if p < 0.05. 
Relative to the control after 24 hours (100%), there appeared to be little uptake of IL-1" 
(Figure 5-9) by Schirmer tear test strips (96 ± 5 %) and silicone sheeting (99 ± 3 %) materials, as 
well as by etafilcon A (99 ± 3 %), polymacon A (92 ± 7 %) and senofilcon A (97 ± 3%). There 
were no statistical differences (p > 0.05) between these materials and the control (Figure 5-13). In 
comparison, cotton (24 ± 7 %, adjusted P-value < 0.0001), balafilcon A (92 ± 4 %, adjusted P-
value 0.0165) and comfilcon A (89 ± 3 %, adjusted P-value 0.0004), exhibited greater uptake 
(Figure 5-9) and were all statistically different from the control after 24 hours (Figure 5-13).   
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Figure 5-9: Percent pg/mL of IL-1( Remaining in Individual Solutions (n = 8) of Eight Different Biomaterials at 24 Hours. 
 
Relative to the control after 24 hours (100%), there appeared to be little uptake of IL-6 
(Figure 5-10) by silicone sheeting (99 ± 6 %) and balafilcon A (109 ± 7 %), comfilcon A (103 ± 
5 %), polymacon A (109 ± 10 %) and senofilcon A (105 ± 4 %). There were no statistical 
differences (p > 0.05) between these materials and the control (Figure 5-14). Etafilcon A (116 ± 
6%, adjusted P-value 0.0019) also did not exhibit uptake (Figure 5-10), even though it was 
statistically different from the control after 24 hours, due to having a value above 100% of the 
control (Figure 5-14). Cotton (14 ± 5 %, adjusted P-value < 0.0001) and Schirmer tear test strips 
(70 ± 12 %, adjusted P-value < 0.0001), exhibited greater uptake (Figure 5-10) and were 




Figure 5-10: Percent pg/mL of IL-6 Remaining in Individual Solutions (n = 8) of Eight Different Biomaterials at 24 Hours. 
 
Relative to the control after 24 hours (100%), there appeared to be little uptake of IL-8 
(Figure 5-11) by etafilcon A (104 ± 5 %) and senofilcon A (96 ± 4 %), as there were no statistical 
differences (p > 0.05) between these materials and the control (Figure 5-15). Cotton (16 ± 3 %, 
adjusted P-value < 0.0001), Schirmer tear test strips (71 ± 9 %, adjusted P-value 0.0002) and 
silicone sheeting (81 ± 5 %, adjusted P-value 0.0004) materials, as well as balafilcon A (64 ± 19 
%, adjusted P-value 0.0277), comfilcon A (61 ±	17 %, adjusted P-value 0.0068) and polymacon 
A (63 ± 17 %, adjusted P-value 0.0105), exhibited greater uptake (Figure 5-11) and were all 




Figure 5-11: Percent pg/mL of IL-8 Remaining in Individual Solutions (n = 8) of Eight Different Biomaterials at 24 Hours. 
 
Relative to the control after 24 hours (100%), there appeared to be little uptake of TNF-# 
(Figure 5-12) only by the silicone sheeting (86 ± 8 %), as there was no statistical difference (p > 
0.05) observed between this material and the control (Figure 5-16). Cotton (14 ± 2 %, adjusted P-
value < 0.0001) and Schirmer tear test strips (64 ± 10 %, adjusted P-value < 0.0001 ), along with 
balafilcon A (64 ± 17 %, adjusted P-value 0.0124), comfilcon A (50 ± 15 %, adjusted P-value 
0.0002), etafilcon A (59 ± 7 %, adjusted P-value < 0.0001), polymacon A (58 ± 15 %, adjusted 
P-value 0.0011) and senofilcon A (82 ± 6 %, adjusted P-value 0.0035), all exhibited greater uptake 
(Figure 5-12) and were statistically different from the control after 24 hours (Figure 5-16). 
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Figure 5-13: Results of Statistical Analyses (Welch’s ANOVAs with T2 Multiple Comparisons Test), for the Data Presented in 
Figure 5-9: (Percent pg/mL of IL-1( Remaining in Individual Solutions (n = 8) of Eight Different Biomaterials at 24 Hours). 
Differences were Considered Significant if p < 0.05. Solid Red = Statistical Difference; Solid Grey = No Statistical Difference 




Figure 5-14: Results of Statistical Analyses (Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons Test), for the 
Data Presented in Figure 5-10: (Percent pg/mL of IL-6 Remaining in Individual Solutions (n = 8) of Eight Different 
Biomaterials at 24 Hours). Differences were Considered Significant if p < 0.05. Solid Red = Statistical Difference; Solid Grey 




Figure 5-15:Results of Statistical Analyses (Welch’s ANOVAs with T2 Multiple Comparisons Test), for the Data Presented in 
Figure 5-11: (Percent pg/mL of IL-8 Remaining in Individual Solutions (n = 8) of Eight Different Biomaterials at 24 hours). 
Differences were considered significant if p < 0.05. Solid Red = Statistical Difference; Solid Grey = No Statistical Difference 





Figure 5-16: Results of Statistical Analyses (Welch’s ANOVAs with T2 Multiple Comparisons Test), for the Data Presented in 
Figure 5-12: (Percent pg/mL of TNF-) Remaining in Individual Solutions (n = 8) of Eight Different Biomaterials at 24 
Hours). Differences were Considered Significant if p < 0.05. Solid Red = Statistical Difference; Solid Grey = No Statistical 
Difference (p > 0.05). 
 
5.1.7 Discussion: Pilot Study #1 and Pilot Study #2 
In the first pilot study, silicone sheeting and senofilcon A (Acuvue Oasys 1-Day with 
HydraLuxe Technology), consistently exhibited no uptake of any of the four cytokines of interest, 
while cotton and Millipore filter paper exhibited uptake for all four cytokines (Figure 5-5 to Figure 
5-8). In the second pilot study, silicone sheeting only exhibited uptake for IL-8 that was statistically 
different from the IL-8 control, while senofilcon A only exhibited uptake of TNF-# that was 
statistically different from the TNF-# control. Uptake by the other biomaterials in both pilot studies 
varied between the cytokines; however, balafilcon A and comfilcon A appeared to uptake higher 
amounts of IL-1", IL-8 and TNF-# than IL-6. In both pilot studies, cotton consistently exhibited 
the highest amount of uptake for all cytokines; however, its ability to serve as an ideal positive 
control may be negated by its ability to also absorb a volume of the soaking solution. Although 
not tested in the second pilot study, Millipore filter paper also exhibited substantial uptake of all 
four cytokines, and since filter paper is much less liquid absorbent than cotton, it may therefore 
have served as a better positive control to validate the methodology used. Conversely, silicone 
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sheeting and perhaps senofilcon A, appeared to be good negative controls as materials that resisted 
cytokine uptake.  
Of concern were the cytokine concentrations measured for the controls after 24 hours in 
both pilot studies. Recall, in pilot study #1, experimental control concentrations were 18 pg/mL, 
15 pg/mL, 9 pg/mL and 3.5 pg/mL for IL-1", IL-6, IL-8 and TNF-#, respectively, which were 
lower than the theoretical concentrations of 19 pg/mL, 23 pg/mL, 18.5 pg/mL and 12 pg/mL for 
IL-1", IL-6, IL-8 and TNF-#, respectively. In pilot study #2, experimental control concentrations 
were 14 pg/mL, 14 pg/mL, 10.5 pg/mL and 6 pg/mL for IL-1", IL-6, IL-8 and TNF-#, 
respectively, which were also lower than the theoretical concentrations of 16 pg/mL, 20 pg/mL, 
15 pg/mL and 10 pg/mL for IL-1", IL-6, IL-8 and TNF-#, respectively. This suggested either an 
unstable cytokine solution as a result of utilizing PBS rather than the MSD’s Diluent 2, potential 
adhesion of the cytokines to the sides of the polystyrene wells, or cytokine denaturation over the 
24-hour uptake period as a result of the incubation temperatures affecting protein stability. For this 
reason, definite comparisons could not be drawn between the contact lens materials and their 
ability to uptake cytokines. For example, concluding that one contact lens material could uptake 
one type of cytokine but not another would be inaccurate, as perhaps there was greater adhesion 
of that cytokine to the sides of the container, or more denaturation, making the contact lens material 
appear to have exhibited greater uptake, when in reality, the cytokine may not have been properly 
quantified by the MSD assay in its entirety as a result. Accordingly, the next set of experiments 
aimed to investigate any differences between PBS and Diluent 2, the material of the soaking 
container, and any effect of the incubation temperature on cytokine uptake. Furthermore, an 
investigation was also carried out to determine whether the results observed which indicated 
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greater than 100% pg/mL cytokines in solution, was at all due to any component of a contact lens 
eluting out into solution and then potentially mimicking cytokines. 
5.2 Investigating Potential Signal Interference by Contact Lenses in the MSD Assay and 
Differences in Diluent 2 and PBS, High-Density Polyethylene and Polypropylene 
5.2.1 Introduction: Pilot Study #3  
 Although Diluent 2 is a proprietary PBS-based solution according to Meso Scale 
Discovery, it also contains other constituents in its recipe, and it was therefore of interest to 
investigate whether creating the cytokine solution utilizing Diluent 2 or PBS would affect the 
stability of the cytokines over time. Additionally, rather than using polystyrene plates, it was of 
interest to investigate whether the use of polypropylene tubes or high-density polyethylene tubes 
would produce more favourable outcomes in terms of preventing potential adhesion of the 
cytokines to the sides of the container. High-density polyethylene tubes had previously been used 
in the laboratory for experiments involving protein extraction from contact lenses, whereas many 
of the items in the MSD assay kits were supplied in polypropylene tubes, suggesting a customary 
use of this material for experiments involving cytokines.  
5.2.2 Materials and Methods: Pilot Study #3 
 An experiment was designed with 6 mL high-density polyethylene (HDPE) tubes (Fisher 
Scientific, Hampton, NH) and 5 mL conical-bottom polypropylene tubes (VWR, Radnor, PA), 
each containing 1 mL of cytokine solution prepared either in Diluent 2 or PBS (n = 3). Samples 
were collected from each tube after a half-hour time period and cytokine concentrations were 
quantified using the MSD assay. This time period was chosen as it was hypothesized that any 
adhesion to the sides of the materials could happen relatively quickly in the presence of a cytokine 
solution. The tubes were left at room temperature on the VWR Advanced 3500 orbital shaker to 
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ensure a dynamic environment, but were not incubated at either 32℃ or 37℃, as the investigation 
aimed to solely evaluate the materials without any potential influence of temperature.  
5.2.3 Results: Pilot Study #3 
 The concentrations of the cytokines in the prepared solutions were 28.05 pg/mL, 37.5 
pg/mL, 30.8 pg/mL and 17.3 pg/mL for IL-1", IL-6, IL-8 and TNF-#, respectively. Results are 
summarized in Figure 5-17 to Figure 5-20. In Diluent 2, the concentration of IL-1" following the 
half-hour uptake period was 26.98 pg/mL in HDPE and 25.84 pg/mL in polypropylene, while in 
PBS, the concentration of IL-1" was 28.73 pg/mL in HDPE and 25.15 pg/mL in polypropylene. 
Statistical analysis performed using an ordinary, one-way ANOVA with Tukey’s Multiple 
Comparisons test, where differences were considered significant if p < 0.05, revealed Diluent 2 in 
HDPE to be statistically different from PBS in polypropylene (adjusted P-value 0.0460), as defined 
by the star (*) symbol, while PBS in HDPE was statistically different from both Diluent 2 in 
polypropylene (adjusted P-value 0.0039) and PBS in polypropylene (adjusted P-value 0.0010), as 
defined by the triangle (∆) symbol.  
In Diluent 2, concentrations of IL-6 following the half-hour uptake period were 31.5 pg/mL 
in HDPE and 32.5 pg/mL in polypropylene, while in PBS, concentrations of IL-6 were 34.1 pg/mL 
in HDPE and 32.3 pg/mL in polypropylene. Statistical analysis performed using an ordinary, one-
way ANOVA with Tukey’s Multiple Comparisons test, where differences were considered 
significant if p < 0.05, revealed no statistical differences between any of the experimental 
conditions for this cytokine.  
In Diluent 2, the concentration of IL-8 following the half-hour uptake period was 28.0 
pg/mL in both HDPE and in polypropylene, while in PBS, the concentration of IL-8 was 30.3 
pg/mL in HDPE and 27.3 pg/mL in polypropylene. Statistical analysis performed using an 
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ordinary, one-way ANOVA with Tukey’s Multiple Comparisons test, where differences were 
considered significant if p < 0.05, revealed no statistical differences between any of the 
experimental conditions for this cytokine. 
 
 
Figure 5-17: pg/mL of IL-1( Remaining in Individual Diluent 2 or PBS Cytokine Solutions (n = 3) in Either HDPE or 
Polypropylene at 0.5 hour. Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons Test were Performed. Diluent 2 
in HDPE was Statistically Different from PBS in Polypropylene, as Defined by the Star (*) Symbol. PBS in HDPE was 







Figure 5-18: pg/mL of IL-6 Remaining in Individual Diluent 2 or PBS Cytokine Solutions (n = 3) in Either HDPE or 
Polypropylene at 0.5 hour. Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons Test were Performed. No 




Figure 5-19: pg/mL of IL-8 Remaining in Individual Diluent 2 or PBS Cytokine Solutions (n = 3) in Either HDPE or 
Polypropylene at 0.5 hour. Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons Test were Performed. No 
Statistical Differences to Report (p > 0.05). 
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In Diluent 2, the concentration of TNF-# following the half-hour uptake period was 16.3 
pg/mL in HDPE and 15.3 pg/mL in polypropylene, while in PBS, the concentration of IL-8 was 
16.3 pg/mL in HDPE and 14.4 pg/mL in polypropylene. Statistical analysis performed using an 
ordinary, one-way ANOVA with Tukey’s Multiple Comparisons test where differences were 
considered significant if p < 0.05, revealed no statistical differences between any of the 
experimental conditions for this cytokine. 
 
 
Figure 5-20: pg/mL of TNF-) Remaining in Individual Diluent 2 or PBS Cytokine Solutions (n = 3) in Either HDPE or 
Polypropylene at 0.5 hour. Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons Test were Performed. No 
Statistical Differences to Report (p > 0.05). 
 
5.2.4 Discussion: Pilot Study #3 
Based on observation from the graphs and the statistical analyses (which did not reveal any 
differences in most cases), there did not appear to be any great disparities between either the use 
of Diluent 2 versus PBS or the use of high-density polyethylene tubes versus polypropylene tubes. 
In all cases, the experimental control cytokine concentrations quantified did deviate to some extent 
from theoretical concentrations; however, the deviation was substantially less than what was 
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observed when polystyrene plates were utilized, where control concentrations of some cytokines 
were sometimes quantified as half the amount that was expected to exist in solution. Ultimately, 
polystyrene plates were no longer utilized, and polypropylene tubes were chosen as the material 
of choice.  
5.2.5 Introduction: Pilot Study #4 
 The results of pilot studies #1 and #2, as described in sections 5.1.3 and 5.1.6 above, 
exhibited some cases where the percent pg/mL of cytokine remaining in solution after the uptake 
period exceeded 100% of the control value. These results were rather unusual, as it was expected 
that sample values would either indicate no uptake by having the same percent of cytokines 
remaining in solution as the control, or there would be some uptake, in which case the percent of 
cytokines remaining in solution would be lower than 100% of the control. Consequently, a fourth 
pilot study was carried out as an extension of pilot study #3 and aimed to determine whether there 
were any differences between soaking a contact lens in a cytokine solution prepared using Diluent 
2 or PBS in polypropylene tubes. This was not evident from pilot studies #1 and #2 where cytokine 
solutions were prepared solely in PBS, and the potential influences of using polystyrene plates and 
incubating at body/eye temperatures may have affected results. Moreover, this was also not evident 
from pilot study #3, where only differences between materials and solutions were tested in the 
absence of any contact lens materials. 
5.2.6 Materials and Methods: Pilot Study #4 
A cytokine solution was prepared from the MSD calibrator blend, as described in section 
4.3 using either Diluent 2 or PBS in polypropylene tubes (n = 6). There were two control conditions 
whereby the tubes contained either only the Diluent 2 or PBS cytokine solutions and no contact 
lens, in addition to two experimental conditions whereby the tubes contained either Diluent 2 or 
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PBS cytokine solutions with etafilcon A (1-Day Acuvue Moist). Samples were collected from each 
tube after a half-hour time period and cytokine concentrations were quantified using the MSD 
assay. Etafilcon A was the lens material of choice because this material, in particular, exceeded 
100% of the control values in both pilot studies #1 and #2, in comparison to the other contact lens 
materials tested. Etafilcon A was soaked in PBS to remove packaging solution as described in 
section 4.3 and dried on lens paper prior to beginning the experiment. A half-hour time period was 
chosen as it was hypothesized that if any additional components on the lens surface were to elute 
out into solution, it could happen quickly within this time frame. Tubes were placed on the VWR 
Advanced 3500 orbital shaker during the duration of the study period in order to ensure a dynamic 
environment.  
5.2.7 Results: Pilot Study #4  
The concentrations of the cytokines prepared in the Diluent 2 solution were 28.6 pg/mL, 
35.9 pg/mL, 30.2 pg/mL and 16.9 pg/mL for IL-1", IL-6, IL-8 and TNF-#, respectively. The 
concentrations of the cytokines prepared in the PBS solution were 30.7 pg/mL, 37.5 pg/mL, 34.0 
pg/mL and 21.3 pg/mL for IL-1", IL-6, IL-8 and TNF-#, respectively. Results are summarized in 
Figure 5-21 to Figure 5-24. Theoretical concentrations of IL-1", IL-6, IL-8 and TNF-# were 28.75 
pg/mL, 38.25 pg/mL, 29.95 pg/mL and 18.4 pg/mL, respectively.  
After a half-hour, there appeared to be no uptake of IL-1" (Figure 5-21) by etafilcon A in 
either Diluent 2 (98 ± 4 %) or in PBS (100 ± 3 %); no uptake of IL-6 (Figure 5-22) by etafilcon 
A in either Diluent 2 (102 ± 4 %) or in PBS (104 ± 4 %); no uptake of IL-8 (Figure 5-23) by 
etafilcon A in either Diluent 2 (100 ± 7 %) or in PBS (103 ± 2 %); and no uptake of TNF-#	(Figure 
5-24) by etafilcon A in either Diluent 2 (101 ± 6 %) or in PBS (103 ± 5 %). This was in comparison 
to each respective control for both Diluent 2 and PBS (100%). In each case, statistical analysis 
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with ordinary, one-way ANOVA and Tukey’s Multiple Comparisons test revealed no significant 
differences between any of the experimental conditions (differences were considered significant if 
p < 0.05). 
 
Figure 5-21: Percent pg/mL of IL-1( Remaining in Individual Diluent 2 or PBS Cytokine Solutions (n = 6) in Either HDPE 
or Polypropylene Tubes Containing Etafilcon A at 0.5 hour. Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons 





Figure 5-22: Percent pg/mL of IL-6 Remaining in Individual Diluent 2 or PBS Cytokine Solutions (n = 6) in Either HDPE or 
Polypropylene Tubes Containing Etafilcon A at 0.5 hour. Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons 




Figure 5-23: Percent pg/mL of IL-8 Remaining in Individual Diluent 2 or PBS Cytokine Solutions (n = 6) in Either HDPE or 
Polypropylene Tubes Containing Etafilcon A at 0.5 hour. Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons 
Test were Performed. No Statistical Differences to Report (p > 0.05). 
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Figure 5-24: Percent pg/mL of TNF-) Remaining in Individual Diluent 2 or PBS Cytokine Solutions (n = 6) in Either HDPE 
or Polypropylene Tubes Containing Etafilcon A at 0.5 hour. Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons 
Test were Performed. No Statistical Differences to Report (p > 0.05). 
 
 
5.2.8 Discussion: Pilot Study #4 
Similar to the results obtained in pilot study #3, while there were no statistical differences 
(p > 0.05) between the controls and the experimental conditions in pilot study #4 and while the 
quantified control concentration of cytokines in either solution of Diluent 2 or PBS were very close 
in comparison, they did appear to resemble theoretical concentrations slightly more when prepared 
in Diluent 2 rather than when prepared in PBS. As a result of this and also to maintain consistency 
with the use of Diluent 2 when running the MSD assays, subsequent experiments utilized Diluent 
2 rather than PBS to prepare cytokine solutions. 
5.2.9 Discussion: Pilot Study #4 Continued - Additional Experiment 
In pilot study #4, similar results were again observed as per pilot studies #1 and #2 for 
etafilcon A, where the percent pg/mL of cytokines in solution was greater than 100% of the control. 
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Accordingly, an additional experiment was carried out to determine whether there were any 
components on the surface of the contact lens materials, although unlikely, that could elute out 
into solution over the uptake period and interfere with the MSD signal or mimic cytokines such 
that it would be quantified through the MSD assay and result in higher concentrations of cytokines 
than expected.  
Over a 24-hour period, with the exceptions of delefilcon A (Dailies Total1) and polymacon 
A (SofLens 38), any soft lens materials utilized in previous experiments, in addition to any soft 
lens materials expected to be utilized in future experiments, were placed in 1 mL of Diluent 2 in 
polypropylene tubes. The diluent 2 did not contain any cytokines. This included balafilcon A 
(PureVision), comfilcon A (Biofinity), etafilcon A (1-Day Acuvue Moist and Acuvue 2), 
omafilcon A (Proclear 1 Day), senofilcon A (Acuvue Oasys 1-Day with HydraLuxe Technology 
and Acuvue Oasys 2-week with Hydraclear Plus) and somofilcon A (Clariti 1 Day). As explained 
in section 5.1.4, delefilcon A would be excluded from future experiments, and polymacon A was 
also not investigated further, due to being an outdated material that is no longer commonly used.   
Prior to beginning the experiment, all materials were soaked in PBS to remove the 
packaging solution and dried on lens paper, as described in section 4.3. Following the 24-hour 
time point, a sample was collected from each tube and analyzed using the MSD assay. Results are 
not shown because for all of the contact lenses tested, there was either minimal interference or no 
interference at all to be reported (in which case the signals were extremely low and below the MSD 
instrument’s lower limit of quantification).  
Given that cytokine concentrations in solution were sometimes quantified to be above 
100% of the control regardless of the type of material used to soak the contact lenses, or whether 
Diluent 2 or PBS was used to prepare the cytokine solutions, and in addition to the fact that the 
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contact lenses on their own exhibited little to no interference with the MSD assay, it was 
reasonably concluded that this observation was due to the normal and expected slight variations 
existing between absolute values that translated into larger differences in percent of control on a 
picogram scale. Refer to section 4.8: “Method of Data Analysis and Presentation” for further 
explanation. 
5.3 Investigating the Effect of Temperature on Cytokine Uptake (Pilot Study #5) 
 Pilot study #5 aimed to investigate whether temperature had any effect on cytokine stability 
over time, which was of interest given the results of pilot studies #1 and #2, where cytokine 
concentrations in the experimental controls deviated largely from theoretical concentrations.  
5.3.1 Methods and Materials 
 One conventional hydrogel, etafilcon A (1-Day Acuvue Moist) and one SiHy, senofilcon 
A (Acuvue Oasys 2-week with Hydraclear Plus) were chosen. The lens materials were soaked in 
PBS to remove packaging solution as described in section 4.3, and dried on lens paper prior to 
being placed in polypropylene tubes containing 1 mL of a cytokine solution prepared from the 
MSD calibrator blend in Diluent 2. Control tubes had 1 mL of the cytokine solution with no contact 
lenses. All tubes were placed in the Innova 4300 Incubator Shaker at 32℃ (eye temperature) and 
25 rpm. Samples were collected after 6 hours and later analyzed using the MSD assay. This time 
point was chosen as it was decided that future experiments would likely investigate cytokine 
uptake onto contact lenses for up to a maximum 6-hour soaking period, which is a reasonable wear 




Theoretical control concentrations were 28.75 pg/mL, 38.35 pg/mL, 29.95 pg/mL and 18.4 
pg/mL for IL-1", IL-6, IL-8 and TNF-#, respectively. After 6 hours, experimental control 
concentrations were 21.12 pg/mL, 32.26 pg/mL, 22.0 pg/mL and 9.57 pg/mL for IL-1", IL-6, IL-
8 and TNF-#, respectively. Also after 6 hours, there appeared to be no difference in uptake of IL-
1" (Figure 5-25) between etafilcon A (103.7 ± 4 %) or senofilcon A (98 ± 3 %), in comparison 
to the control or in comparison to each other. This was also the case for the uptake of IL-6 (Figure 
5-26) by etafilcon A (106 ± 5 %) and senofilcon A (104 ± 2 %); IL-8 (Figure 5-27) by etafilcon 
A (108 ± 7 %) or senofilcon A (103 ± 1 %); and for the uptake of TNF-# (Figure 5-28) by etafilcon 
A (105 ± 7 %) or senofilcon A (101 ± 4 %). Statistical analyses with ordinary, one-way ANOVAs 
and Tukey’s Multiple Comparisons test revealed no significant differences between any of the 





Figure 5-25: Percent pg/mL of IL-( Remaining in Cytokine Solutions Containing Either etafilcon A or senofilcon A (n = 3), 
at 6 hours of Incubation at 32℃. Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons Test were Performed. No 




Figure 5-26: Percent pg/mL of IL-6 Remaining in Cytokine Solutions Containing Either etafilcon A or senofilcon A (n = 3), 
at 6 hours of Incubation at 32℃. Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons Test were Performed. No 




Figure 5-27: Percent pg/mL of IL-8 Remaining in Cytokine Solutions Containing Either etafilcon A or senofilcon A (n = 3), 
at 6 hours of Incubation at 32℃. Ordinary One-Way ANOVA with Tukey’s Multiple Comparisons Test were Performed. No 
Statistical Differences to Report (p > 0.05). 
 
 
Figure 5-28: Percent pg/mL of TNF-) Remaining in Cytokine Solutions Containing Either etafilcon A or senofilcon A (n = 
3), at 6 hours of Incubation at 32℃. Ordinary One-Way ANOVA with Tukey’s Multiple Comparisons Test were Performed. 




While there were no statistical differences (p > 0.05) between the experimental controls 
and the samples to indicate cytokine uptake onto either etafilcon A or senofilcon A for any of the 
four cytokines of interest, the experimental control cytokine concentrations after 6 hours did 
appear to be somewhat lower than the theoretical cytokine concentrations. It appeared that the 
incubation temperature may have somewhat affected the stability of the cytokines over time, with 
some cytokines being more greatly affected than others (e.g., for TNF-#). Since incubating the 
contact lenses certainly did not enhance cytokine uptake, moving forward, all experiments were 
run at room temperature, and sample tubes were not incubated at eye temperature. While this may 
not have been representative of ocular conditions, the goal of this thesis was to investigate the 
inherent properties of contact lenses for cytokine uptake, and hence conditions that could interfere 
with this outcome were desirably eliminated. Future work could instead elaborate on the results of 
these experiments by incorporating additional parameters in a clinical setting, such as investigating 
the effect of ocular temperature on cytokine uptake, once the fundamental science is well 
understood.   
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Chapter 6: Uptake Using a Standard Blend of Cytokines 
6.1 Preface  
The experiments presented in this chapter explored eight different types of soft contact lens 
materials for the uptake of IL-1", IL-6, IL-8 and TNF-# cytokines using a standard blend. The 
standard blend refers to the MSD calibrator blend, which contains ten cytokines at lot-specific 
concentrations. Utilizing a standard blend is advantageous as it has been prepared to MSD’s 
specifications, has been validated for the MSD assay, and individual analyte concentrations have 
been tested and verified for quality control. Preparation of the standard blend followed the 
procedure described in section 4.3 using Diluent 2, which was concluded to be the solution of 
choice in Chapter 5: As also outlined in section 4.3, all contact lenses utilized were soaked in PBS 
to remove packaging solution and dried on Fisherbrand lens paper prior to beginning each 
investigation. All experiments presented in this chapter were performed at room temperature on 
the VWR Advanced 3500 orbital shaker to ensure a dynamic soaking environment.  
6.2 Investigating Conventional Hydrogels for Cytokine Uptake Ability 
6.2.1 Introduction 
Of the contact lens materials listed in Table 3-4, etafilcon A and omafilcon A were the 
conventional hydrogels of interest studied for cytokine uptake. The other conventional hydrogel 
listed in Table 3-4 that was initially studied was polymacon A; however, as mentioned, this 
material ceased to be investigated further beyond the pilot studies. Etafilcon A and omafilcon A 
were of interest due to having been studied in the literature for protein deposition, specifically 
etafilcon A which had shown to deposit more positively-charged protein than omafilcon A, due to 
having an overall negative charge.58-60 
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6.2.2 Materials and Methods 
1-Day Acuvue Moist (etafilcon A) and Proclear 1 Day (omafilcon A) contact lenses were 
placed in polypropylene tubes (n = 3) containing 1 mL of the prepared cytokine solution with 
theoretical IL-1", IL-6, IL-8 and TNF-# concentrations of 28.05 pg/mL, 37.5 pg/mL, 30.8 pg/mL 
and 17.3 pg/mL, respectively. Control tubes contained 1 mL of the cytokine solution with no 
lenses. Experimental tubes contained the contact lenses which were soaked for 1 hour. Previously, 
pilot study #4 investigated uptake onto etafilcon A for only a half-hour time period (refer to section 
5.2.7). Although pilot studies #1 and #2 did explore the omafilcon A material, the results from 
those studies were inconclusive due to the many potential influencing factors discussed throughout 
Chapter 5:, and thus omafilcon A lenses were also included in this study. At the 1-hour time point, 
60 -L samples were collected from each tube and cytokine concentrations were quantified the 
same day using the MSD assay.   
6.2.3 Results  
After 1 hour, the experimental control concentrations of IL-1", IL-6, IL-8 and TNF-# were 
quantified by the MSD assay as 26.33 pg/mL, 35.83 pg/mL, 29.32 pg/mL and 15.63 pg/mL, 
respectively. There appeared to be no difference in uptake after 1 hour for IL-1" (Figure 6-1) 
between etafilcon A (99 ± 7 %) or omafilcon A (102 ± 8 %), in comparison to the control (100%), 
or in comparison to each other. This was also the case for the uptake of IL-6 (Figure 6-2) by 
etafilcon A (101 ± 8 %) and omafilcon A (107 ± 5 %); IL-8 (Figure 6-3) by etafilcon A (99 ± 11 
%) and omafilcon A (96 ± 5 %); and for the uptake of TNF-# (Figure 6-4) by etafilcon A (102 ± 
8 %) and omafilcon A (100 ± 2 %). Statistical analyses with ordinary, one-way ANOVAs and 
Tukey’s Multiple Comparisons test, where differences were considered significant if p < 0.05, 





Figure 6-1: Percent pg/mL of IL-1( Remaining in Cytokine Solutions Containing Either etafilcon A or omafilcon A (n = 3) 
Contact Lens Materials at 1 Hour. Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons Test were Performed. No 




Figure 6-2: Percent pg/mL of IL-6 Remaining in Cytokine Solutions Containing Either etafilcon A or omafilcon A (n = 3) 
Contact Lens Materials at 1 Hour. Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons Test were Performed. No 
Statistical Differences to Report (p > 0.05). 
 
 
Figure 6-3: Percent pg/mL of IL-8 Remaining in Cytokine Solutions Containing Either etafilcon A or omafilcon A (n = 3) 
Contact Lens Materials at 1 Hour. Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons Test were Performed. No 




Figure 6-4: Percent pg/mL of TNF-) Remaining in Cytokine Solutions Containing Either etafilcon A or omafilcon A (n = 3) 
Contact Lens Materials at 1 Hour. Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons Test were Performed. No 




After 1 hour, etafilcon A and omafilcon A materials did not exhibit any uptake of the four 
cytokines of interest at the given concentrations. Comparing this to the results obtained in section 
5.2.7, where the uptake of cytokines onto etafilcon A material was investigated during a half-hour 
time period as part of pilot study #4, it appeared that both of these time periods were inadequate 
for detecting uptake onto this material. Moreover, it appeared that the 1-hour time period was also 
insufficient for detecting uptake onto omafilcon A material.  
Referring to Table 3-2, the isoelectric points (pI) of the cytokines of interest, as determined 
through physical characterizations, were stated in the literature to be approximately 6.9 – 7.0 (IL-
1")85, 4.986 or 5.0 – 6.0 (IL-6)87, 9.489 (IL-8) and 5.0 – 7.091 or 5.391,92 (TNF-#). According to 
Meso Scale Discovery Scientific Support, the pH of Diluent 2 is approximately 7.4 (slightly basic). 
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Since all of IL-1", IL-6 and TNF-# have reported pI values falling below this pH, the surface of 
these cytokines should be predominately negatively charged in the standard blend soaking 
solution.83 In contrast, IL-8 should have a predominately positively charged surface due to its pI 
value falling above the pH of the soaking solution.83 Recall from Table 3-4 that etafilcon A is 
negatively charged overall and omafilcon A is zwitterionic due to having both a positive and 
negative charge (hence it is neutral).59 If the surface charge of cytokines is a dominating factor 
influencing uptake, it would be expected then that etafilcon A would exhibit less attraction for the 
uptake of IL-1", IL-6, or TNF-#, as a result of the contact lens material and cytokine having a 
similar charge. In comparison, etafilcon A would be more likely to uptake IL-8, as a result of an 
attraction between the opposing charges, although the results of this particular experiment did not 
indicate so. Omafilcon A may resist protein deposition in part due to its principal monomer 
phosphorylcholine, which provides an overall neutral charge and has been documented in the 
literature to aid in lowering protein adsorption to contact lenses of this material.107,108  
6.3 Investigating Conventional Hydrogels with a SiHy for Cytokine Uptake Ability 
6.3.1 Introduction – Experiment #1 
As neither a half-hour soaking period for etafilcon A, nor a 1-hour soaking period for 
etafilcon A and omafilcon A, provided any indication of uptake for the four cytokines of interest 
onto the lens materials, a 6-hour time period was instead explored. In addition to utilizing the 1-
Day Acuvue Moist (etafilcon A) and Proclear 1 Day (omafilcon A) contact lenses as in the prior 
experiment, Acuvue Oasys 2-week with Hydraclear Plus (senofilcon A), was also incorporated 
into the experimental design as a commonly used SiHy material to be investigated. Although 
etafilcon A and senofilcon A materials were previously studied at a 6-hour time point in pilot study 
#5, that study explored the effect of temperature (section 5.3.2) and due to the experimental control 
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concentrations differing vastly from theoretical controls (especially for IL-8 and TNF-#), the 
materials were again explored, this time with more stable controls and without incubation at 32℃. 
6.3.2 Materials and Methods – Experiment #1 
1-Day Acuvue Moist (etafilcon A), Proclear 1 Day (omafilcon A) and Acuvue Oasys 2-
week with Hydraclear Plus (senofilcon A), were placed in polypropylene tubes (n = 3) containing 
1 mL of a prepared cytokine solution. Control tubes contained 1 mL of the cytokine solution with 
no contact lenses. Theoretical concentrations of IL-1", IL-6, IL-8 and TNF-# were 28.3 pg/mL, 
35.6 pg/mL, 27.8 pg/mL and 18.45 pg/mL, respectively. At the 6-hour time point, 60 -L samples 
were collected from each tube, and cytokine concentrations were quantified the same day using 
the MSD assay.   
6.3.3 Results – Experiment #1 
Control solutions evaluated at 6 hours contained IL-1", IL-6, IL-8 and TNF-# at 
concentrations of 26.42 pg/mL, 32.68 pg/mL, 24.76 pg/mL and 13.06 pg/mL, respectively. 
Statistical analyses were performed using ordinary, one-way ANOVAs with Tukey’s Multiple 
Comparisons test. Differences were considered significant if p < 0.05. After 6 hours, there 
appeared to be no difference in uptake for IL-1" (Figure 6-5) between etafilcon A (95 ± 7 %) or 
senofilcon (95 ± 2 %), in comparison to the control (100%) or in comparison to each other. In 
contrast, there appeared to be some uptake of IL-1" (Figure 6-5) by omafilcon A (82 ± 2 %), as 
the material was statistically different from the control (adjusted P-value 0.0024), from etafilcon 
A (adjusted P-value 0.0185) and from senofilcon A (adjusted P-value 0.0198), as defined by the 




Figure 6-5: Percent pg/mL of IL-1( Remaining in Cytokine Solutions Containing Either etafilcon A, omafilcon A, or 
senofilcon A (n = 3) Contact Lens Materials at 6 Hours. Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons 





Figure 6-6: Percent pg/mL of IL-6 Remaining in Cytokine Solutions Containing Either etafilcon A, omafilcon A, or 
senofilcon A (n = 3) Contact Lens Materials at 6 Hours. Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons 
Test were Performed. No Statistical Differences to Report (p > 0.05). 
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There was little uptake of IL-6 (Figure 6-6) by etafilcon A (105 ± 10 %), omafilcon A (91 
± 4 %) and senofilcon A (100 ± 3 %). Likewise, there was little uptake of IL-8 (Figure 6-7) by 
etafilcon A (91 ± 17 %), omafilcon A (70 ± 10 %) and senofilcon A (99 ± 1 %), as well as of 
TNF-# (Figure 6-8) by etafilcon A (84 ±	20 %), omafilcon A (53 ± 12 %) and senofilcon A (97 
± 15 %). There were no statistical differences (p > 0.05) between the respective controls and the 
contact lens materials tested for any of these three cytokines of interest.  
 
 
Figure 6-7: Percent pg/mL of IL-8 Remaining in Cytokine Solutions Containing Either etafilcon A, omafilcon A, or 
senofilcon A (n = 3) Contact Lens Materials at 6 Hours. Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons 





Figure 6-8: Percent pg/mL of TNF-) Remaining in Cytokine Solutions Containing Either etafilcon A, omafilcon A, or 
senofilcon A (n = 3) Contact Lens Materials at 6 Hours. Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons 
Test were Performed. No Statistical Differences to Report (p > 0.05). 
   
6.3.4 Discussion – Experiment #1 
While etafilcon A and senofilcon A did not exhibit any uptake of cytokines IL-6, IL-8 or 
TNF-# that were statistically different from the control or from each other after 6 hours, omafilcon 
A did appear to exhibit some uptake of IL-1" that was statistically different from the control and 
from both etafilcon A and senofilcon A materials after 6 hours. When comparing the differences 
between these three contact lens materials, between etafilcon A and omafilcon A there is a 
difference of ionicity, as the former is ionic and the latter is nonionic (Table 3-4), while they share 
the same high water content characteristic (58% for etafilcon A and 60% for omafilcon A).59 
Senofilcon A is a contact lens material of low water content (38%) and is also nonionic, similarly 
to omafilcon A, but in contrast to etafilcon A (Table 3-4).59 
Based on the results of this experiment, etafilcon A and senofilcon A appeared to act similar 
to each other, though they differ in both their ionicity and water content characteristics. 
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Additionally, while omafilcon A shares similar characteristics with both etafilcon A (high water 
content) and with senofilcon A (nonionic), it appeared to act slightly differently from both 
materials, as it exhibited some uptake of IL-1" – a cytokine that should have a negatively-charged 
surface in the standard blend solution based on its pI.59,85 Furthermore, it was interesting that 
omafilcon A had this interaction with IL-1", but not with IL-6 or TNF-#, which should also have 
negatively-charged surfaces in the standard blend solution based on their pI.86,87,91,92 As a result, a 
second experiment utilizing the same etafilcon A, omafilcon A and senofilcon A materials, aimed 
to explore the reproducibility of the results previously obtained. 
6.3.5 Introduction – Experiment #2 
To explore the reproducibility of the results obtained in sections 5.2.7 (where uptake onto 
etafilcon A material was investigated over a half-hour time period), 6.2.3 (where uptake onto 
etafilcon A and omafilcon A materials were investigated over a 1-hour time period) and 6.3.3 
(where uptake onto etafilcon A, omafilcon A and senofilcon A materials were investigated over a 
6-hour time period), a second experiment explored cytokine uptake onto all three of these contact 
lens materials over the same time periods of a half-hour, 1 hour and 6 hours. This allowed for the 
investigation of uptake onto omafilcon A and senofilcon A materials after a half-hour time point, 
at which they were not previously explored and in doing so, this would potentially provide insight 
into whether these materials may exhibit uptake earlier on during the soaking period. Likewise, 
senofilcon A had not yet been evaluated at 1 hour in the previous experiments either.  
6.3.6 Materials and Methods – Experiment #2 
1-Day Acuvue Moist (etafilcon A), Proclear 1 Day (omafilcon A) and Acuvue Oasys 2-
week with Hydraclear Plus (senofilcon A), were placed in polypropylene tubes (n = 3) containing 
1 mL of a prepared cytokine solution. Control tubes contained 1 mL of the cytokine solution with 
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no contact lenses. At each time point, 60 -L of the solution was pipetted out from each tube and 
stored in a -80℃ freezer to be analyzed by the MSD assay. Thus, half-hour, 1-hour, and 6-hour 
samples were collected from the same tubes containing the etafilcon A, omafilcon A, and 
senofilcon A materials. Between the 1-hour and 6-hour time points, there was 880	-L of the 
solution remaining in each tube, which was still a sufficient volume to cover the materials in their 
entirety. Theoretical concentrations of IL-1", IL-6, IL-8 and TNF-# were 28.3 pg/mL, 35.6 pg/mL, 
27.8 pg/mL and 18.45 pg/mL, respectively. 
6.3.7 Results – Experiment #2 
At a half-hour, control concentrations of IL-1", IL-6, IL-8 and TNF-# were 28.92 pg/mL, 
34.4 pg/mL, 29.3 pg/mL and 17.14 pg/mL, respectively. At 1 hour, control concentrations of IL-
1", IL-6, IL-8 and TNF-# were 31.68 pg/mL, 38.99 pg/mL, 31.88 pg/mL and 16.92 pg/mL, 
respectively. At 6 hours, control concentrations of IL-1", IL-6, IL-8 and TNF-# were 27.97 
pg/mL, 35.92 pg/mL, 26.34 pg/mL and 11.87 pg/mL, respectively. Statistical analyses were 
performed using two-way, repeated measures ANOVAs with Tukey’s Multiple Comparisons test, 
where differences were considered significant if p < 0.05.  
At the half-hour time point, there was no uptake of any of the four cytokines of interest 
onto either etafilcon A, omafilcon A, or senofilcon A materials. Relative to the control (100%), 
the percent pg/mL remaining in solution at this time point was 103 ± 5 % (etafilcon A), 104 ± 3 
% (omafilcon A) and 104 ± 2 % (senofilcon A) for IL-1" (Figure 6-9); 106 ± 3 % (etafilcon A), 
110 ± 3 % (omafilcon A) and 102 ± 3 % (senofilcon A) for IL-6 (Figure 6-10); 102 ± 4 % 
(etafilcon A), 106 ± 3 % (omafilcon A) and 103 ± 4 % (senofilcon A) for IL-8 (Figure 6-11); and 
97 ± 4 % (etafilcon A), 101 ± 4 % (omafilcon A) and 100 ± 4 % (senofilcon A) for TNF-# (Figure 
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6-12). There were no statistical differences (p > 0.05) between the control or the contact lens 
materials for any of the cytokines at this time point.  
At the 1-hour time point, there was no uptake of IL-1", IL-6 or IL-8 onto either etafilcon 
A, omafilcon A, or senofilcon A materials. Relative to the control (100%), the percent pg/mL 
remaining in solution at this time point was 93 ± 3 % (etafilcon A), 92 ± 3 % (omafilcon A) and 
94 ± 3 % (senofilcon A) for IL-1" (Figure 6-9); 92 ± 6 % (etafilcon A), 98 ± 1 % (omafilcon A) 
and 95 ± 3 % (senofilcon A) for IL-6 (Figure 6-10); and 90 ± 3 % (etafilcon A), 90 ± 2 % 
(omafilcon A) and 92 ± 1 % (senofilcon A) for IL-8 (Figure 6-11). For TNF-# (Figure 6-12), the 
percent pg/mL remaining in solution after 1 hour was 86 ± 10 % (etafilcon A), 80 ± 6 % 
(omafilcon A) and 90 ± 3 % (senofilcon A). There was a statistical difference for both etafilcon 
A (adjusted P-value 0.0375) and omafilcon A (adjusted P-value 0.0026) relative to the control at 





Figure 6-9: Percent pg/mL of IL-1( Remaining in Cytokine Solutions Containing Either etafilcon A, omafilcon A, or 
senofilcon A (n = 3) Contact Lens Materials, at Half-Hour, 1-Hour and 6-Hour Time Points. Two-way Repeated Measures 
ANOVAs with Tukey’s Multiple Comparisons Test were Performed. No Statistical Differences to Report (p > 0.05). 
 
 
Figure 6-10: Percent pg/mL of IL-6 Remaining in Cytokine Solutions Containing Either etafilcon A, omafilcon A, or 
senofilcon A (n = 3) Contact Lens Materials, at Half-Hour, 1-Hour and 6-Hour Time Points. Two-way Repeated Measures 




At the 6-hour time point, there was no uptake of any of the four cytokines of interest onto 
either etafilcon A, omafilcon A, or senofilcon A materials. Relative to the control (100%), the 
percent pg/mL remaining in solution at this time point was 102 ± 4 % (etafilcon A), 95 ± 8 % 
(omafilcon A) and 98 ± 6 % (senofilcon A) for IL-1" (Figure 6-9); 109 ± 3 % (etafilcon A), 99 
± 10 % (omafilcon A) and 105 ± 3 % (senofilcon A) for IL-6 (Figure 6-10); 104 ± 4 % (etafilcon 
A), 93 ± 9 % (omafilcon A) and 101 ± 10 % (senofilcon A) for IL-8 (Figure 6-11); and 90 ± 11 
% (etafilcon A), 90 ± 7 % (omafilcon A) and 90 ± 5% (senofilcon A) for TNF-# (Figure 6-12). 
There were no statistical differences (p > 0.05) between the control or the contact lens materials 








Figure 6-11: Percent pg/mL of IL-8 Remaining in Cytokine Solutions Containing Either etafilcon A, omafilcon A, or 
senofilcon A (n = 3) Contact Lens Materials, at Half-Hour, 1-Hour and 6-Hour Time Points. Two-way Repeated Measures 
ANOVAs with Tukey’s Multiple Comparisons Test were Performed. No Statistical Differences to Report (p > 0.05). 
 
 
Figure 6-12: Percent pg/mL of TNF-) Remaining in Cytokine Solutions Containing Either etafilcon A, omafilcon A, or 
senofilcon A (n = 3) Contact Lens Materials, at Half-Hour, 1-Hour and 6-Hour Time Points. Two-way Repeated Measures 
ANOVAs with Tukey’s Multiple Comparisons Test were Performed. At 1 hour, etafilcon A and omafilcon A were both 
Statistically Different from the Control at 1 Hour, as Defined by the Star Symbols (*).  
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6.3.8 Discussion – Experiment #2 
In previous experiments, when uptake onto etafilcon A material after a half-hour time 
period was explored (section 5.2.7), in addition to uptake onto etafilcon A and omafilcon A after 
a 1-hour time period (section 6.2.3) and uptake onto etafilcon A, omafilcon A and senofilcon A 
after a 6-hour time period (section 6.3.3), there was no indication of uptake onto any of these 
materials at any of the three time points, except for IL-1" onto omafilcon A after 6 hours of 
soaking. In this experiment, cytokine uptake was collectively investigated at a half-hour, 1-hour, 
and 6-hour time points, which allowed uptake onto omafilcon A and senofilcon A materials to be 
further explored at time points which they were not investigated for previously. 
Similar to the previous experiments, in this experiment there was also no indication of 
uptake onto any of the contact lens materials, except for TNF-# onto both etafilcon A and 
omafilcon A materials after 1 hour of soaking. At 6 hours, however, there was no indication of 
uptake onto these materials, as there was no statistical difference (p > 0.05) between the percent 
pg/mL remaining in the solution of the control, in comparison to the solutions containing etafilcon 
A or omafilcon A materials. It was interesting that omafilcon A appeared to be the common 
material in these experiments that exhibited slight uptake, in comparison to the other materials 
tested, even if the specific cytokine or the time point at which these results were observed differed 
among the experiments.  
From the results of this experiment, however, it could not conclusively be said that the 
statistical difference observed for etafilcon A or omafilcon A was a true indication of uptake. 
Supporting this is the interesting observation where there did not appear to be any uptake onto 
these materials at the 6-hour time point, even though there appeared to be uptake at the 1-hour 
time point. A possible explanation for this, though unlikely, could be that the TNF-# cytokine was 
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loosely bound to the surface of these materials and was released back into the soaking solution 
sometime between the 1-hour and 6-hour time points. This would not, however, be indicative of 
true uptake for the cytokine onto the contact lens material. Another possible explanation for the 
fluctuation in measurement observed was hypothesized to be, in part, due to the 1 mL soaking 
volume, which could have complicated the measurement of small differences in cytokine 
concentrations on a picogram scale.  
6.4 Reducing the Soaking Volume  
6.4.1 Introduction 
Considering a 1000 -L (1 mL) soaking volume, a 400 -L soaking volume and a 200 -L 
soaking volume, differences in cytokine uptake would likely be more easily detectable with a 
smaller soaking volume such as 200 -L. For example, if etafilcon A was to consistently absorb 10 
pg of a given cytokine, then in a 1000 -L solution at 100 pg/mL concentration, where there would 
be 100 pg of that particular cytokine in solution, absorption of 10 pg would result in the remaining 
concentration in solution to be 90 pg/mL following uptake. In contrast, in a 400 -L solution at 100 
pg/mL concentration, there would be 40 pg of the cytokine in solution, and absorption of 10 pg 
would result in the concentration remaining in solution to be 75 pg/mL. Detecting a 25 pg/mL 
difference (between 100 pg/mL and 75 pg/mL) by the MSD instrument, could likely be easier than 
detecting a 10 pg/mL difference (between 100 pg/mL and 90 pg/mL). Alternatively, if the soaking 
volume were to be reduced even further, such as in a 200 -L solution at 100 pg/mL concentration, 
there would be 20 pg of the cytokine in solution and absorption of 10 pg would result in the 
concentration remaining in solution to be 50 pg/mL. Detecting this 50 pg/mL difference (between 
100 pg/mL and 50 pg/mL), could potentially be even easier in comparison to both the 25 pg/mL 
or 10 pg/mL difference.  
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The hypothesis above, however, only holds true under two assumptions: the initial 
concentration must remain constant and one contact lens material must absorb the same amount of 
a particular cytokine each time. Nonetheless, it was of interest to investigate the effect of reducing 
the soaking volume, in order to determine whether this would change how precisely cytokine 
uptake onto a contact lens material could be detected by the MSD instrument. Two experiments 
were run to investigate the uptake of cytokines onto etafilcon A, omafilcon A and senofilcon A 
contact lens materials, using both 400	-L and 200 -L soaking solution volumes.  
6.4.2 Materials and Methods – Experiment #1 
Given that the omafilcon A material had exhibited the greatest potential for uptake of 
cytokines, it was the first material chosen to explore initially for experiment #1 of the reduced 
soaking volume series. A cytokine standard blend solution was prepared, of which 200 -L was 
placed in plastic moulds (n = 3) designed specifically in size to fit contact lenses. Proclear 1 Day 
(omafilcon A) contact lenses were placed in the plastic moulds and another 200 -L of the cytokine 
solution was pipetted on top of the lens (total volume 400 -L). The lens moulds were then placed 
inside every other well of Corning 6-well polystyrene plates (Corning, Corning, NY). PBS was 
used to fill the in-between empty wells, in order to maintain a humid environment and to ensure 
that the cytokine solution would not evaporate over time. The plates were also wrapped in Parafilm 
wrapping film (Fisher Scientific, Hampton, NH). At 1-hour and 6-hour time points, 60 -L of each 
sample was collected and stored in a -80℃ freezer to later be analyzed with the MSD assay. 
Theoretical cytokine concentrations were 28.3 pg/mL, 35.6 pg/mL, 27.8 pg/mL and 18.45 pg/mL 
for IL-1", IL-6, IL-8 and TNF-#, respectively.  
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6.4.3 Results – Experiment #1  
An aliquot of the cytokine standard blend solution obtained approximately 5 minutes 
following preparation was later quantified by the MSD assay to have cytokine concentrations of 
26.1 pg/mL, 35.5 pg/mL, 24.3 pg/mL and 11.4 pg/mL for IL-1", IL-6, IL-8 and TNF-#, 
respectively. At 1 hour, control concentrations of IL-1", IL-6, IL-8 and TNF-# were 25.67 pg/mL, 
38.32 pg/mL, 23.66 pg/mL and 10.36 pg/mL, respectively. At 6 hours, control concentrations of 
IL-1", IL-6, IL-8 and TNF-# were 26.66 pg/mL, 38.88 pg/mL, 24.26 pg/mL and 9.02 pg/mL, 
respectively.  
Relative to the control (100%), there was no uptake of any of the four cytokines of interest 
onto omafilcon A material at 1 hour. The percent pg/mL remaining in solution was 98 ± 1 % for 
IL-1" (Figure 6-13); 102 ± 1 % for IL-6 (Figure 6-14); 103 ± 0.5 % for IL-8 (Figure 6-15); and 
93 ± 5 % for TNF-# (Figure 6-16). Statistical analyses performed using two-way, repeated 
measures ANOVAs with Sidak’s Multiple Comparisons test (where differences were considered 
significant if p < 0.05), revealed no statistical difference (p > 0.05) between omafilcon A and the 
control for any of the cytokines at this time point.  
At 6 hours, there was a statistical difference between omafilcon A and the control (adjusted 
P-value 0.0454) for IL-1", as defined by the star (*) symbol (Figure 6-13). The percent pg/mL of 
this cytokine remaining in solution relative to the control (100%) was 95 ± 3 %. In contrast, there 
were no statistical differences (p > 0.05) between omafilcon A and the controls for IL-6, IL-8, or 
TNF-# at this time point. Percent pg/mL remaining in solution at 6 hours was 102 ± 3 % for IL-6 




Figure 6-13: Percent pg/mL of IL-1( Remaining in Reduced Volumes of Cytokine Solutions Containing omafilcon A (n = 3) 
Contact Lens Material, at 1-Hour and 6-Hour Time Points. Two-way Repeated Measures ANOVAs with Sidak’s Multiple 




Figure 6-14: Percent pg/mL of IL-6 Remaining in Reduced Volumes of Cytokine Solutions Containing omafilcon A (n = 3) 
Contact Lens Material, at 1-Hour and 6-Hour Time Points. Two-way Repeated Measures ANOVAs with Sidak’s Multiple 
Comparisons Test was Performed. No Statistical Differences to Report (p > 0.05).  
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Figure 6-15: Percent pg/mL of IL-8 Remaining in Reduced Volumes of Cytokine Solutions Containing omafilcon A (n = 3) 
Contact Lens Material, at 1-Hour and 6-Hour Time Points. Two-way Repeated Measures ANOVAs with Sidak’s Multiple 
Comparisons Test was Performed. No Statistical Differences to Report (p > 0.05). 
 
 
Figure 6-16: Percent pg/mL of TNF-) Remaining in Reduced Volumes of Cytokine Solutions Containing omafilcon A (n = 3) 
Contact Lens Material, at 1-Hour and 6-Hour Time Points. Two-way Repeated Measures ANOVAs with Sidak’s Multiple 
Comparisons Test was Performed. No Statistical Differences to Report (p > 0.05). 
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6.4.4 Materials and Methods – Experiment #2 
The second “reduced soaking volume” experiment utilized polypropylene specimen cups 
(VWR, Radnor, PA) and sponges cut to sizes that would fit inside the cups, covering the majority 
of the empty space. The sponges were soaked in warm water and a lens mould was placed on top 
of each sponge. The purpose of utilizing sponges was to create a humid environment once the 
specimen cups were capped, in order to prevent evaporation of the soaking solution. 1-Day Acuvue 
Moist (etafilcon A) and Proclear 1 Day (omafilcon A) contact lenses were placed inside the moulds 
(n = 3) and 200 -L of a prepared cytokine standard blend solution was pipetted on the top surface 
of the lenses only. Separately, Acuvue Oasys 2-week with Hydraclear Plus (senofilcon A) contact 
lenses were also evaluated. The time points chosen for these experiments were 2 hours (rather than 
1 hour) and 6 hours. At the specified time points, 60 -L of each sample was collected and stored 
in a -80℃ freezer to later be analyzed with the MSD assay.  
6.4.5 Results – Experiment #2 
For the experiment involving etafilcon A and omafilcon A materials, theoretical cytokine 
concentrations were 29.45 pg/mL, 36.8 pg/mL, 28.7 pg/mL and 19.0 pg/mL for IL-1", IL-6, IL-8 
and TNF-#, respectively. An aliquot of the cytokine standard blend solution obtained 
approximately 5 minutes following preparation was later quantified by the MSD assay to have 
cytokine concentrations of IL-1", IL-6, IL-8 and TNF-# at 28.62 pg/mL, 36.0 pg/mL, 30.03 pg/mL 
and 16.13 pg/mL, respectively. At 2 hours, control concentrations of IL-1", IL-6, IL-8 and TNF-
# were 28.97 pg/mL, 35.03 pg/mL, 30.18 pg/mL and 15.17 pg/mL, respectively. At 6 hours, 
control concentrations of IL-1", IL-6, IL-8 and TNF-# were 28.64 pg/mL, 33.96 pg/mL, 29.41 
pg/mL and 13.73 pg/mL, respectively.  
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Relative to the control (100%), there was no uptake of any of the four cytokines of interest 
onto either of the two contact lens materials at 2 hours or at 6 hours. At 2 hours, the percent pg/mL 
remaining in solution was 95 ± 2 % (etafilcon A) and 94 ± 4 % (omafilcon A) for IL-1" (Figure 
6-17); 101 ± 1 % (etafilcon A) and 101 ± 4 % (omafilcon A) for IL-6 (Figure 6-18); 97 ± 2 % 
(etafilcon A) and 96 ± 6 % (omafilcon A) for IL-8 (Figure 6-19); and 97 ± 4 % (etafilcon A) and 
94 ± 7 % (omafilcon A) for TNF-# (Figure 6-20). At 6 hours, the percent pg/mL remaining in 
solution was 95 ± 2 % (etafilcon A) and 93 ± 3 % (omafilcon A) for IL-1" (Figure 6-17); 101 ± 
1 % (etafilcon A) and 101 ± 6 % (omafilcon A) for IL-6 (Figure 6-18); 97 ± 1 % (etafilcon A) 
and 97 ± 1 % (omafilcon A) for IL-8 (Figure 6-19); and 104 ± 2 % (etafilcon A) and 99 ± 5 % 
(omafilcon A) for TNF-# (Figure 6-20). Statistical analyses performed using two-way, repeated 
measures ANOVAs with Tukey’s Multiple Comparisons test (where differences were considered 
significant if p < 0.05), revealed no statistical differences (p > 0.05) between the materials 




Figure 6-17: Percent pg/mL of IL-1( Remaining in Reduced Volumes of Cytokine Solutions Containing Either etafilcon A or 
omafilcon A (n = 3) Contact Lens Materials, at 2-Hour and 6-Hour Time Points. Two-way Repeated Measures ANOVAs with 




Figure 6-18: Percent pg/mL of IL-6 Remaining in Reduced Volumes of Cytokine Solutions Containing Either etafilcon A or 
omafilcon A (n = 3) Contact Lens Materials, at 2-Hour and 6-Hour Time Points. Two-way Repeated Measures ANOVAs with 
Tukey’s Multiple Comparisons Test were Performed. No Statistical Differences to Report (p > 0.05). 
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Figure 6-19: Percent pg/mL of IL-8 Remaining in Reduced Volumes of Cytokine Solutions Containing Either etafilcon A or 
omafilcon A (n = 3) Contact Lens Materials, at 2-Hour and 6-Hour Time Points. Two-way Repeated Measures ANOVAs with 




Figure 6-20: Percent pg/mL of TNF-) Remaining in Reduced Volumes of Cytokine Solutions Containing Either etafilcon A 
or omafilcon A (n = 3) Contact Lens Materials, at 2-Hour and 6-Hour Time Points. Two-way Repeated Measures ANOVAs 
with Tukey’s Multiple Comparisons Tests were Performed. No Statistical Differences to Report (p > 0.05). 
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For the next experiment where the senofilcon A material was investigated only, theoretical 
cytokine concentrations were identical to the previous experiment with etafilcon A and omafilcon 
A, as the same calibrator blend was utilized to prepare the soaking solution. According to MSD 
specifications, reconstituted calibrator blends are stable through three freeze-thaw cycles. 
Theoretical concentrations were therefore 29.45 pg/mL, 36.8 pg/mL, 28.7 pg/mL and 19 pg/mL 
for IL-1", IL-6, IL-8 and TNF-#, respectively. An aliquot of the cytokine standard blend solution 
obtained approximately 5 minutes following preparation was later quantified by the MSD assay to 
have cytokine concentrations of IL-1", IL-6, IL-8 and TNF-# at 23.59 pg/mL, 27.88 pg/mL, 23.76 
pg/mL and 9.22 pg/mL, respectively. At 2 hours, control concentrations of IL-1", IL-6, IL-8 and 
TNF-# were 25.17 pg/mL, 30.06 pg/mL, 25.09 pg/mL and 9.18 pg/mL, respectively. At 6 hours, 
control concentrations of IL-1", IL-6, IL-8 and TNF-# were 24.81 pg/mL, 29.42 pg/mL, 25.32 
pg/mL and 8.81 pg/mL, respectively. Although experimental concentrations deviated somewhat 
from the theoretical concentrations (perhaps as a result of the freeze-thaw), especially for TNF-#, 
this did not affect the results, as individual results were presented relative to the control for specific 
time points and hence any deviations were accounted for.  
Relative to the control (100%), there was no uptake of any of the four cytokines of interest 
onto the senofilcon A material at 2 hours or at 6 hours. The percent pg/mL remaining in solution 
after 2 hours was 99 ± 3 % for IL-1" (Figure 6-21); 101 ± 4 % for IL-6 (Figure 6-22); 101 ± 2 
% for IL-8 (Figure 6-23); and 102 ± 3 % for TNF-# (Figure 6-24). In contrast at 6 hours, the 
percent pg/mL remaining in solution was 97 ± 3 % for IL-1" (Figure 6-21); 102 ± 6 % for IL-6 
(Figure 6-22); 100 ± 0.3 % for IL-8 (Figure 6-23); and 99 ± 3 % for TNF-# (Figure 6-24). 
Statistical analyses performed using two-way, repeated measures ANOVAs with Sidak’s Multiple 
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Comparisons test (where differences were considered significant if p < 0.05), revealed no statistical 
differences (p > 0.05) between senofilcon A and the control for either time points.  
 
 
Figure 6-21: Percent pg/mL of IL-1( Remaining in Reduced Volumes of Cytokine Solutions Containing senofilcon A (n = 3) 
Contact Lens Material, at 2-Hour and 6-Hour Time Points. Two-way Repeated Measures ANOVAs with Sidak’s Multiple 
Comparisons Test was Performed. No Statistical Differences to Report (p > 0.05).  
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Figure 6-22: Percent pg/mL of IL-6 Remaining in Reduced Volumes of Cytokine Solutions Containing senofilcon A (n = 3) 
Contact Lens Material, at 2-Hour and 6-Hour Time Points. Two-way Repeated Measures ANOVAs with Sidak’s Multiple 




Figure 6-23: Percent pg/mL of IL-8 Remaining in Reduced Volumes of Cytokine Solutions Containing senofilcon A (n = 3) 
Contact Lens Material, at 2-Hour and 6-Hour Time Points. Two-way Repeated Measures ANOVAs with Sidak’s Multiple 
Comparisons Test was Performed. No Statistical Differences to Report (p > 0.05).  
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Figure 6-24: Percent pg/mL of TNF-) Remaining in Reduced Volumes of Cytokine Solutions Containing senofilcon A (n = 
3) Contact Lens Material, at 2-Hour and 6-Hour Time Points. Two-way Repeated Measures ANOVAs with Sidak’s Multiple 
Comparisons Test was Performed. No Statistical Differences to Report (p > 0.05). 
 
6.4.6 Discussion – Reduced Soaking Volume Experiments #1 and #2 
Reducing the soaking volume from 1000 -L to 400 -L and a further reduction to 200 -L, 
did not appear to produce results that differed vastly from that which was already gathered through 
the previous studies. While no uptake was quantified from the cytokine solutions containing 
etafilcon A, omafilcon A and senofilcon A materials, even when soaked in smaller volumes, this 
did not necessarily negate the likelihood that reducing the soaking volume could facilitate 
quantification of uptake by the MSD instrument. While it is possible that reducing the soaking 
volume could improve the detection of uptake, as a result of the differences in the initial and final 
concentrations being larger and potentially more easily differentiated from each other on a 
picogram scale (as described in section 6.4.1), this would not be evident if the contact lens 
materials resist cytokine uptake in the first place. 
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Given the number of experiments performed thus far and the common result observed 
among them of little to no uptake of the cytokines of interest onto etafilcon A, omafilcon A or 
senofilcon A contact lens materials, it appeared more likely that these materials did not interact 
with the cytokines of interest in such a way that would allow for the cytokines to be taken up onto 
their surface over time, rather than the soaking volume or some other portion of the methodology 
preventing proper quantification of the cytokines in solution. However, the next set of experiments 
attempted to focus more closely on the interaction between cytokines and contact lens materials 
by better modelling ocular conditions, through the use of artificial tear solution (ATS), as a means 
to improve the interaction between the cytokines and the contact lens materials, and potentially 
result in more enhanced levels of uptake.  
6.5 Investigating the Effects of Using Artificial Tear Solution on Cytokine Uptake by 
Contact Lenses 
6.5.1 Introduction 
The “artificial tear solution” (ATS) used in these studies closely mimics the human tear 
film as it is composed of many of the same constituents, including a complex salt solution of 
calcium chloride (0.5 mM), glucose (0.2 mM), hydrochloric acid (26.0 mM), potassium chloride 
(16.0 mM), potassium hydrogen carbonate (3.0 mM), sodium carbonate (12.0 mM), sodium 
chloride (90.0 mM), sodium citrate (1.5 mM), sodium phosphate dibasic (24.0 mM) and urea (1.2 
mM); a 6-lipid stock of cholesterol (0.0018 mg/mL), cholesteryl oleate (0.024 mg/mL), oleic acid 
(0.0018 mg/mL), oleic acid methyl ester (0.012 mg/mL), phosphatidylcholine (0.0005 mg/mL) 
and triolein (0.016 mg/mL); in addition to bovine serum albumin (0.2 mg/mL), bovine colostrum 
lactoferrin (1.80 mg/mL), bovine immunoglobulin G (0.02 mg/mL), bovine submaxillary mucin 
(0.15 mg/mL) and hen egg lysozyme (1.90 mg/mL).109 ATS can also share similar constituents to 
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that of Diluent 2, including bovine serum albumin, immunoglobulin G and sodium chloride, as 
well as a similar pH (typically between 7.2 – 7.6 for ATS versus 7.4 for Diluent 2).  
The use of ATS in the following experiments aimed to more accurately model ocular 
conditions and when compared to the experiments performed in a Diluent 2 cytokine solution, 
could provide insight into whether there is a component in the human tear film that may potentially 
aid cytokine uptake onto the contact lens materials of interest. It was hypothesized that perhaps 
this component could somehow enhance cytokine uptake, which would not otherwise be evident 
through the in vitro experiments presented in this chapter thus far, where the cytokines were 
suspended in a solution of Diluent 2 alone. Utilizing ATS, however, could potentially allow for 
the exploration of a possible indirect route of cytokine uptake onto contact lens materials – one 
whereby the cytokines bind a component of the human tear film and it is this component that, 
along with the bound cytokines, would deposit onto the surface of the contact lens materials. 
6.5.2 Materials and Methods – ATS Experiment #1 
Two experiments were performed utilizing ATS. For both experiments, ATS was prepared 
in-house (protocol undisclosed), without bovine immunoglobulin G (for cost purposes), with a pH 
between 7.2 – 7.6 (typically 7.4) and the concentrations of all other constituents as outlined in 
section 6.5.1). In the first experiment, 1-Day Acuvue Moist (etafilcon A), Proclear 1 Day 
(omafilcon A) and Acuvue Oasys 2-week with Hydraclear Plus (senofilcon A), were soaked 
overnight (between 12-24 hours) in polypropylene tubes containing 1 mL ATS. This step followed 
the routine PBS soak to remove any contact lens packaging solution, as described in section 4.3. 
After the ATS soak, the lenses were placed in polypropylene tubes (n = 3) containing 1 mL of the 
cytokine standard blend solution (prepared in Diluent 2). The contact lenses were dried on 
Fisherbrand lens paper in between the PBS and ATS soaks, as well as prior to being transferred 
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from ATS to the standard blend solution. Alike to experiment #2 described in section 6.3.6, 60 -L 
of each sample was pipetted out from the tubes at the half-hour, 1-hour and 6-hour time points, 
and stored in a -80℃ freezer to later be analyzed by the MSD assay. Theoretical concentrations of 
IL-1", IL-6, IL-8 and TNF-# were 26.0 pg/mL, 37.45 pg/mL, 27.3 pg/mL and 15.55 pg/mL, 
respectively. 
6.5.3 Results – ATS Experiment #1 
After a half-hour, control concentrations of IL-1", IL-6, IL-8 and TNF-# were 27.77 
pg/mL, 36.55 pg/mL, 27.90 pg/mL and 14.32 pg/mL, respectively. At 1 hour, control 
concentrations of IL-1", IL-6, IL-8 and TNF-# were 28.98 pg/mL, 39.08 pg/mL, 28.19 pg/mL and 
14.07 pg/mL, respectively. At 6 hours, control concentrations of IL-1", IL-6, IL-8 and TNF-# 
were 27.0 pg/mL, 38.21 pg/mL, 27.17 pg/mL and 11.2 pg/mL, respectively. Statistical analyses 
were performed using two-way, repeated measures ANOVAs with Tukey’s Multiple Comparisons 
test, where differences were considered significant if p < 0.05. The results obtained in this 
experiment were quite similar to those obtained from the experiment outlined in section 6.3.7. 
These experiments were essentially identical, with the only difference being that this experiment 
involved an additional soaking step in ATS, prior to investigating uptake using the cytokine 
standard blend solution in Diluent 2.  
 Similar to the results outlined in section 6.3.7, at the half-hour time point, there was no 
uptake of any of the four cytokines of interest onto either etafilcon A, omafilcon A, or senofilcon 
A materials. Relative to the control (100%), the percent pg/mL remaining in solution at this time 
point was 99 ± 5 % (etafilcon A), 99 ± 0.5 % (omafilcon A) and 103 ± 4 % (senofilcon A) for 
IL-1"	(Figure 6-25); 97 ± 6 % (etafilcon A), 103 ± 3 % (omafilcon A) and 102 ± 4 % (senofilcon 
A) for IL-6 (Figure 6-26); 95 ± 3 % (etafilcon A), 101 ± 3 % (omafilcon A) and 102 ± 2 % 
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(senofilcon A) for IL-8 (Figure 6-27); and 97 ± 6 % (etafilcon A), 96 ± 1 % (omafilcon A) and 
102 ± 2 % (senofilcon A) for TNF-# (Figure 6-28). There were no statistical differences (p > 0.05) 
between the control or the materials for any of the cytokines at this time point.  
At the 1-hour time point, there was no uptake of IL-1", IL-6, or IL-8 onto either etafilcon 
A, omafilcon A, or senofilcon A materials. Relative to the control (100%), the percent pg/mL 
remaining in solution at this time point was 93 ± 5 % (etafilcon A), 93 ± 2 % (omafilcon A) and 
97 ± 3 % (senofilcon A) for IL-1" (Figure 6-25); 96 ± 9 % (etafilcon A), 102 ± 1 % (omafilcon 
A) and 99 ± 6 % (senofilcon A) for IL-6 (Figure 6-26); and 101 ± 6 % (etafilcon A), 98 ± 2 % 
(omafilcon A) and 101 ± 5 % (senofilcon A) for IL-8 (Figure 6-27). For TNF-# (Figure 6-28), the 
percent pg/mL remaining in solution after 1 hour was 93 ± 7 % (etafilcon A), 85 ± 5 % (omafilcon 
A) and 101 ± 4 % (senofilcon A). There was a statistical difference for omafilcon A relative to the 
control (adjusted P-value 0.0388), suggesting potential uptake of TNF-# onto this material, as well 
as a statistical difference for omafilcon A relative to senofilcon A (adjusted P-value 0.0207) at this 
time point, both of which are defined by the star (*) symbol. This was similar to the result obtained 
for TNF-# in section 6.3.7 (Figure 6-12), where omafilcon A was also statistically different from 
the control at 1 hour.  
At the 6-hour time point, there was no uptake of IL-1", IL-6, or IL-8 onto either etafilcon 
A, omafilcon A, or senofilcon A materials. Relative to the control (100%), the percent pg/mL 
remaining in solution at this time point was 96 ± 4 % (etafilcon A), 95 ± 1 % (omafilcon A) and 
101 ± 3 % (senofilcon A) for IL-1"	(Figure 6-25); 98 ± 9 % (etafilcon A), 103 ± 3 % (omafilcon 
A) and 106 ± 3 % (senofilcon A) for IL-6 (Figure 6-26); and 93 ± 8 % (etafilcon A), 93 ± 3 % 
(omafilcon A) and 103 ± 7 % (senofilcon A) for IL-8 (Figure 6-27). For TNF-# (Figure 6-28), the 
percent pg/mL remaining in solution at this time point was 93 ± 4 % (etafilcon A), 85 ± 11 % 
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(omafilcon A) and 102 ± 12 % (senofilcon A). As defined by the star (*) symbol, there was a 
statistical difference for omafilcon A relative to the control (adjusted P-value 0.0364), suggesting 
potential uptake of TNF-# onto this material, and omafilcon A was also statistically different from 
senofilcon A (adjusted P-value 0.0150) at this time point. In this case, this result was not similar 
to that obtained for TNF-# in section 6.3.7 (Figure 6-12), where omafilcon A was not statistically 
different from the control at 6 hours.  
 
 
Figure 6-25: Percent pg/mL of IL-1( Remaining in Cytokine Solutions Containing Either etafilcon A, omafilcon A, or 
senofilcon A (n = 3) Contact Lens Materials Pre-Soaked in ATS, at Half-Hour, 1-Hour and 6-Hour Time Points. Two-way 
Repeated Measures ANOVAs with Tukey’s Multiple Comparisons Test were Performed. No Statistical Differences to Report 





Figure 6-26: Percent pg/mL of IL-6 Remaining in Cytokine Solutions Containing Either etafilcon A, omafilcon A, or 
senofilcon A (n = 3) Contact Lens Materials Pre-Soaked in ATS, at Half-Hour, 1-Hour and 6-Hour Time Points. Two-way 
Repeated Measures ANOVAs with Tukey’s Multiple Comparisons Test were Performed. No Statistical Differences to Report 
(p > 0.05). 
 
 
Figure 6-27: Percent pg/mL of IL-8 Remaining in Cytokine Solutions Containing Either etafilcon A, omafilcon A, or 
senofilcon A (n = 3) Contact Lens Materials Pre-Soaked in ATS, at Half-Hour, 1-Hour and 6-Hour Time Points. Two-way 
Repeated Measures ANOVAs with Tukey’s Multiple Comparisons Tests were Performed. No Statistical Differences to Report 
(p > 0.05).  
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Figure 6-28: Percent pg/mL of TNF-) Remaining in Cytokine Solutions Containing Either etafilcon A, omafilcon A, or 
senofilcon A (n = 3) Contact Lens Materials Pre Soaked in ATS, at Half-Hour, 1-Hour and 6-Hour Time Points. Two-way 
Repeated Measures ANOVAs with Tukey’s Multiple Comparisons Test were Performed. At 1 hour and 6 hours, omafilcon A 
was Statistically Different from the Respective Controls and from senofilcon A, as Defined by the Star (*) Symbols.  
 
6.5.4 Materials and Methods – ATS Experiment #2  
In contrast to ATS experiment #1 described above, the second experiment was performed 
entirely in ATS. After soaking 1-Day Acuvue Moist (etafilcon A), Proclear 1 Day (omafilcon A) 
and Acuvue Oasys 2-week with Hydraclear Plus (senofilcon A) contact lenses in PBS and drying 
them on Fisherband lens paper, the lenses were transferred into polypropylene tubes (n = 3) 
containing 1 mL of a cytokine solution in ATS. This solution was prepared by reconstituting the 
lyophilized MSD calibrator blend in 1 mL (1000 -L) of Diluent 2, and then transferring 650 -L 
of the 1000 -L reconstituted solution into 12,350 -L of ATS, in order to provide the desired final 
volume of 13,000 -L for the experiment. The samples were evaluated for cytokine uptake after a 
6-hour time period, when 60 -L was pipetted out from each tube and stored in a -80℃ freezer to 
later be analyzed by the MSD assay. As per MSD’s guidelines, it was necessary for the lyophilized 
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calibrator blend to be reconstituted in MSD Diluent 2 and therefore it could not be reconstituted 
in ATS. Apart from the 650 -L volume of Diluent 2 in the overall solution, the remaining 12,350 
-L volume was ATS, whereas previous experiments would have entirely utilized Diluent 2 for the 
soaking solution.  
6.5.5 Results – ATS Experiment #2  
Theoretical concentrations of IL-1", IL-6, IL-8 and TNF-# were 26.0 pg/mL, 37.45 pg/mL, 
27.3 pg/mL and 15.55 pg/mL, respectively. An aliquot of the cytokine standard blend solution 
obtained approximately 5 minutes following preparation was later quantified by the MSD assay to 
have cytokine concentrations of 23.68 pg/mL, 37.91 pg/mL, 28.11 pg/mL and 14.43 pg/mL for 
IL-1", IL-6, IL-8 and TNF-#, respectively. At 6 hours, control concentrations of IL-1", IL-6, IL-
8 and TNF-# were 19.34 pg/mL, 35.64 pg/mL, 30.68 pg/mL and 15.28 pg/mL, respectively. 
Statistical analyses were performed using ordinary one-way ANOVAs with Tukey’s Multiple 
Comparisons test. Differences were considered significant if p < 0.05.  
There did not appear to be any uptake of IL-1" (Figure 6-29) relative to the control (100%) 
for either etafilcon A (106 ± 2 %), omafilcon A (102 ± 1 %) or senofilcon A (97 ± 3 %). Etafilcon 
A was statistically different from the control (adjusted P-value 0.0496), as defined by the number 
(#) symbol, however, this was as a result of having a value greater than 100% of the control and 
was therefore not indicative of uptake. Additionally, senofilcon A was statistically different from 
etafilcon A (adjusted P-value 0.0040) and omafilcon A (adjusted P-value 0.0479), as defined by 
the star (*) symbol, although again, this did not indicate uptake, as neither of these materials were 
statistically different from the 6-hour control.  
There was no uptake of IL-6 (Figure 6-30), IL-8 (Figure 6-31), or TNF-# (Figure 6-32) 
onto any of the contact lens materials tested either. Relative to the control (100%) for IL-6, the 
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percent pg/mL remaining in solution was 109 ± 4 % (etafilcon A), 110 ± 8 % (omafilcon A) and 
108 ± 7 % (senofilcon A). Relative to the control (100%) for IL-8, the percent pg/mL remaining 
in solution was 102 ± 3 % (etafilcon A), 102 ± 3 % (omafilcon A) and 99 ± 7 % (senofilcon A). 
Lastly, relative to the control (100%) for TNF-#, the percent pg/mL remaining in solution was 99 
± 7 % (etafilcon A), 96 ± 2 % (omafilcon A) and 98 ± 4 % (senofilcon A). Statistical analyses 
did not reveal any differences between the control and any of these materials at 6 hours, or between 
the materials themselves.  
 
 
Figure 6-29: Percent pg/mL of IL-1( Remaining in ATS Cytokine Solutions Containing Either etafilcon A, omafilcon A, or 
senofilcon A (n = 3) Contact Lens Materials at 6 Hours. Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons 
Test were Performed. Senofilcon A was Statistically Different from both etafilcon A and omafilcon A Only, as Defined by the 
Star (*) Symbol, but was Not Statistically Different from the Control. Etafilcon A was Statistically Different from the Control, 




Figure 6-30: Percent pg/mL of IL-6 Remaining in ATS Cytokine Solutions Containing Either etafilcon A, omafilcon A, or 
senofilcon A (n = 3) Contact Lens Materials at 6 Hours. Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons 
Test were Performed. No Statistical Differences to Report (p > 0.05). 
 
 
Figure 6-31: Percent pg/mL of IL-8 Remaining in ATS Cytokine Solutions Containing Either etafilcon A, omafilcon A, or 
senofilcon A (n = 3) Contact Lens Materials at 6 Hours. Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons 




Figure 6-32: Percent pg/mL of TNF-) Remaining in ATS Cytokine Solutions Containing Either etafilcon A, omafilcon A, or 
senofilcon A (n = 3) Contact Lens Materials at 6 Hours. Ordinary One-Way ANOVAs with Tukey’s Multiple Comparisons 
Test were Performed. No Statistical Differences to Report (p > 0.05). 
 
 
6.5.6  Discussion – ATS Experiments #1 and #2 
While there may have been some uptake onto omafilcon A contact lens material at 1 hour 
(85 ± 5 %) and at 6 hours (85 ± 11 %), in comparison to the respective controls, when this material 
was pre-soaked in ATS prior to being soaked in the cytokine solution in Diluent 2, this result was 
not observed for any of the other materials tested, regardless of if the materials were either pre-
soaked in ATS or soaked entirely in an ATS solution containing cytokines. Thus, there did not 
appear to be much difference in cytokine uptake onto the contact lens materials under these 
experimental conditions, in comparison to when the materials were soaked in a Diluent 2 cytokine 
solution only. It is important to note that the ATS utilized in the presented experiments above did 
not include all components of the tear film (such as IgG, IgM or IgA), and that many different 
versions of ATS can be prepared. Since the results obtained from ATS experiments #1 and #2 were 
in accordance with previous results, however, this helped to support the use of Diluent 2 for 
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preparing cytokine solutions in subsequent experiments, and ATS was no longer utilized due to 
cost purposes.  
6.6 Testing Additional Contact Lens Materials 
6.6.1 Introduction 
The experiments presented throughout Chapter 6 thus far explored cytokine uptake onto 
two high-water content conventional hydrogels differing in their ionicity. This was the ionic 
etafilcon A (1-Day Acuvue Moist) and nonionic omafilcon A (Proclear 1 Day) contact lens 
materials. Additionally, senofilcon A (Acuvue Oasys 2-week with Hydraclear Plus), a low water, 
nonionic SiHy, was explored for contrast. Of these, omafilcon A appeared to be the material that 
exhibited some amount of uptake, though this was not consistently evident throughout all of the 
experiments, but rather an occasional result that was observed for either IL-1" or TNF-# cytokines 
specifically.   
To contrast the senofilcon A material, SiHy materials of high water content, nonionic 
property, i.e., somofilcon A (Clariti 1 Day) and low water content, nonionic property, i.e., 
comfilcon A (Biofinity) were also investigated, in addition to a low water content, but ionic SiHy 
material i.e., balafilcon A (PureVision). Studying uptake of the four cytokines of interest onto 
these additional materials would allow for further comparisons between somofilcon A and 
omafilcon A materials, which differ only in their class of material (SiHy vs. conventional hydrogel, 
respectively), but share both high water content and nonionic characteristics. In contrast, 
comparisons between somofilcon A and senofilcon A would also allow for an investigation of 
differences in uptake between the same class of soft contact lens material (SiHy), that share a 
nonionic character but differ in their water content levels. As well, comparisons between balafilcon 
A and etafilcon A could also be drawn for ionic materials of different classes (SiHy vs. 
conventional hydrogel, respectively) and different water content levels (low water content vs. high 
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water content, respectively). In addition, between comfilcon A and omafilcon A, comparisons 
could be drawn in regard to materials of different classes that share a nonionic character, but are 
of different water content levels as well.  
6.6.2 Materials and Methods 
In the first experiment, PureVision (balafilcon A) and Biofinity (comfilcon A) contact 
lenses were prepared as described in section 4.3 and placed in polypropylene tubes (n = 3) 
containing 1 mL of the cytokine standard blend solution. Control tubes contained only 1 mL of the 
cytokine solution. Samples were evaluated for cytokine uptake at 1-hour and 6-hour time points, 
when 60 -L was pipetted out from each tube and stored in a -80℃ freezer to later be analyzed by 
the MSD assay. In the second experiment, the same procedure was repeated for Clariti 1 Day 
(somofilcon A) contact lenses. Statistical analyses were performed using two-way, repeated 
measures ANOVAs with Tukey’s Multiple Comparisons test. Differences were considered 
significant if p < 0.05. 
6.6.3 Results – Balafilcon A and Comfilcon A 
Theoretical cytokine concentrations were 28.05 pg/mL, 37.5 pg/mL, 30.8 pg/mL and 17.3 
pg/mL for IL-1", IL-6, IL-8 and TNF-#, respectively. An aliquot of the cytokine standard blend 
solution obtained approximately 5 minutes following preparation was later quantified by the MSD 
assay to have cytokine concentrations of 27.30 pg/mL, 33.90 pg/mL, 30.23 pg/mL and 14.90 
pg/mL for IL-1", IL-6, IL-8 and TNF-#, respectively. At 1 hour, control concentrations of IL-1", 
IL-6, IL-8 and TNF-# were 28.51 pg/mL, 35.78 pg/mL, 31.50 pg/mL and 15.41 pg/mL, 
respectively. At 6 hours, control concentrations of IL-1", IL-6, IL-8 and TNF-# were 28.59 
pg/mL, 35.90 pg/mL, 31.66 pg/mL and 13.26 pg/mL, respectively. 
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There appeared to be no uptake of IL-1" (Figure 6-33) relative to the control (100%) at 1 
hour, as the percent pg/mL remaining in solution was 97 ± 1 % for balafilcon A and 97 ± 1 % for 
comfilcon A. In contrast at 6 hours, there did appear to be some uptake by the materials as the 
percent pg/mL remaining in solution was 90 ± 3 % for balafilcon A and 87 ± 2 % for comfilcon 
A, relative to the control (100%). There was a statistical difference between the 6-hour control and 
both balafilcon A (adjusted P-value < 0.0001) and comfilcon A (adjusted P-value < 0.0001), as 
defined by star (*) symbols.  
 
 
Figure 6-33: Percent pg/mL of IL-1( Remaining in Cytokine Solutions Containing Either balafilcon A or comfilcon A (n = 3) 
Contact Lens Materials, at 1-Hour and 6-Hour Time Points. Two-way Repeated Measures ANOVAs with Tukey’s Multiple 
Comparisons Test were Performed. At 6 Hours, balafilcon A and comfilcon A were Statistically Different from the 6-Hour 




Figure 6-34: Percent pg/mL of IL-6 Remaining in Cytokine Solutions Containing Either balafilcon A or comfilcon A (n = 3) 
Contact Lens Materials, at 1-Hour and 6-Hour Time Points. Two-way Repeated Measures ANOVAs with Tukey’s Multiple 
Comparisons Test were Performed. No Statistical Differences to Report (p > 0.05).   
 
 
For IL-6 (Figure 6-34), there did not appear to be any uptake by balafilcon A or comfilcon 
A at either 1 hour or 6 hours, as there were no statistical differences (p > 0.05) between these 
materials and the respective controls. Relative to the 1-hour control (100%), the percent pg/mL 
remaining in solution was 99 ± 7 % for balafilcon A and 100 ± 2 % for comfilcon A. In contrast, 
relative to the 6-hour control (100%), the percent pg/mL remaining in solution was 100 ± 4 % for 





Figure 6-35: Percent pg/mL of IL-8 Remaining in Cytokine Solutions Containing Either balafilcon A or comfilcon A (n = 3) 
Contact Lens Materials, at 1-Hour and 6-Hour Time Points. Two-way Repeated Measures ANOVAs with Tukey’s Multiple 
Comparisons Test were Performed. At 6 Hours, balafilcon A and comfilcon A were Statistically Different from the 6-Hour 
Control, as Defined by the Star (*) Symbols.  
 
 
There appeared to be no uptake of IL-8 (Figure 6-35) relative to the control (100%) at 1 
hour, as the percent pg/mL remaining in solution was 90 ± 12 % for balafilcon A and 100 ± 4 % 
for comfilcon A. In contrast, at 6 hours, there did appear to be some uptake by the materials as the 
percent pg/mL remaining in solution was 85 ± 5 % for balafilcon A and 81 ± 5 % for comfilcon 
A, relative to the control (100%). There was a statistical difference between the 6-hour control and 
both balafilcon A (adjusted P-value 0.0269) and comfilcon A (adjusted P-value 0.0066), as defined 
by the star (*) symbols.  
For TNF-# (Figure 6-36), there appeared to be no uptake relative to the control (100%) at 
1 hour, as the percent pg/mL remaining in solution was 98 ± 23 % for balafilcon A and 88 ± 8 % 
for comfilcon A. In contrast, at 6 hours, there did appear to be some uptake by balafilcon A 
material, as the percent pg/mL remaining in solution was 75 ± 12 %. However, at this time point, 
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there was no uptake by comfilcon A, as the percent pg/mL remaining in solution was 80 ± 5 %. 
There was a statistical difference only between the 6-hour control and balafilcon A (adjusted P-
value 0.0489), as defined by the star (*) symbol.  
 
 
Figure 6-36: Percent pg/mL of TNF-) Remaining in Cytokine Solutions Containing Either balafilcon A or comfilcon A (n = 
3) Contact Lens Materials, at 1-Hour and 6-Hour Time Points. Two-way Repeated Measures ANOVAs with Tukey’s Multiple 
Comparisons Test were Performed. At 6 Hours, balafilcon A and comfilcon A were Statistically Different from the 6-Hour 
Control, as Defined by the Star (*) Symbol.  
 
 
6.6.4 Results – Somofilcon A 
Theoretical cytokine concentrations were 28.7 pg/mL, 36.3 pg/mL, 27.75 pg/mL and 17.85 
pg/mL for IL-1", IL-6, IL-8 and TNF-#, respectively. An aliquot of the cytokine standard blend 
solution obtained approximately 5 minutes following preparation was later quantified by the MSD 
assay to have cytokine concentrations of IL-1", IL-6, IL-8 and TNF-# at 21.30 pg/mL, 35.36 
pg/mL, 21.62 pg/mL and 10.59 pg/mL, respectively. At 1 hour, control concentrations of IL-1", 
IL-6, IL-8 and TNF-# were 25.68 pg/mL, 35.11 pg/mL, 26.36 pg/mL and 13.38 pg/mL, 
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respectively. At 6 hours, control concentrations of IL-1", IL-6, IL-8 and TNF-# were 28.06 
pg/mL, 34.61 pg/mL, 26.29 pg/mL and 11.70 pg/mL, respectively. 
Relative to the control (100%), there was no uptake of any of the four cytokines of interest 
onto somofilcon A material at 1 hour or at 6 hours. The percent pg/mL remaining in solution after 
1 hour was 98 ± 3 % for IL-1" (Figure 6-37); 94 ± 5 % for IL-6 (Figure 6-38); 89 ± 12 % for IL-
8 (Figure 6-39); and 90 ± 15 % for TNF-# (Figure 6-40). In contrast, at 6 hours, the percent pg/mL 
remaining in solution was 98 ± 3 % for IL-1" (Figure 6-37); 99 ± 8 % for IL-6 (Figure 6-38); 91 
± 7 % for IL-8 (Figure 6-39); and 93 ± 7 % for TNF-# (Figure 6-40). Statistical analyses 
performed using two-way, repeated measures ANOVAs with Sidak’s Multiple Comparisons test 
(where differences were considered significant if p < 0.05), revealed no statistical differences 
between somofilcon A and the control for either time points (p > 0.05).  
 
 
Figure 6-37: Percent pg/mL of IL-1( Remaining in Cytokine Solutions Containing somofilcon A (n = 3) Contact Lens 
Material, at 1-Hour and 6-Hour Time Points. Two-way Repeated Measures ANOVAs with Sidak’s Multiple Comparisons Test 




Figure 6-38: Percent pg/mL of IL-6 Remaining in Cytokine Solutions Containing somofilcon A (n = 3) Contact Lens 
Material, at 1-Hour and 6-Hour Time Points. Two-way Repeated Measures ANOVAs with Sidak’s Multiple Comparisons Test 
was Performed. No Statistical Differences to Report (p > 0.05). 
 
 
Figure 6-39: Percent pg/mL of IL-8 Remaining in Cytokine Solutions Containing somofilcon A (n = 3) Contact Lens 
Material, at 1-Hour and 6-Hour Time Points. Two-way Repeated Measures ANOVAs with Sidak’s Multiple Comparisons Test 
was Performed. No Statistical Differences to Report (p > 0.05). 
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Figure 6-40: Percent pg/mL of TNF-) Remaining in Cytokine Solutions Containing somofilcon A (n = 3) Contact Lens 
Material, at 1-Hour and 6-Hour Time Points. Two-way Repeated Measures ANOVAs with Sidak’s Multiple Comparisons Test 
was Performed. No Statistical Differences to Report (p > 0.05). 
 
6.6.5 Discussion – Balafilcon A, Comfilcon A and Somofilcon A 
Of the additional SiHy materials tested, somofilcon A did not exhibit any uptake of the 
cytokines of interest over the 6-hour study period; however, balafilcon A and comfilcon A 
materials did exhibit some uptake at 6 hours when compared to the control. Interestingly, 
balafilcon A and comfilcon A are both low water content materials that differ in their ionicity. 
Balafilcon A is ionic (negatively charged due to its principal monomer N-vinyl aminobutyric acid), 
while comfilcon A is nonionic.58,100 Both of these materials exhibited some uptake of IL-1" and 
IL-8, while balafilcon A additionally exhibited some uptake of TNF-#, which comfilcon A did 
not. Recall, the surface of IL-1" and TNF-# should be predominately negatively charged based 
on their pI values and the pH of the standard blend soaking solution.83,85,91,92 In contrast, the surface 
of IL-8 should be predominately positively charged.83,89 Based on this, it appeared that the pI 
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values were not a significant factor that influenced cytokine uptake, as the results obtained were 
not in accordance with expected results should the pI values have influenced uptake. For example, 
a negatively charged material such as balafilcon A should have resisted uptake of negatively 
charged IL-1" and TNF-# in the standard blend solution.58,59,83,85,91,92 While balafilcon A did 
uptake IL-8, which has a positively charged surface in the standard blend solution, it did not exhibit 
uptake of this cytokine in greater amounts than did comfilcon A, which is a nonionic material that 
would potentially have less attraction for a charged cytokine.83 Moreover, in the previous 
experiments presented throughout Chapter 5: and Chapter 6:, etafilcon A did not exhibit uptake of 
positively charged IL-8 in the standard blend solution either, even though it is also a negatively 
charged material - akin to balafilcon A.59,83,89  
Furthermore, when comparing the results of this experiment to previous experiments, there 
are some similarities between balafilcon A and comfilcon A in regard to the uptake of particular 
cytokines, however, parallels cannot be drawn between these materials in terms of what would be 
influencing this uptake that is observed. For example, balafilcon A, comfilcon A, and omafilcon 
A exhibited uptake of IL-1"; however, there was no single characteristic (e.g., same class of 
material, water content, or ionicity), that was collectively shared among all three of them.58,59,100 
Furthermore, balafilcon A and omafilcon A both exhibited uptake of TNF-#, yet they both also 
differ in their class of material, water content and ionicity as well.58,59  
Although the following observations are not conclusive, perhaps the uptake of IL-8 could 
be dependent on the water content of a contact lens material, as both balafilcon A and comfilcon 
A did exhibit some uptake of IL-8 and they are both low water content materials.58,100 Although, 
if this were definitely the case, then senofilcon A material should have also exhibited uptake of 
IL-8, as it is also a low water content SiHy material.59 Furthermore, another observation is the 
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consistent lack of IL-6 uptake onto any of the materials tested in the experiments presented in 
Chapter 5: and Chapter 6:. This could perhaps be due to the size of IL-6, as it is one of the larger 
cytokines of the four cytokines of interest15 (Table 3-2) and according to Meso Scale Discovery 
Scientific Support, its predicted size in the calibrator blend (which was used to prepare the cytokine 
solution), is 20.3 kDa, while the predicted sizes of IL-1", IL-8 and TNF-# are 17 kDa, 8 kDa and 
17.5 kDa, respectively. Given that the results of the experiments thus far remained inconclusive as 
to what exactly may or may not have influenced cytokine uptake onto the contact lens materials 
investigated, the subsequent experiment presented below explored whether utilizing higher 
concentrations of the cytokines of interest in the soaking solution could instead result in greater 
uptake onto the contact lens materials.  
6.7 Testing Uptake Under Higher Cytokine Concentrations 
6.7.1 Introduction 
The experiments presented in Chapter 5: and Chapter 6: investigated uptake onto various 
contact lens materials at concentrations near the lower range reported in the literature (Table 3-3). 
These concentrations were representative of uptake under basal cytokine concentrations within the 
eye. The next experiment utilized a standard blend of higher cytokine concentrations to explore 
uptake under simulated inflammatory ocular conditions. Additionally, this was accompanied by 
an extended soaking period for up to 7 days. It was hypothesized that perhaps there would be more 
uptake by the contact lens materials if soaked at higher concentrations over a longer period of time. 
Reusable contact lenses were chosen for this experiment due to the 7-day soaking period, 
as exploring uptake within this time would not be applicable to daily disposable contact lenses. 
One reusable contact lens was chosen from the conventional hydrogel class of materials and the 
other from the SiHy class. For the conventional hydrogel, etafilcon A material was chosen from 
one of the two conventional hydrogel materials that had previously been tested. While omafilcon 
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A appeared to exhibit more uptake than etafilcon A in the previous studies, Proclear 1 Day 
(omafilcon A) is a disposable contact lens and other omafilcon A material lenses were either 
multifocal or toric and were therefore not of interest to be utilized in the study. Acuvue 2, on the 
other hand, is a commonly used, reusable contact lens of etafilcon A material. For the SiHy, 
comfilcon A material (Biofinity) was chosen over balafilcon A (PureVision). Although both of 
these materials exhibited uptake for some of the cytokines when tested at lower concentrations, 
choosing comfilcon A better contrasted etafilcon A and allowed for investigations of differences 
in not only the class of material (conventional vs. SiHy), but also water content and ionicity. 
Comfilcon A is a low water content, nonionic material, while etafilcon A is a high water content, 
ionic material.59,100  
6.7.2 Materials and Methods 
Acuvue 2 (etafilcon A) and Biofinity (comfilcon A) contact lenses were prepared as 
described in section 4.3 and placed in polypropylene tubes (n = 3) containing 1 mL of a cytokine 
standard blend solution that was prepared by combining two MSD calibrator blends of the same 
lot number. Control tubes contained only 1 mL of this cytokine solution with no contact lenses. 
The polypropylene tubes were wrapped in parafilm to prevent evaporation over the 7-day soaking 
period. 60 -L samples were collected at 24 hours, 72 hours (3 days), and at the 7-day mark.  
The cytokine soaking solution was not exchanged for fresh cytokine solution at the time 
points mentioned, as this would have introduced potential complications to the study that had not 
been investigated in the experiments thus far. In a clinical example, if there was uptake onto a 
reusable contact lens material, when the lens is removed from the eye at the end of the day, cleaned 
and placed into a care system in a contact lens case, it may be possible that any cytokines remaining 
on the surface of the lens could release back into the solution. This would then introduce questions 
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in regard to how tightly bound the cytokines are to the lenses and whether they can be washed off 
when the lenses are cleaned, in addition to questions about the level of release that could be 
expected should the cytokines not be washed off the surface of the lens, and also whether the 
cytokines could uptake back onto the lenses as they soak in the care system overnight and hence 
be reintroduced to the ocular surface when the same lens is worn again the next day. The 
experiments presented in this thesis did not focus on testing for cytokine release from contact lens 
materials, because many of the materials tested did not even exhibit an initial uptake of cytokines. 
Based on this, it was not expected that there would be much release from the lenses over the 7-day 
study period regardless.  
6.7.3 Results 
Theoretical cytokine concentrations were 106.97 pg/mL, 142.69 pg/mL, 118.94 pg/mL and 
66.88 pg/mL for IL-1", IL-6, IL-8 and TNF-#, respectively. An aliquot of the cytokine standard 
blend solution obtained approximately 5 minutes following preparation was later quantified by the 
MSD assay to have cytokine concentrations of 92.86 pg/mL, 129.46 pg/mL, 92.93 pg/mL and 
39.38 pg/mL for IL-1", IL-6, IL-8 and TNF-#, respectively. At 24 hours, control concentrations 
of IL-1", IL-6, IL-8 and TNF-# were 94.33 pg/mL, 126.93 pg/mL, 108.88 pg/mL and 41.75 
pg/mL, respectively. At 72 hours, control concentrations of IL-1", IL-6, IL-8 and TNF-# were 
96.15 pg/mL, 119.32 pg/mL, 112.28 pg/mL and 34.21 pg/mL, respectively. At 7 days, control 
concentrations of IL-1", IL-6, IL-8 and TNF-# were 93.94 pg/mL, 113.06 pg/mL, 111.10 pg/mL 
and 28.59 pg/mL, respectively. Statistical analyses were performed using two-way, repeated 
measures ANOVAs with Tukey’s Multiple Comparisons tests. Differences were considered 
significant if p < 0.05. 
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At 24 hours, there was no uptake of any of the four cytokines of interest onto either contact 
lens material tested. Relative to the control (100%), the percent pg/mL remaining in solution at 
this time was 103 ± 2 % (etafilcon A) and 103 ± 2 % (comfilcon A) for IL-1" (Figure 6-41); 101 
± 4 % (etafilcon A) and 98 ± 1 % (comfilcon A) for IL-6 (Figure 6-42); 103 ± 2 % (etafilcon A) 
and 104 ± 2 % (comfilcon A) for IL-8 (Figure 6-43); as well as 103 ± 1 % (etafilcon A) and 114 
± 2 % (comfilcon A) for TNF-# (Figure 6-44). Additionally, there were no statistical differences 
between the materials and the control at this time point (p > 0.05), with the exception of comfilcon 
A being statistically different from both the control (adjusted P-value 0.0056) and etafilcon A 
(adjusted P-value 0.0185) for TNF-#, as defined by the number (#) symbol. In both cases, 
however, this was as a result of the value of comfilcon A exceeding 100% of the control and was 
therefore not indicative of uptake. 
 
 
Figure 6-41: Percent pg/mL of IL-1( Remaining in Higher Concentration Cytokine Solutions Containing Either etafilcon A 
or comfilcon A (n = 3) Contact Lens Materials, at 24-hours, 72-hours and 7-day Time Points. Two-way Repeated Measures 




Figure 6-42: Percent pg/mL of IL-6 Remaining in Higher Concentration Cytokine Solutions Containing Either etafilcon A or 
comfilcon A (n = 3) Contact Lens Materials, at 24-hours, 72-hours and 7-day Time Points. Two-way Repeated Measures 
ANOVAs with Tukey’s Multiple Comparisons Test were Performed. No Statistical Differences to Report (p > 0.05). 
 
 
Likewise, at 72 hours, there was also no uptake of any of the four cytokines of interest onto 
either contact lens material tested. Relative to the control (100%), the percent pg/mL remaining in 
solution at this time was 95 ± 2 % (etafilcon A) and 97 ± 2 % (comfilcon A) for IL-1" (Figure 
6-41); 102 ± 2 % (etafilcon A) and 101 ± 4 % (comfilcon A) for IL-6 (Figure 6-42); 100 ± 6 % 
(etafilcon A) and 98 ± 6 % (comfilcon A) for IL-8 (Figure 6-43); as well as 102 ± 3 % (etafilcon 
A) and 115 ± 3 % (comfilcon A) for TNF-# (Figure 6-44). Additionally, there were no statistical 
differences between the materials and the control at this time point (p > 0.05), except between 
comfilcon A and both the control (adjusted P-value 0.0036) and etafilcon A (adjusted P-value 
0.0090) for TNF-#. However, again, this was due to the value of comfilcon A exceeding 100% of 




Figure 6-43: Percent pg/mL of IL-8 Remaining in Higher Concentration Cytokine Solutions Containing either etafilcon A or 
comfilcon A (n = 3) Contact Lens Materials, at 24-hours, 72-hours, and 7-day Time Points. Two-way Repeated Measures 
ANOVAs with Tukey’s Multiple Comparisons Test were Performed. At 7 Days, comfilcon A was Statistically Different from 
the 7-Day Control, as Defined by the Star (*) Symbol.  
 
 
At the 7-day mark, there was no uptake of IL-1" or TNF-# onto either contact lens material 
tested. Relative to the control (100%), the percent pg/mL remaining in solution at this time was 95 
± 3 % (etafilcon A) and 96 ± 4 % (comfilcon A) for IL-1" (Figure 6-41) and 98 ± 6 % (etafilcon 
A) and 99 ± 3 % (comfilcon A) for IL-6 (Figure 6-42). There were no statistical differences 
between these materials and the control (p > 0.05). For IL-8 (Figure 6-43), the percent pg/mL 
remaining in solution was 90 ± 2 % (etafilcon A) and 90 ± 7 % (comfilcon A). There was a 
statistical difference between comfilcon A and the control (adjusted P-value 0.0382), indicating 
uptake, as defined by the star (*) symbol; however, there was no statistical difference between 
etafilcon A and the control (p > 0.05). In contrast, there appeared to be some uptake of TNF-# 
(Figure 6-44) onto both materials, as the percent pg/mL remaining in solution was 90 ± 4 % 
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(etafilcon A) and 88 ± 10 % (comfilcon A). Moreover, there was a statistical difference between 
both etafilcon A and the control (adjusted P-value 0.0489), as defined by the triangle (∆) symbol, 
as well as between comfilcon A and the control (adjusted P-value 0.0161), as defined by the star 
(*) symbol.  
 
 
Figure 6-44: Percent pg/mL of TNF-) Remaining in Higher Concentration Cytokine Solutions Containing Either etafilcon A 
or comfilcon A (n = 3) Contact Lens Materials, at 24-hours, 72-hours, and 7-day Time Points. Two-way Repeated Measures 
ANOVAs with Tukey’s Multiple Comparisons Test were Performed. At both 24 Hours and 72 Hours, comfilcon A was 
Statistically Different from the Control and etafilcon A at the Respective Time Point, as Defined by the Number (#) Symbol, 
Due to Having a Value Greater than 100% of the Respective Control. At 7 Days, comfilcon A was Statistically Different from 
the 7-Day Control, as Defined by the Star (*) Symbol and etafilcon A was also Statistically Different from the 7-Day Control, 
as Defined by the Triangle (∆) Symbol.  
 
6.7.4 Discussion  
Consistent with the results obtained in section 6.6.3, comfilcon A again appeared to uptake 
IL-8 at the 6-hour time point. In contrast, there was also some evidence for uptake of TNF-#, 
contrary to the result obtained in section 6.6.3, where comfilcon A instead exhibited uptake of IL-
1". Interestingly, etafilcon A did not exhibit uptake of IL-8 and contrary to comfilcon A, it is a 
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high water content material.59 Similar to balafilcon A and omafilcon A, etafilcon A did exhibit 
uptake of TNF-#, even though it is a negatively charged material and TNF-# should have a 
negatively charged surface in the standard blend solution.83,91,92 Again, this uptake does not appear 
to be heavily influenced by the pI of the cytokine or the ionicity of the material, nor does it appear 
to be influenced by the water content of the material, since all three of these materials (balafilcon 
A, etafilcon A and omafilcon A), exhibited some uptake of TNF-#, yet two of these materials are 
of high water content, while the other is a low water content material.58,59 
 Finally, increasing the concentration of cytokines in solution did not significantly alter the 
levels of cytokine uptake onto the contact lens materials tested, even when the soaking period was 
increased to 7 days. As a result, the next chapter of the thesis aimed to utilize an entirely different 
source of cytokines, by investigating the uptake of IL-1", IL-6, IL-8 and TNF-# produced directly 
from human corneal epithelial cells. Not only would this provide more clinical relevance through 
better modeling ocular conditions, as human corneal epithelial cells secrete cytokines in the 
eye3,16,17, but this would also allow for an investigation of uptake using more freshly prepared 
cytokine solutions directly from human corneal epithelial cells cultured in the laboratory.   
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Chapter 7: Uptake Using Human Corneal Epithelial Cells Supernatant  
7.1 Introduction 
As discussed in section 1.1, the human cornea is comprised of five layers – one of which 
is the corneal epithelium.1 The cells of the human corneal epithelium, termed, human corneal 
epithelial cells (HCECs), produce both a basal level of cytokines and an amplified level if 
damaged, in order to initiate the corneal wound healing (repair) process.1,3,16,17 The experiments 
presented in Chapter 7: utilized cytokines sourced directly from cells of human corneas, rather 
than recombinant cytokines from the MSD calibrator blend. This allowed for the simulation of an 
in vivo model more closely depicting the interaction of a contact lens when placed onto the corneal 
epithelium during wear (Figure 2-2).  
Cytokines produced by HCECs were collected from cell culture supernatants. Through an 
initial pilot study (data not presented), HCECs were tested for the production of basal amounts of 
the four cytokines of interest. In addition to producing IL-1", IL-6, IL-8 and TNF-#, HCECs also 
produced IFN-$, IL-2, IL-4, IL-10, IL-12p70 and IL-13. Other cytokines were not tested for, 
although it is possible that the cells did produce additional cytokines. Of the ten cytokines that 
were tested for, IFN-$, IL-1", IL-2, IL-4, IL-10, IL-12p70, IL-13 and TNF-# were produced at 
extremely low concentrations (all below 3 pg/mL), while higher concentrations of IL-6 and IL-8 
were produced (around 85 pg/mL). Of note, however, was the variability that existed in cytokine 
concentrations produced by HCECs with each culture. This variability depended on many factors, 
including when the supernatant was collected (if it was collected from freshly cultured cells or 
older cells), how often the cell culture media was changed and the number of cells/mL grown per 
flask. Regardless, a similar trend was always observed whereby in the case of the four cytokines 
of interest, IL-1" and TNF-# were produced at significantly lower concentrations than IL-6 and 
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IL-8. Additionally, as a result of the variability, the concentrations of the cytokines in the collected 
cell culture supernatants were quantified by the MSD assay prior to their use as soaking solutions 
for the contact lenses. 
7.2 Culturing Human Corneal Epithelial Cells  
Human corneal epithelial cells (Millipore Sigma, Burlington, MA) were cultured under 
sterile conditions in Corning BioCoat Collagen 1-coated Flasks (Corning, Corning, NY), 
containing EpiGRO Human Ocular Epithelia (Millipore Sigma, Burlington, MA), which was 
supplemented, as per the manufacturer’s guidelines, with 0.5 mL of 5 -g/mL Apo-Transferrin, 0.5 
mL of 1.0 -M Epinephrine, 0.5 mL of 5 -g/mL Hydrocortisone Hemisuccinate, 0.5 mL of 5 -g/mL 
rh Insulin, 1 mL EpiFactor O (proprietary final concentration), 2 mL of 0.4 % EpiFactor P and 15 
mL of 6 mM L-Glutamine (Millipore Sigma, Burlington, MA). The flasks containing the cells 
were incubated at 37℃	with 5% CO2 and grown to 80% confluency. The cells were regularly 
observed using a microscope and the cell culture supernatant was replaced approximately every 2-
3 days with fresh EpiGRO Human Ocular Epithelia Media containing supplements. The cell 
culture supernatants were stored in 15 mL polypropylene centrifuge tubes (Corning, Corning, NY) 
in a -80℃ freezer. 60 -L aliquots were separately stored in 0.6 mL Axygen microtubes (Axygen, 
Inc, Union City, CA) and later analyzed with the MSD assay to quantify cytokine concentrations 
prior to commencing each experiment.  
7.3 Uptake of HCEC-derived IL-1(, IL-6, IL-8 and TNF-) onto Contact Lens Materials 
7.3.1 Introduction  
An investigation of HCEC-derived IL-1", IL-6, IL-8 and TNF-# uptake onto contact lens 
materials was performed in two separate experiments. In the first experiment, levels of IL-1" and 
TNF-# uptake were quantified from solutions of two conventional hydrogels and three SiHys, 
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while in the second experiment, uptake levels of IL-6 and IL-8 were quantified in solutions 
containing the same contact lens materials. The four cytokines of interest were evaluated 
separately due to the differences in concentration that existed between them. Since IL-1" and 
TNF-# were generally produced at lower concentrations, while IL-6 and IL-8 were generally 
produced at higher concentrations, the supernatant solutions had to be diluted separately, such that 
the concentrations of the samples pipetted into each well of the 96-well MSD plate fell between 
both the lower and upper limits of quantification (Table 4-4). Thus, it was not possible to 
appropriately quantify IL-1" and TNF-# with IL-6 and IL-8 collectively, such that the 
concentrations of the first two did not fall below the lower limit of quantification, or that the 
concentrations of the second two did not fall above the upper limit of quantification.  
For the conventional hydrogels, etafilcon A and omafilcon A were both chosen to be 
studied. Omafilcon A had previously shown some cytokine uptake throughout the experiments 
presented in sections 6.3.3, 6.3.7, 6.4.3 and 6.5.3, and while etafilcon A had exhibited less uptake 
than omafilcon A, it did exhibit some uptake in the experiment presented in section 6.3.7, as well 
as in section 6.7.3, when it was soaked in a higher concentration of TNF-# after 7 days. Since 
there was potential for obtaining high cytokine concentrations from HCECs, this contact lens 
material was incorporated into the study design for further investigation as well.  
Of the silicone hydrogels tested thus far, balafilcon A, comfilcon A and senofilcon A were 
chosen. Balafilcon A and comfilcon A were chosen as they previously exhibited some cytokine 
uptake in the experiment presented in section 6.6.3 and likewise to etafilcon A, comfilcon A also 
exhibited uptake of TNF-# (as well as IL-8), after 7 days (section 6.7.3). Between senofilcon A 
and somofilcon A, although neither material exhibited any uptake of cytokines when the MSD 
calibrator blend solution was utilized, senofilcon A (due to being more commonly used), was 
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chosen to be investigated for any difference in its uptake ability in a solution of cytokines derived 
from HCECs.    
7.3.2 Materials and Methods 
Human corneal epithelial cells were cultured as described in section 7.2 and the cell culture 
supernatants were collected and quantified with the MSD assay. PureVision (balafilcon A), 
Biofinity (comfilcon A), 1-Day Acuvue Oasys (etafilcon A), Proclear 1 Day (omafilcon A) and 
Acuvue Oasys 2-week with Hydraclear Plus (senofilcon A), were prepared as described in section 
4.3 and placed in polypropylene tubes (n = 3) containing 1 mL of the HCEC culture supernatant. 
Control tubes contained only 1 mL of the supernatant solution with no contact lenses. 60 -L 
samples were collected at 1 hour and again at 6 hours. Statistical analyses were performed using 
two-way, repeated measures ANOVAs with Tukey’s Multiple Comparisons test. Differences were 
considered significant if p < 0.05. 
7.3.3 Results – Experiment #1: IL-1( and TNF-) 
The concentrations of IL-1" and TNF-# initially quantified from an aliquot of the cell 
culture supernatant of the batch of HCECs cultured for this experiment were 2.36 pg/mL and 4.96 
pg/mL, respectively. While these concentrations were lower than those previously tested using the 
MSD calibrator blend, they were greater than that which was quantified from the HCEC culture 
supernatant tested in the pilot study (0.27 pg/mL and 0.77 pg/mL for IL-1" and TNF-#, 
respectively). Furthermore, this allowed for an investigation of uptake at a low concentration, 
which was different and unique from other experiments. On the day of the study, the mean cytokine 
concentrations in the 1-hour control solutions, as quantified by the MSD assay, were 2.73 pg/mL 
and 5.06 pg/mL for IL-1" and TNF-#, respectively, and in the 6-hour control solutions were 2.69 
pg/mL and 4.50 pg/mL for IL-1" and TNF-#, respectively.   
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Relative to the control at 1 hour (100%), there was no uptake of IL-1" (Figure 7-1) onto 
either balafilcon A (102.4 ± 2 %), comfilcon A (100 ± 2 %), etafilcon A (99 ± 4 %), omafilcon 
A (99 ± 2 %) or senofilcon A (98 ± 1 %). Additionally, relative to the 6-hour control (100%), 
there was also no uptake of IL-1" (Figure 7-1) onto balafilcon A (95 ± 1 %), comfilcon A (96 ± 
6 %), etafilcon A (92 ± 6 %), omafilcon A (95 ± 2 %) or senofilcon A (93 ± 3%). There were no 
statistical differences between the concentration of IL-1" remaining in solutions containing the 
contact lens materials of interest and the respective controls at 1 hour or at 6 hours (p > 0.05).  
 
 
Figure 7-1: Percent pg/mL of IL-1( Remaining in HCEC-Derived Cytokine Solutions Containing either balafilcon A, 
comfilcon A, etafilcon A, omafilcon A, or senofilcon A (n = 3) Contact Lens Materials, at 1-Hour and 6-Hour Time Points. 
Two-way Repeated Measures ANOVAs with Tukey’s Multiple Comparisons Test were Performed. No Statistical Differences to 
Report (p > 0.05).  
 
Relative to the control at 1 hour (100%), there was also no uptake of TNF-# (Figure 7-2) 
onto balafilcon A (106 ± 2 %), comfilcon A (91 ± 5 %), etafilcon A (97 ± 5%), omafilcon A (89 
± 6 %) or senofilcon A (91 ± 6 %). Moreover, the only statistical difference observed at this time 
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point was between balafilcon A and each of comfilcon A (adjusted P-value 0.0429), omafilcon A 
(0.0171) and senofilcon A (0.0302), as defined by the number (#) symbol. However, since 
balafilcon A was not statistically different from the respective control, there was no indication of 
uptake and hence the statistical differences were as a result of the value of balafilcon A exceeding 
100% of the control.  
 
 
Figure 7-2: Percent pg/mL of TNF-) Remaining in HCEC-Derived Cytokine Solutions Containing either balafilcon A, 
comfilcon A, etafilcon A, omafilcon A, or senofilcon A (n = 3) Contact Lens Materials, at 1-Hour and 6-Hour Time Points. 
Two-way Repeated Measures ANOVAs with Tukey’s Multiple Comparisons Test were Performed. At 1 Hour, balafilcon A was 
Statistically Different from Each of comfilcon A, omafilcon A and senofilcon A, as Defined by the Number (#) Symbol, Due to 
Having a Value Greater than 100% of the Control. At 6 Hours, comfilcon A, etafilcon A and omafilcon A were Each 
Statistically Different from the 6-Hour Control, as Defined by the Star (*), Triangle (∆) and Square (∎) Symbols, 
Respectively.    
 
 
At 6 hours, there appeared to be some uptake of TNF-# (Figure 7-2) onto comfilcon A (79 
± 3 %), etafilcon A (86 ± 7 %) and omafilcon A (82 ± 2 %) relative to the control (100%). 
However, there was no uptake of this cytokine onto balafilcon A (88 ± 5 %) or senofilcon A (87 
± 11 %), as there were no statistical differences between these materials and the respective control 
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(p > 0.05). In contrast, there was a statistical difference between the 6-hour control and each of 
comfilcon A (adjusted P-value 0.0012), etafilcon A (adjusted P-value 0.0395) and omafilcon A 
(adjusted P-value 0.0079), as defined by the star (*), triangle (∆) and square (∎) symbols, 
respectively.  
7.3.4 Results – Experiment #2: IL-6 and IL-8 
The concentrations of IL-6 and IL-8 initially quantified from an aliquot of the cell culture 
supernatant of the batch of HCECs cultured for this experiment were 808 pg/mL and 2438 pg/mL, 
respectively. These concentrations were appreciably higher than those previously obtained from 
the MSD calibrator blend, even when two calibrator blends were combined, as described in the 
experiment presented in section 6.7.3. These higher concentrations were obtained by extending the 
number of days between culture media changes and collecting supernatant from older cells. On the 
day of the study, the mean cytokine concentrations in the 1-hour control solutions, as quantified 
by the MSD assay, were 342 pg/mL and 1885 pg/mL for IL-6 and IL-8, respectively, and in the 6-
hour control solutions were 356 pg/mL and 1995 pg/mL for IL-6 and IL-8, respectively. 
Relative to the control at 1 hour (100%), there was no uptake of IL-6 (Figure 7-3) onto 
either balafilcon A (106 ± 7 %), comfilcon A (107 ± 2 %), etafilcon A (109 ± 4 %), omafilcon A 
(121 ± 7 %) or senofilcon A (115 ± 8 %). The only statistical difference observed at this time 
point was between omafilcon A and the respective control (adjusted P-value 0.0097), as defined 
by the number (#) symbol; however, this was due to the value of omafilcon A exceeding 100% of 
the control and was therefore not an indication of uptake.  
Moreover, relative to the 6-hour control (100%), there was also no uptake of IL-6 (Figure 
7-3) onto balafilcon A (95 ± 4 %), comfilcon A (102 ± 10 %), etafilcon A (98 ± 3 %), omafilcon 
A (104 ± 7 %) or senofilcon A (99 ± 6%). There were no statistical differences observed between 
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the concentrations of IL-6 in any of the solutions containing the contact lens materials of interest 
in comparison to the respective control (p > 0.05). 
 
 
Figure 7-3: Percent pg/mL of IL-6 Remaining in HCEC-Derived Cytokine Solutions Containing either balafilcon A, 
comfilcon A, etafilcon A, omafilcon A, or senofilcon A (n = 3) Contact Lens Materials, at 1-Hour and 6-Hour Time Points. 
Two-way Repeated Measures ANOVAs with Tukey’s Multiple Comparisons Test were Performed. At 1-Hour, omafilcon A 
was Statistically Different from the 1-Hour Control, as Defined by the Number (#) Symbol, Due to Having a Value Greater 
than 100% of the Control.  
 
 
Relative to the control at 1 hour (100%), there was no uptake of IL-8 (Figure 7-4) onto 
either balafilcon A (108 ± 13 %), comfilcon A (105 ± 8 %), etafilcon A (109 ± 5 %), omafilcon 
A (113 ± 9 %) or senofilcon A (107 ± 3 %). Furthermore, relative to the 6-hour control (100%), 
there was also no uptake of IL-8 (Figure 7-4) onto balafilcon A (92 ± 2 %), comfilcon A (92 ± 15 
%), etafilcon A (87 ± 5 %), omafilcon A (85 ± 8 %) or senofilcon A (81 ± 3%). There were no 
statistical differences observed between the concentrations of IL-8, at either the 1-hour or 6-hour 




Figure 7-4: Percent pg/mL of IL-8 Remaining in HCEC-Derived Cytokine Solutions Containing either balafilcon A, 
comfilcon A, etafilcon A, omafilcon A, or senofilcon A (n = 3) Contact Lens Materials, at 1-Hour and 6-Hour Time Points. 
Two-way Repeated Measures ANOVAs with Tukey’s Multiple Comparisons Test were Performed. No Statistical Differences to 
Report (p > 0.05).  
 
 
7.3.5 Discussion – Experiments #1 and #2 
Of the contact lens materials tested, only comfilcon A, etafilcon A and omafilcon A 
exhibited some uptake of TNF-# after 6 hours of soaking in the cytokine solution. Uptake was not 
observed for any of the other cytokines, by any other material.  The results of these experiments 
were similar to the results of the experiments presented in sections 6.5.3 and 6.7.3, where uptake 
of TNF-# was observed after 6 hours onto omafilcon A when the material was pre-soaked in ATS, 
as well as onto comfilcon A and etafilcon A materials after a 7-day soaking period in a solution of 
higher cytokine concentration.  
The pH of the HCEC culture supernatant was expected to be approximately 7.5 ±	0.2, as 
this was the pH of the EpiGRO Human Ocular Epithelia Media provided in its certificate of 
analysis. Thus, since the pH of the solution was similar to that of both Diluent 2 and ATS, similar 
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theoretical results were expected based on cytokine pI values, as explained in section 6.2.4. While 
TNF-# should have a predominately negatively-charged surface at this pH83,91,92 and therefore 
have a less affinity for negatively-charged etafilcon A material59, in this case, uptake of TNF-# 
onto etafilcon A was observed. Under many other experimental conditions presented throughout 
this thesis, however, this was certainly not a consistent observation. Additionally, there did not 
appear to be a consistent trend of interaction between the contact lens materials and the cytokines 
of interest to conclusively determine a single factor contributing to uptake. 
7.4 Uptake of High Concentration HCEC-derived IL-6 and IL-8 onto Contact Lens 
Materials Over 7 Days  
7.4.1 Introduction 
The final experiment of the thesis repeated the experiment previously outlined in section 
6.7, where one conventional hydrogel (etafilcon A) and one SiHy (comfilcon A) were investigated 
for cytokine uptake over a 7-day soaking period. In this case, the source of cytokines was from 
HCEC culture supernatant, rather than a combination of MSD calibrator blends. Additionally, the 
aim of this experiment was to investigate uptake at the highest possible cytokine concentration that 
could be obtained through a HCEC culture. As per section 6.7, reusable contact lenses were chosen 
for this experiment, as exploring uptake within a 7-day period would not be applicable to daily 
disposable contact lenses.  
7.4.2 Materials and Methods 
Human corneal epithelial cells were cultured as described in section 7.2 and the cell culture 
supernatants were collected and quantified with the MSD assay. Acuvue 2 (etafilcon A) and 
Biofinity (comfilcon A) contact lenses were prepared as described in section 4.3 and placed in 
polypropylene tubes (n = 3) containing 1 mL of a HCEC culture supernatant containing cytokines. 
Control tubes contained only 1 mL of the supernatant solution with no contact lenses. The 
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polypropylene tubes were wrapped in parafilm to prevent evaporation over the 7-day soaking 
period. 60 -L samples were collected at 24 hours, 72 hours (3 days) and at the 7-day mark. 
Statistical analyses were performed using two-way, repeated measures ANOVAs with Tukey’s 
Multiple Comparisons test. Differences were considered significant if p < 0.05. 
7.4.3 Results 
The concentrations of IL-6 and IL-8 initially quantified from an aliquot of the cell culture 
supernatant of the batch of HCECs cultured for this experiment were 3613 pg/mL and 12,300 
pg/mL, respectively. These concentrations were considerably higher than those previously tested 
using either the MSD calibrator blend or obtained from other HCEC culture supernatants. 
Furthermore, these concentrations represent the higher range of basal cytokine values (Table 3-3) 
reported in the literature.66,68,70 On the day of the study, the mean cytokine concentrations in the 
24-hour control solutions, as quantified by the MSD assay, were 2720 pg/mL and 9819 pg/mL for 
IL-6 and IL-8, respectively; in the 72-hour control solutions were 2656 pg/mL and 10,047 pg/mL 
for IL-6 and IL-8, respectively; and in the 7-day control solutions were 2288 pg/mL and 8520 
pg/mL for IL-6 and IL-8, respectively. The high concentrations of these cytokines in this case were 
obtained through growing a larger number of cells/mL per flask, extending the number of days 
between culture media changes and collecting supernatant from older cells. 
Given the high concentrations of IL-6 and IL-8, a 50-fold dilution factor was necessary 
when quantifying the concentrations of these cytokines by the MSD assay. Subsequently, the 
concentrations of IL-1" and TNF-# fell below the lower limit of detection of the MSD instrument, 
and therefore results for these cytokines are not reported. An initial quantification of the cell culture 
supernatant, however, revealed the concentrations of IL-1" and TNF-# to be roughly 1 pg/mL and 
9 pg/mL. Evidently, a similar trend was observed as before, whereby IL-1" and TNF-# were 
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produced in lower concentrations by HCECs, in comparison to IL-6 and IL-8, which were 
produced at higher concentrations. Since previous experiments had already investigated the uptake 
of IL-1" and TNF-# at low concentrations, from both MSD calibrator blend and HCEC culture 
supernatant sources, results were not anticipated to be different and therefore it was not necessary 
to test the uptake of these particular cytokines again in this experiment.  
Relative to the 24-hour control (100%), there was no uptake of IL-6 (Figure 7-5) onto either 
comfilcon A (108 ± 16 %) or etafilcon A (91 ± 2 %) and no uptake of IL-8 (Figure 7-6) onto 
comfilcon A (108 ± 9 %) or etafilcon A (96 ± 5 %). Furthermore, relative to the 72-hour control 
(100%), there was no uptake of IL-6 (Figure 7-5) onto either comfilcon A (97 ± 3 %) or etafilcon 
A (94 ± 7 %) and no uptake of IL-8 (Figure 7-6) onto comfilcon A (85 ± 10 %) or etafilcon (85 
± 7 %). There were no statistical differences observed at either time point between the respective 
control and either comfilcon A or etafilcon A material (p > 0.05). 
Relative to the 7-day control (100%), there was also no uptake of IL-6 (Figure 7-5) onto 
comfilcon A (113 ± 11 %) or etafilcon A (102 ± 17 %). For IL-8 (Figure 7-6), there was no uptake 
onto comfilcon A (87 ± 6 %); however, there did appear to be some uptake onto etafilcon A (80 
± 5 %). While there were no statistical differences observed between the control and comfilcon A 
at this time point (p > 0.05), there was a statistical difference between etafilcon A and the control 





Figure 7-5: Percent pg/mL of IL-6 Remaining in Higher Concentrations of HCEC-Derived Cytokine Solutions, Containing 
either balafilcon A or comfilcon A (n = 3) Contact Lens Materials, at 24-Hour, 72-Hour and 7-Day Time Points. Two-way 
Repeated Measures ANOVAs with Tukey’s Multiple Comparisons Test Were Performed. No Statistical Differences to Report 
(p > 0.05).   
 
 
Figure 7-6: Percent pg/mL of IL-8 Remaining in Higher Concentrations of HCEC-Derived Cytokine Solutions, Containing 
either balafilcon A or comfilcon A (n = 3) Contact Lens Materials, at 24-Hour, 72-Hour and 7-Day Time Points. Two-way 
Repeated Measures ANOVAs with Tukey’s Multiple Comparisons Test Were Performed. At 7 Days, etafilcon A was 
Statistically Different from the 7-Day Control, as Defined by the Star (*) Symbol.  
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7.4.4 Discussion 
In this experiment, there only appeared to be some uptake of IL-8 onto etafilcon A at the 
7-day time point. When this exact experiment was performed using MSD calibrator blends, there 
appeared to be some uptake of IL-8 onto comfilcon A (rather than etafilcon A), as well as uptake 
of TNF-# onto both comfilcon A and etafilcon A (6.7.3). In section 7.3.4, the concentrations of 
IL-6 and IL-8 tested were 342 pg/mL and 1885 pg/mL. These concentrations were the highest 
concentrations of cytokines that had been tested in comparison to all preceding experiments and 
were approximately 10 and 100 times larger than the concentrations of the cytokines obtained from 
a single MSD calibrator blend. In this experiment, even higher concentrations of IL-6 and IL-8 
were tested (roughly 2000 pg/mL and 8500 pg/mL, respectively). Regardless of utilizing a very 
high concentration of cytokines in solution over a 7-day soaking period, there did not appear to be 
substantial amounts of uptake onto the contact lens materials. Moreover, even with the small 
apparent amount of uptake for etafilcon A, again, there appeared to be no identifiable trend for this 





Chapter 8: Conclusions and Future Work  
8.1 A Summary  
Based on the pilot studies performed, it appeared that cotton consistently exhibited the 
highest amount of uptake for all of the four cytokines of interest, however, due to its ability to also 
absorb a volume of the soaking solution, it may not have served as an ideal positive control. 
Hypothetically, if cotton were to absorb only liquid with no cytokines, the concentration of the 
cytokines in the soaking container would appear higher, as a result of a decrease in the soaking 
volume. In contrast, if cotton were to absorb both cytokines and some liquid (as in the pilot 
studies), while absorbing some of the soaking liquid (i.e., decreasing volume), will increase the 
concentration of cytokines in the soaking container, even if there is absorption of these cytokines, 
the amount of uptake cannot correctly be quantified since the initial concentration before uptake 
would not be representative of the true value due to this change in volume. In the pilot studies 
where cotton was investigated as a positive control, however, the appropriate experimental 
controls were employed, which contained only a volume of the cytokine solution with no cotton 
material. The cytokine concentrations quantified from the experimental controls were then 
regarded as the “initial concentrations”, to which the concentrations from the solutions containing 
cotton were compared, in order to determine the amount of uptake over the specified time period. 
While Millipore filter paper also exhibited substantial uptake of all four cytokines and is much less 
liquid absorbent than cotton, thereby potentially serving as a better positive control, future 
experiments could place an emphasis on determining a biomaterial with more clinical relevance 
that could serve as a positive control, ideally one that can deposit cytokines with no absorption of 
liquid.   
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When considering the experiments outlined in Chapter 6:and Chapter 7:, of the contact lens 
materials tested in these two chapters (balafilcon A, comfilcon A, etafilcon A, omafilcon A, 
senofilcon A and somofilcon A), it was only balafilcon A, comfilcon A, etafilcon A and omafilcon 
A that exhibited any amount of cytokine uptake – though these amounts varied between 
experiments and between the cytokines of interest. Senofilcon A and somofilcon A did not exhibit 
any uptake of IL-1", IL-6, IL-8 or TNF-#. Additionally, there was no uptake of IL-6 by any of the 
contact lens materials investigated.  
Uptake of IL-1" was demonstrated by omafilcon A following a 6-hour soak in a MSD 
calibrator blend-derived cytokine solution (Figure 6-5) and following a 6-hour soak in a reduced 
volume MSD calibrator blend-derived cytokine solution (Figure 6-13). Both balafilcon A and 
comfilcon A also demonstrated uptake of IL-1" following a 6-hour soak in a MSD calibrator blend 
derived-cytokine solution (Figure 6-33). Uptake of IL-8 was demonstrated by balafilcon A and 
comfilcon A following a 6-hour soak in a MSD calibrator blend-derived cytokine solution (Figure 
6-35); by comfilcon A following a 7-day soak in a MSD calibrator blend-derived cytokine solution 
of higher concentration (Figure 6-43);  and also by etafilcon A following a 7-day soak in a HCEC-
derived cytokine solution of very high concentration (Figure 7-6).  
 Uptake of TNF-# was demonstrated by etafilcon A and omafilcon A after a 1-hour soak in 
a MSD calibrator blend-derived cytokine solution (Figure 6-12), although this was likely not 
indicative of true uptake as no uptake was observed at the 6-hour time period. Additionally, it 
appeared that there was some uptake of TNF-# by omafilcon A following a 6-hour soak in a MSD 
calibrator blend derived-cytokine solution, after the material was pre-soaked in an ATS solution 
(Figure 6-28). Balafilcon A also exhibited uptake of TNF-# following a 6-hour soak in a MSD 
calibrator blend-derived cytokine solution (Figure 6-36). Comfilcon A and etafilcon A exhibited 
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uptake of TNF-# following a 7-day soak in a MSD calibrator blend-derived cytokine solution of 
higher concentration (Figure 6-44). Comfilcon A, etafilcon A, and omafilcon A exhibited uptake 
of TNF-# following a 6-hour soak in a HCEC-derived cytokine solution (Figure 7-2).  
 Interestingly, there were two conventional hydrogels (etafilcon A and omafilcon A) and 
two SiHys (balafilcon A and comfilcon A), which appeared to exhibit uptake of IL-1", IL-8 and 
TNF-#. Of the conventional hydrogels, both were of high water content and one was 
ionic/negatively charged (etafilcon A), while the other was zwitterionic/neutral (omafilcon A).59 
Of the SiHys, in contrast, both were of low water content and similarly, one was ionic/negatively 
charged (balafilcon A), while the other was nonionic (comfilcon A).59,100 
 It did not appear that the isoelectric points of the cytokines or the ionicity of the contact 
lens materials greatly influenced cytokine uptake, as a trend did not seem to exist for uptake. For 
example, etafilcon A (negatively charged), exhibited some uptake of TNF-# (negatively charged 
surface based on its pI and the pH of the solution utilized), while other materials of nonionic nature 
also exhibited uptake of TNF-#.59,83,91,92 Furthermore, in some experiments, etafilcon A did not 
exhibit uptake of TNF-# at all. Moreover, etafilcon A exhibited uptake of IL-8 (positively charged 
surface based on its pI and the pH of the solution utilized) in some experiments, while in other 
experiments, no uptake of IL-8 onto etafilcon A was observed.59,83,89  
 It also did not appear that the water content of the contact lens materials greatly influenced 
uptake. While it could be hypothesized (based on the results of the experiments presented in this 
thesis), that to demonstrate uptake of IL-1", IL-8 or TNF-#, a high water content conventional 
hydrogel or a low water content silicone hydrogel contact lens material must be utilized, this would 
not be consistent with the observation that senofilcon A, a SiHy of low water content, did not 
exhibit cytokine uptake. Perhaps it could also be hypothesized that for conventional hydrogels, 
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having a high water content is enough to have some uptake of IL-1", IL-8 or TNF-#, while for 
SiHys, a material of ionic nature is required. This would not, however, be consistent with the 
observation that comfilcon A, a nonionic material, did demonstrate some uptake of these 
cytokines. 
Perhaps in the case of omafilcon A, the zwitterionic character is important for its interaction 
with cytokines. In that case, perhaps there is a certain pH of soaking solution that could give the 
surface of the zwitterion a certain charge, thereby making it more ideal for cytokine interaction. 
Alternatively, perhaps the structure of the cytokine or the contact lens is not uniform, and a purely 
positive or purely negative character is not required for uptake. Rather, perhaps different areas on 
the surface of the cytokine or contact lens may be more positive or more negative and result in 
different interactions than what may be expected. Moreover, it is possible that for some materials, 
the level of water content determines how hydrated the surface of the lens is and hence influences 
pore sizes in the contact lens material to which cytokines could potentially adhere. 
 Of the four cytokines of interest, it is of note that there was consistently no uptake of IL-6 
demonstrated by any material. As hypothesized in section 6.6.5, this could possibly be due to the 
size of this cytokine, as it is one of the larger cytokines15 of the four (Table 3-2), and also based 
on its predicted size in the MSD calibrator blend (20.3 kDa according to Meso Scale Discovery 
Scientific Support, while the predicted sizes of IL-1", IL-8 and TNF-# are 17 kDa, 8 kDa and 17.5 
kDa, respectively). Given that a molecular weight of 20.3 kDa is not substantially greater than 17 
kDa or 17.5 kDa, however, it is possible that the oligomeric state of IL-6 may instead play a role 
in its ability to uptake onto the contact lens materials.110  
Human IL-1" naturally occurs as a 17.5 kDa84 monomer9, while human TNF-# naturally 
occurs as a 17.5 kDa homotrimer.111 In contrast, the oligomeric state of human IL-8 appears to be 
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concentration-dependent.112,113 For example, it has been reported in the literature that this protein 
exists in a dimeric state at millimolar (mM) concentrations and exists in a monomeric state at 
nanomolar (nM) concentrations, with a dissociation constant (Kd) for dimerization reported as 10-
20 -M.112,113 As a result, while the molecular weight of monomeric IL-8 is reported between 6-8 
kDa15, the molecular size of the dimeric state can therefore be between 12-16 kDa. Supporting 
this, Kendrick and colleagues reported through their investigation that the molecular size of the 
wild-type IL-8 dimer was calculated as approximately 17 kDa.113 The concentrations utilized 
throughout the experiments presented in this thesis were calculated to be less than 2 nM and thus, 
the IL-8 was predicted to be in its monomeric state accordingly.112,113  
While human IL-6 naturally occurs as a 21-28 kDa15 monomer9,110, it has been reported in 
the literature that due to exhibiting an aggregation-prone nature, human IL-6 may also exist as a 
multimer composed of several aggregates ranging in molecular size.110 Hence, it is possible that 
the IL-6 in the lyophilized MSD calibrator blend utilized for the experiments presented in this 
thesis, or even that obtained from a culture of human corneal epithelial cells, could have formed 
this multimeric complex through aggregation.110 According to Meso Scale Discovery Scientific 
Support, the cytokines within the calibrator blend are biologically active and therefore exhibit the 
same oligomeric state as the endogenous cytokines. Thus, depending on the number of aggregates 
for IL-6, this would increase the overall molecular size of the multimer above its monomeric 
molecular size, which could have affected the ability of this protein to interact with the surface of 
the contact lens materials tested, such that deposition could not occur. Alternatively, it could be 
possible that the presence of the aggregates alone, irrespective of molecular size, may have 
hindered the protein’s ability to deposit onto the contact lens materials. 
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 It has been suggested in the literature that the very act of wearing a contact lens is 
intrinsically inflammatory.95 This idea was presented in a paper by Nathan Efron, who explored 
this notion and concluded that hydrogel lens wear meets all five criteria outlining the classical and 
clinical definition of inflammation (i.e., heat, swelling, pain, redness and loss of function), in 
addition to all two criteria outlining a subclinical definition of inflammation (i.e., cellular reactions 
and biochemical reactions).95 Similarly, silicone hydrogel wear met four of the total seven criteria 
(pain, loss of function, cellular reactions and biochemical reactions), and was therefore concluded 
to be inflammatory in nature as well.95 Efron suggested that all contact lens wear, whether it be a 
hydrogel or silicone hydrogel contact lens material, induces a state of “para-inflammation”, or a 
chronic, low-grade (non-damaging) inflammation on the ocular surface, close to that of the ocular 
surface’s basal state, in order to restore the ocular surface’s homeostasis.95 As a result, Efron also 
suggested that during lens wear, the ocular surface has an “upregulated immune status”, which in 
turn serves a protective function in that any antigens presented to the ocular surface can be more 
promptly dealt with due to the “heightened alert” state of the eye.95 
 In the body, and therefore in the eyes as well, there is always an immune response present 
to a certain degree, as a basal level of immune cells or inflammatory markers (such as cytokines), 
exist in both the blood and in the tears.64-70,93,94,114 In the eye, this basal level of immune cells or 
inflammatory markers may exist as a result of the physiological but proinflammatory shift that 
takes place on the surface of the eye during sleep, when tear production is reduced and limited 
oxygen is able to reach the eyes as they are closed.18 As mentioned earlier in section 2.6, 
complement activation is known to increase in the tear film during the first few hours of sleep and 
a significant influx of neutrophils later follows.18 In addition, an increase in TLR expression in 
conjunctival epithelial cells has also been observed due to hypoxic ocular conditions during 
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sleep.18 Based on the idea that contact lens wear can intrinsically be inflammatory, it could be 
possible that the basal level of cytokines on the ocular surface may be higher in a contact lens 
wearer, in comparison to an individual who does not wear contact lenses.95 Similarly, different 
individuals may therefore have different threshold levels for comfort. Thus, it would not be 
appropriate to assume that contact lens discomfort can occur only as a result of large quantities of 
cytokines from the tear film depositing onto the contact lens material, such that the threshold for 
comfort is surpassed. Should a particular contact lens material exhibit uptake of cytokines, it may 
also be possible that contact lens discomfort could arise from having deposited the basal amounts 
of cytokines onto the lens material, such that not enough cytokines remain in the tears to maintain 
a standard, basal level of inflammatory markers that would otherwise exist.  
A question then arises as to what would constitute an ideal contact lens and the answer to 
this question depends on the type of cytokine in question (i.e., proinflammatory or anti-
inflammatory). Based on the results of the experiments presented in this thesis, since none of the 
contact lens materials investigated exhibited substantial amounts of cytokine uptake, it may be 
said that any of these contact lens materials could potentially be an ideal lens that would not cause 
discomfort from the deposition of inflammatory markers. This can only be said, however, for the 
four cytokines of interest and therefore, it cannot conclusively be said that these contact lens 
materials will not deposit other cytokines or inflammatory proteins, resulting in discomfort. In the 
case that both a reusable or daily disposable contact lens do exhibit uptake of proinflammatory 
cytokines, it would be more ideal for the daily disposable contact lens to deposit the cytokines, 
rather than the reusable contact lens, given that the daily disposable contact lens will be discarded 
at the end of the day and not worn again. In contrast, with a reusable contact lens, any deposited 
cytokines would likely denature once the contact lens is placed into the care system at the end of 
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the day, given that a large number of care systems utilize peroxide-based96 storage solutions. The 
denatured cytokines, however, may remain adhered to the surface of the contact lens and once 
inserted back onto the eye the next day, may cause discomfort or irritation.58 Additionally, there 
may also be some degree of bacteria, bacterial parts, or debris bound to contact lenses that can 
result in additional discomfort or irritation96, and the degree of this discomfort or irritation may 
persist longer when utilizing a reusable contact lens, rather than a daily disposable contact lens. In 
this case, uptake of a proinflammatory cytokine by a daily disposable contact lens would be the 
most ideal, as it may aid in dampening an immune response in the context of inflammatory ocular 
conditions (such as DES or allergies), without causing collateral damage to the ocular tissue. The 
reusable contact lens would not be ideal due to the issues with protein denaturation as discussed 
above. In contrast, the uptake of an anti-inflammatory cytokine may not be ideal for either a daily 
disposable or reusable contact lens material. In the context of DES or allergies, it may be beneficial 
to have the presence of anti-inflammatory cytokines on the ocular surface to mitigate the immune 
response and therefore, having a contact lens material (of either wear modality), that could deposit 
anti-inflammatory cytokines such that they are removed from the ocular surface would not be ideal.  
8.2 Future Work  
While it appears that any amount of cytokine uptake observed by balafilcon A, comfilcon 
A, etafilcon A and omafilcon A contact lens materials was minor, perhaps these “minor” quantities 
of uptake are actually the maximum amounts of deposition of these cytokines onto the lens 
materials, given the small size and surface area of a contact lens. Additional experiments would 
therefore be required to determine the clinical relevance of this amount of uptake. For example, 
perhaps small quantities of uptake are sufficient to initiate local inflammation on the corneal 
surface and contribute to symptoms of contact lens discomfort. In the literature, while many 
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investigators have researched the levels of tear cytokines in both contact lens wearers and 
individuals who do not wear contact lenses, it is evident that large discrepancies exist in the levels 
quantified (refer to Table 3-3).64-70,93,94 As explained in section 2.8, this may be due to the short 
half-life of each cytokine74-77, resulting in quick degradation of the proteins that may falsely mimic 
uptake.  
The assay utilized for the experiments presented in this thesis (apart from the MSD 
immunoassay), was an indirect measurement of cytokine uptake (subtractive assay), in that the 
amounts of uptake onto the contact lens materials quoted relative to the 100% controls, reflected 
the values remaining in the solutions over time. Thus, a limitation to this study design was that any 
differences between the control values and the values remaining in the solutions containing the 
contact lens materials of interest, were surmised to have been taken up onto the surface of that 
material. Thus, while the appropriate experimental controls were utilized, these differences (which 
were considered to be amounts of uptake), were not confirmed by a supplementary extraction 
assay. An assay that could provide clinical relevance while also serving as a more direct 
measurement of uptake can be utilized in future experiments. This includes thin slicing of the 
contact lens in conjunction with an ELISA assay, use of a confocal microscope to observe the 
biological effects of co-incubating contact lens materials soaked in a cytokine solution with human 
corneal epithelial cells, or co-incubation of contact lenses with a human macrophage cell line and 
an ELISpot assay to evaluate cytokine responses.   
Given that there are more than 1400 unique proteins in the tear film7 and the experiments 
presented in this thesis focused only on four types of inflammatory proteins (cytokines) present in 
the tear film, there exists a realm of possibility in regard to other types of inflammatory proteins 
that can be evaluated in the future for deposition onto contact lens materials. Some cytokines of 
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interest could include allergy cytokine IL-4 that is over-expressed by a Th2 response during 
allergic conjunctivitis, or another cytokine of the IL-1 family, such as IL-1#, which is produced 
by macrophages and also exists in the corneal epithelial cells where it is stored and released upon 
infection or trauma.3,10,13,21 Ideally, any additional cytokines to be investigated should be one that 
exists at a high concentration in the eye, or one that is considered to be highly biologically active.  
It is known that the use of silicone hydrogels is associated with two times the risk of 
inflammatory complications (corneal infiltrative events), in comparison to pHEMA-based 
hydrogels.96 The results presented in this thesis did not appear to indicate that the uptake of 
proinflammatory cytokines IL-1", IL-6, IL-8, or TNF-#, onto either balafilcon A, comfilcon A, 
senofilcon A or somofilcon A silicone hydrogel materials, result in the increased risk of 
inflammatory complications or discomfort that has been documented. Thus, the question still 
remains in regard to what factors may result in this statistic to be true. One hypothesis presented 
in the literature is that the hydrophobic nature of silicone hydrogels may attract more bacteria and 
a low water content may promote the adhesion of the bacteria to the lens surface.96 Another 
hypothesis is that the low oxygen permeability of hydrogels may promote the adhesion of 
denatured proteins with retained antimicrobial efficacy to the lens, whereas silicone hydrogels 
would lack this efficacy as a result of having higher oxygen permeability.96  
8.3 Conclusion 
The inherent properties of the contact lens materials tested under these experimental 
conditions did not appear to exhibit any uptake of IL-6 and furthermore, did not appear to exhibit 
substantial uptake of IL-1", IL-8, or TNF-#. These conditions included the use of a lyophilized 
standard blend of recombinant cytokines, or cytokines derived directly from human corneal 
epithelial cells; low, moderate or high cytokine concentrations; and with or without additional 
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surface modifications (i.e., ATS soak) to the contact lens materials, such that the ocular surface of 
a clinically-worn contact lens was mimicked. Thus, the inflammatory complications that have been 
reported in the literature with contact lens wear of SiHy or conventional hydrogel material,52 which 
are thought to contribute to contact lens discomfort51,56, may not be due to the interaction of these 
contact lens materials with IL-1", IL-6, IL-8 or TNF-# inflammatory markers. As a result, it is 
possible that contact lens discomfort may be attributed to other factors such as biofilm formation 
on contact lens cases; differences in contact lens wettability; differential uptake of constituents in 
contact lens solutions onto contact lens materials; or the interaction of a contact lens with tear 
components that are not inflammatory markers. This work, in part, helped to address issues 
surrounding ocular inflammation and contributed to providing a better understanding of the role 
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